

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [editorial.bmjopen@bmj.com](mailto:editorial.bmjopen@bmj.com)

# BMJ Open

## Relations of Magnesium Intake to Cognitive Impairment and Dementia Among Women participated in Women's Health Initiative Memory Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030052
Article Type:	Research
Date Submitted by the Author:	25-Feb-2019
Complete List of Authors:	Lo, Kenneth; Brown University, Liu, Qing; Brown University Madsen, Tracy; Brown University Rapp, Steve; Wake Forest University Chen, Jiu-Chiuan; University of Southern California Neuhouser, Marian; Fred Hutchinson Cancer Research Center Shadyab, Aladdin; University of California San Diego Pal, Lubna; Yale University Lin, Xiaochen; Brown University Shumaker, Sally; Wake Forest University Manson, JoAnn; Brigham and Women's Hospital Liu, Prof. Simin; Brown University
Keywords:	Dementia < NEUROLOGY, NUTRITION & DIETETICS, EPIDEMIOLOGY

SCHOLARONE™  
Manuscripts

1  
2 Title: Relations of Magnesium Intake to Cognitive Impairment and Dementia Among Women  
3 participated in Women's Health Initiative Memory Study  
4  
5  
6  
7

8  
9 Authors' names and positions: Kenneth Lo (0000-0003-4624-2737), postdoctoral fellow,  
10 kenneth\_lo@brown.edu <sup>1,2</sup>, Qing Liu, PhD candidate, qing\_liu@brown.edu <sup>2</sup>, Tracy Madsen,  
11 assistant professor, tracy\_madsen@brown.edu <sup>3</sup>, Steve Rapp, professor,  
12 srapp@wakehealth.edu <sup>4</sup>, Jiu-Chiuan Chen, associate professor, jcchen@usc.edu <sup>5</sup>, Marian  
13 Neuhouser, professor, mneuhaus@WHI.org <sup>6</sup>, Aladdin H. Shadyab, postdoctoral fellow,  
14 aladdinhs@yahoo.com <sup>7</sup>, Lubna Pal, professor, lubna.pal@yale.edu <sup>8</sup>, Xiaochen Lin,  
15 postdoctoral fellow, xiaochen\_lin@brown.edu <sup>2</sup>, Sally Shumaker, professor,  
16 sshumake@wakehealth.edu <sup>4</sup>, JoAnn E Manson, professor, jmanson@rics.bwh.harvard.edu <sup>9</sup>,  
17 Simin Liu (0000-0002-8696-4833), professor, simin\_liu@brown.edu <sup>1,2,10</sup>  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 Address of each author: 1: Departments of Cardiology, Guangdong Provincial People's  
31 Hospital, Guangdong Academy of Medical Sciences, China, 2: Centre for Global  
32 Cardiometabolic Health, Department of Epidemiology, School of Public Health, Brown  
33 University, USA, 3: Department of Emergency Medicine, Alpert Medical School, Brown  
34 University, USA, 4: School of Medicine, Wake Forest University, USA, 5: Department of  
35 Preventive Medicine, University of Southern California, USA, 6: Division of Public Health  
36 Sciences, Fred Hutchinson Cancer Research Center, USA, 7: Department of Family and  
37 Preventive Medicine, University of California, San Diego, USA, 8: School of Medicine, Yale  
38 University, USA, 9: Division of Preventive Medicine, Department of Medicine, Brigham and  
39 Women's Hospital, Harvard Medical School, 10: Departments of Surgery and Medicine,  
40 Brown University Alpert School of Medicine  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 Correspondence to: Simin Liu, Centre for Global Cardiometabolic Health, Department of  
51 Epidemiology, School of Public Health, Brown University, Providence, Rhode Island, USA  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

Objective: To examine the associations of dietary and supplemental magnesium (Mg) with cognitive outcomes in aging women.

Design, setting and participants: We analyzed data from Women's Health Initiative Memory Study (WHIMS) and Women's Health Initiative Memory Study-Epidemiology of Cognitive Health (WHIMS-ECHO), which involved 7,479 postmenopausal women aged 65 to 79 with cognitive decline at enrollment.

Main outcome measures: Physician adjudicated mild cognitive impairment (MCI) and/or probable dementia (PD).

Results: Among postmenopausal women from WHIMS and WHIMS-ECHO with over 20 years of follow-up, 6,473 of them were included in the analysis after excluding women who had extreme values of dietary energy intake, had missing or extreme BMI values, with prevalent MCI/PD at baseline, received only one cognitive assessment, or had been followed-up for less than one year. A total of 765 participants (11.8%) developed MCI or PD. When compared with the lowest tertile, the second tertile of total Mg intake was significantly associated with 33% lower adjusted risk of combined MCI/PD (HR = 0.67, 95% C.I. = 0.51, 0.88,  $p < 0.01$ ) and 35% lower risk of MCI (HR = 0.65, 95% C.I. = 0.47, 0.88,  $p = 0.01$ ) in fully adjusted model (adjusted for demographic characteristics, diet, lifestyle, medication use and medical history). The third tertile did not appear to have significant protective effect against MCI or PD.

Conclusions: Total Mg intake between Estimated Average Requirement and Recommended Dietary Allowances may be associated with lower risk of composite MCI/PD and MCI, while further increment of Mg intake did not provide additional benefit. Higher Mg intake from diet should be an effective strategy in preventing cognitive decline.

Trial registration: [clinicaltrials.gov](http://clinicaltrials.gov) (NCT00685009)

## Article focus

- To examine the associations of dietary and supplemental magnesium (Mg) with cognitive outcomes in aging women.

## Key messages

- Total Mg intake between Estimated Average Requirement and Recommended Dietary Allowances may be associated with lower risk of cognitive decline, while further increment of Mg intake did not provide additional benefit.

## Strengths and limitations of this study

- A large prospective cohort with long follow-up, and careful adjudication of MCI/PD events to ensure a high quality of outcome assessment.
- Lacking information on serum Mg levels in the studied population.
- The present cohort included only postmenopausal women, and the findings may not be generalizable to elder men.

## Background

Mild cognitive impairment (MCI) involves onset and evolution of cognitive impairments beyond those expected based on an individual's age and education but not significant enough to interfere with her or his daily activities.<sup>1</sup> Cognitive function might decline progressive over time for people with MCI, which impaired their memory, reasoning, language and visuospatial abilities. Individuals are diagnosed with dementia when their cognitive decline has interfered with daily function.<sup>2</sup> Dementia affects approximately 47 million people worldwide, and its prevalence is expected to more than triple by 2050.<sup>3</sup> The prevalence of dementia and associated medical costs have increased dramatically in recent years in parallel with the aging population globally, which has increased the healthcare burden to communities, families and individuals.<sup>3</sup> Compared to older men, older women have higher lifetime risk for dementia<sup>4, 5</sup> and faster progression of cognitive impairment following

1  
2 diagnosis.<sup>6</sup> Therefore, identifying strategies for dementia prevention particularly those that  
3  
4 are safe, cost-effective, and readily accessible to elderly women is of both public health and  
5  
6 clinical significance.  
7  
8  
9

10  
11 Magnesium (Mg) has long been thought of to prevent vascular outcomes. Recent work has  
12  
13 shown that magnesium may regulate N-methyl-D-aspartate (NMDA) receptors, which affect  
14  
15 critical functions of the central nervous system including neuronal development, plasticity  
16  
17 and neurodegeneration. NMDA receptor is permeable to calcium, sodium and potassium ions  
18  
19 and can be blocked by Mg ions.<sup>7</sup> While strong neurobiological data are in support of the  
20  
21 role of Mg intake for normal neuron functioning by helping to prevent the destruction of  
22  
23 neurons resulting from NMDA-induced excitotoxicity<sup>8</sup>, few prospective studies have directly  
24  
25 examined the relation between Mg intake (dietary and/or supplements) and risk of dementia.<sup>9</sup>  
26  
27  
28  
29 <sup>10</sup> We therefore conducted a prospective investigation of the role of Mg intake in the  
30  
31 development of two constructs of cognitive decline, namely mild cognitive impairment  
32  
33 (MCI) and probable dementia (PD) among older women who participated in the Women's  
34  
35 Health Initiative Memory Study (WHIMS; 1995-2008) and were followed in the WHIMS-  
36  
37 Epidemiology of Cognitive Health Outcomes (WHIMS-ECHO; 2008-onwards) Study.  
38  
39  
40  
41

## 42 43 **Methods**

### 44 45 *Data source*

46  
47 WHI Memory Study (WHIMS) is an ancillary study to the WHI Hormone Trial (N=27,347  
48  
49 for the whole trial) that was designed to assess the effect of postmenopausal hormone therapy  
50  
51 (HT) on dementia risk.<sup>11</sup> Invitation to participate was sent to WHI Hormone Therapy Trial  
52  
53 women that aged 65 to 79 years without dementia at enrollment.<sup>12</sup> Following termination of  
54  
55 the HT intervention, in WHIMS (1995-2008, 7,479 participants) and subsequent WHIMS-  
56  
57 ECHO follow-up (2008 onwards, ~2900 participants), there were continued annual  
58  
59  
60

1  
2 assessments of cognitive function and adjudication of all-cause dementia and MCI status.  
3  
4  
5

6  
7 Participants were eligible for inclusion in the present analysis if they completed the WHI  
8  
9 Food Frequency Questionnaire (FFQ) and dietary supplement questionnaire at baseline. We  
10  
11 further excluded women who had extreme values of dietary energy intake (<600 kcal or  
12  
13 >5000 kcal), had missing or extreme BMI values (BMI<15 kg/m<sup>2</sup> or BMI>50 kg/m<sup>2</sup>), women  
14  
15 with prevalent MCI/PD at baseline and received only one Modified Mini- Mental State  
16  
17 Examination (3MSE) for cognitive assessment. Lastly, to avoid reverse causation between  
18  
19 dietary intake and disease onset, we only included women who had been followed-up for at  
20  
21 least one year. Details of participant selection are illustrated in **Figure 1**.  
22  
23  
24  
25

#### 26 27 *Outcome Variable*

28  
29 The WHIMS and WHIMS-ECHO protocol used a multi-phase approach to identify cases of  
30  
31 MCI and PD. From 1995 through 2007 (WHIMS), participants were screened annually in  
32  
33 clinic by trained and certified examiners with the Modified Mini- Mental State Examination  
34  
35 (3MSE). The 3MSE ranges from 0 to 100, and initial cut-points for further testing are 72 or  
36  
37 lower for participants with <9 years of education, and 76 or lower for participants with 9  
38  
39 years or more of education. After July 1, 1998 the cut points were 80 and 88 respectively.  
40  
41 Participants who scored below the education-adjusted 3MSE cut-point received the in-depth  
42  
43 multi-phased evaluation,<sup>13</sup> including a battery of neuropsychologic tests, history and physical,  
44  
45 neuropsychiatric evaluation, and an interview of friend or family member to assess functional  
46  
47 status<sup>11</sup>.  
48  
49  
50  
51

52  
53  
54 Beginning in 2008 (WHIMS-ECHO), an annual validated cognitive test battery that included  
55  
56 the Telephone Interview for Cognitive Status-modified (TICSm)<sup>14</sup> and other validated tests of  
57  
58 cognitive function were administered by telephone. <sup>15</sup> To justify replacing 3MSE assessment  
59  
60

1  
2 with TICSm, a validation study was conducted. Results showed that the 3MSE scores  
3  
4 predicted by TICSm was highly correlated (0.82) with 3MSE scores,<sup>16</sup> while the  
5  
6 transformation of WHIMS 3MSE and WHIMS-ECHO TICSm data into relative percentile  
7  
8 ranks fit the trajectories of global cognitive function.<sup>17</sup> For women who screened positive  
9  
10 (i.e., TICSm<31) during WHIMS-ECHO follow-up, a reliable and pre-identified informant  
11  
12 was interviewed by telephone using the standardized Dementia Questionnaire to assess the  
13  
14 history of cognitive and behavioral changes, functional impairments, and health events that  
15  
16 can affect cognitive functioning.<sup>18</sup>  
17  
18  
19  
20  
21

22 All available participant data in both WHIMIS and WHIMS-ECHO were submitted to a  
23  
24 central adjudication committee at the WHIMS clinical coordinating center. The committee  
25  
26 had experts experienced in neurological examinations and neuropsychiatric evaluations,  
27  
28 where cases are classified as no impairment, MCI or PD.<sup>19</sup> Outcome classification was based  
29  
30 on the DSM-IV criteria for dementia<sup>20</sup> and Petersen's MCI criteria<sup>1</sup>.  
31  
32  
33  
34  
35

### 36 *Exposure variable*

37  
38 Dietary Mg intake at baseline was derived using the baseline WHI semi-quantitative food  
39  
40 frequency questionnaire (FFQ).<sup>21</sup> The nutrient database for the WHI FFQ uses the Nutrition  
41  
42 Data Systems for Research (NDS-R, version 2005, University of Minnesota Nutrition  
43  
44 Coordinating Center, Minneapolis, MN) food and nutrient database.<sup>22</sup> Data on current dietary  
45  
46 supplements at baseline were assessed by a special dietary supplement inventory interviewer-  
47  
48 administered questionnaire.<sup>23</sup> Participants were asked to bring all current supplements to the  
49  
50 WHI baseline clinic visit. Staff members directly transcribed the ingredients for each  
51  
52 supplement, which has demonstrated high correlation (ranged from 0.8 to 1.0) with photo-  
53  
54 copied labels in validation study.<sup>24</sup> Total Mg intake was calculated by summation of dietary  
55  
56 and supplemental Mg intake. To test the linear relationship between total Mg intake and  
57  
58  
59  
60



1  
2 MCI/PD, levels of Mg intake were categorized per 100mg increments or categorized into  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

MCI/PD, levels of Mg intake were categorized per 100mg increments or categorized into tertiles.

### *Covariates*

At WHI baseline, WHIMS participants completed questionnaires on various information, including demographics (age, race-ethnicity), socioeconomic status (education in years), lifestyle factors (diet, smoking, alcohol use, physical activity), family or personal disease history (family history of diabetes or heart diseases, personal history of diabetes, heart diseases, cancer or related risk factors) and medication use (use of anti-inflammatory drugs, anti-hyperlipidemia drugs, anti-depressants, anti-hypertensive drugs or diuretics). Height and weight were measured at baseline for calculating Body Mass Index (BMI).

### *Data analysis*

Descriptive statistics were demonstrated by tertiles of total magnesium intake. In order to preserve statistical power with regard to the sample size, tertile was chosen instead of quartile or quintile in the present study. The differences between tertiles were tested by one-way ANOVA for continuous variables and chi-square test for categorical variables. To examine the relationship between total Mg intake and incident MCI and/or PD, Cox proportional hazards regression models were used with results presented as hazard ratios (HRs) and associated 95% confidence intervals (95% CI). Non-cases were censored at the time of the last follow-up (WHIMS or WHIMS-ECHO), death, or at the end of 2012 (the year with the most updated data from WHIMS-ECHO), whichever came first. With reference to the common analysis strategies of other WHIMS studies,<sup>25-27</sup> the end-point of MCI/PD was presented as a combined end-point in primary analyses. MCI and PD were treated as secondary end-points respectively. The event time was defined as the time of screening by global cognitive tests (either 3MS or TICSm) that triggered the subsequent work-up that

1  
2 concluded with the central adjudication of first MCI/PD. If a participant had progressed from  
3 MCI to PD, she was classified as a case of PD instead of MCI. To test the assumption of Cox  
4 proportional hazards model, i.e. whether the predictive ability of independent variables  
5 changed with time, we calculated interactions of predictor variables and the survival time  
6 (time to event or the end of follow-up) and included the interaction term in the models. A  
7 sensitivity analysis was performed by using dietary or supplementary Mg intake only and was  
8 categorized in tertiles and per 100mg increments.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 To ensure robustness of regression analysis, we have controlled for confounders with  
21 reference to previous studies of cognitive decline. Model 1 was the minimally adjusted model  
22 and included age at baseline, region in U.S., race/ethnicity, assignment arm of HT trial, BMI  
23 at baseline<sup>28</sup> and smoking status.<sup>29</sup> Model 2 included covariates in Model 1 plus education,<sup>30</sup>  
24 dietary variables and physical activity (alcohol intake, energy expenditure from recreational  
25 physical activity, total intake of vitamin B6/9/12, total intake of calcium and vitamin D),<sup>27, 31-</sup>  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
34 as well as medical history and medication use (baseline self-reported status of diabetes  
(identified by the question ‘Did a doctor ever say that you had sugar diabetes or high blood  
sugar when you were not pregnant?’),<sup>35</sup> cardiovascular disease (includes cardiac arrest,  
congestive heart failure, cardiac catheterization, coronary bypass surgery, angioplasty of  
coronary arteries, carotid endarterectomy/angioplasty, atrial fibrillation or aortic aneurysm)<sup>36</sup>  
and cancer (except for skin melanoma),<sup>37</sup> prior use of menopausal replacement therapy,<sup>38</sup>  
personal history of hypertension,<sup>39</sup> personal history of high cholesterol requiring  
medications,<sup>40</sup> family medical history of diabetes, family history of heart attack or stroke,  
medication use (anti-inflammatory drugs, anti-hyperlipidemia drugs, anti-depressants, anti-  
hypertensive drugs or diuretics at baseline).<sup>41, 42</sup> Only participants with complete data were  
included in each regression model. All statistical analyses were performed with R 3.5.1. P  
values less than 0.05 were considered statistically significant.

### *Patient and public involvement*

No patients were involved in the design process of this study, setting the research question, or the outcome measures nor were they involved in the analysis, interpretation, and writing of the results. With regard to the long follow-up period, dissemination to these groups is not applicable.

## **Results**

### *Participant Characteristics*

A total of 6,473 participants were included in the analyses. The baseline characteristics of participants in the WHIMS by tertiles are presented in **Table 1**. Women in the highest tertile of Mg intake tended to have, on average, lower BMI, greater energy expenditure from recreational physical activity and higher levels of all dietary variables as shown by one-way ANOVA. As demonstrated by chi-square test, Non-Hispanic White women, participants enrolled in controlled group of Estrogen+Progestin trial, participants with  $\geq 7$  alcohol drinks per week, being a past smoker or receiving post-college education were more prevalent to have the highest level of Mg intake.

### *Total Magnesium intake and risk of Mild Cognitive Impairment/Probable Dementia*

**Table 2** illustrates the association between total Mg intake and risk of MCI and/or PD. A total of 208 (9.6%), 142 (6.5%) and 155 (7.2%) women developed MCI across the increasing tertiles of total Mg intake, while 133 (6.2%), 118 (5.4%) and 144 (6.7%) women developed PD. Total Mg intake per 100mg increment was not associated with risk of MCI and/or PD in any of the Cox models assuming a linear association. When using the lowest tertile as the referent, the second tertile of total Mg intake was associated with risk of composite MCI/PD (HR = 0.65, 95% C.I. = 0.51, 0.88,  $p < 0.01$ ) and MCI (HR = 0.65, 95% C.I. = 0.47, 0.88,

1  
2 p=0.01) in fully adjusted model. None of the associations between Mg intake (both  
3  
4 continuous or categorical variable) and the risk of PD were significant. After full  
5  
6 adjustments, interactions between most predictor variables and survival time were not  
7  
8 significant (p value ranged from 0.05 to 0.45), so the proportional hazard assumption was not  
9  
10 violated (**Table 2**). The only exception was the null association between total magnesium  
11  
12 intake per 100mg increment and the risk of MCI (p value for interaction with time=0.03).  
13  
14  
15  
16  
17

### *Dietary Magnesium intake and risk of Mild Cognitive Impairment/Probable Dementia*

18  
19  
20 **Table 3** illustrates the association between dietary Mg intake and risk of MCI and/or PD. A  
21  
22 total of 190 (8.8%), 169 (7.8%) and 146 (6.8%) women developed MCI across the increasing  
23  
24 tertiles of dietary Mg intake, while 132 (6.1%), 119 (5.5%) and 144 (6.7%) women  
25  
26 developed PD. None of the associations between dietary Mg intake (both continuous or  
27  
28 categorical variable) and the risk of MCI and/or PD were significant in the fully adjusted  
29  
30 model (Model 2). After full adjustments, interactions between predictor variables and  
31  
32 survival time were not significant (p value ranged from 0.29 to 0.58), so the proportional  
33  
34 hazard assumption was not violated (**Table 3**).  
35  
36  
37  
38  
39  
40

## **Discussion**

### *Summary of findings*

41  
42  
43 We examined the association between dietary Mg intake and cognitive impairment in a  
44  
45 geographically-diverse cohort of post-menopausal women in a sub-cohort of the WHI. When  
46  
47 compared with the lowest tertile, the second tertile of total daily Mg intake was associated  
48  
49 with lower risk of composite MCI/PD and MCI after statistical adjustment for demographic  
50  
51 characteristics, diet, lifestyle, medication use and medical history. No association was found  
52  
53 between Mg intake and PD. Higher Mg intake may be associated with lower risk of mild  
54  
55 cognitive impairment, but not necessarily in a dose-response manner. Although Mg intake  
56  
57  
58  
59  
60

1  
2 from dietary source only did were not significantly associate with MCI/PD, the results  
3  
4 appeared to be intuitive because the levels of Mg intake from dietary source was lower than  
5  
6 the sum of dietary and supplemental source. Although the association between total  
7  
8 magnesium intake per 100mg increment and the risk of MCI violated the assumption of Cox  
9  
10 regression, this result did not alter the interpretation of overall findings.  
11  
12  
13

### 14 15 16 *Comparison with previous literature*

17  
18 Our findings were consistent with two previous studies that demonstrated the lowest risk  
19  
20 cognitive decline among participants with moderate Mg intake. Ozawa and colleagues  
21  
22 assessed the association between self-reported dietary intake of minerals (potassium, calcium,  
23  
24 and magnesium) and dementia risk among Japanese older adults.<sup>9</sup> The hazard ratio for the  
25  
26 development of all-cause dementia was 0.63 (95% CI = 0.40–1.01) for the highest quartile  
27  
28 ( $\geq 196$  mg/d) of Mg intake compared to the lowest quartile ( $\leq 147$  mg/d). For our study, the  
29  
30 hazard ratio for the development of probable dementia was also insignificant (HR: 1.05, 95%  
31  
32 CI = 0.48–2.29) for the highest tertile ( $> 337.6$  mg/d) of Mg intake compared to the lowest  
33  
34 tertile ( $< 236.9$  mg/d). In another study from the Netherlands, a “U” shaped distribution in the  
35  
36 association between Mg levels and cognition was observed such that both low ( $\leq 0.79$   
37  
38 mmol/L) levels (HR=1.32) and high ( $\geq 0.90$  mmol/L) serum Mg levels (HR=1.30) were  
39  
40 associated with increased risk of all-cause dementia.<sup>43</sup> For our study, comparing with the  
41  
42 lowest tertile, the second tertile of total Mg intake was associated with lowest risk of  
43  
44 combined MCI/PD and MCI after adjusting for various confounders. The present findings do  
45  
46 support total Mg intake (238.6–341.2mg) between Estimated Average Requirement  
47  
48 (estimated nutrient intake to meet the requirement of half the healthy individuals, 265mg/day  
49  
50 for women  $> 51$  years old) and Recommended Dietary Allowances (sufficient average daily  
51  
52 dietary intake level to meet the nutrient requirement of 97 to 98% healthy individuals,  
53  
54 320mg/day for women  $> 51$  years old) is optimal for preventing cognitive decline,<sup>44, 45</sup> while  
55  
56  
57  
58  
59  
60

1  
2 further increment of Mg intake did not provide additional benefit. Another observation is that  
3  
4 total Mg intake had similar magnitude of association with MCI/PD and MCI but associated  
5  
6 with the risk of PD without statistical significance. In other words, total Mg intake is more  
7  
8 protective against MCI. Since we only assessed baseline diet, it is possible that long follow-  
9  
10 up period weakened the association between Mg intake and dementia.  
11  
12  
13

### 14 15 *Strengths and Limitations*

16  
17 Strengths of the current analyses include the use of data from a large prospective cohort with  
18  
19 long follow-up, and careful adjudication of MCI/PD events to ensure a high quality of  
20  
21 outcome assessment. However, some limitations of assessment of Mg intake from dietary  
22  
23 sources should be noted. We are lacking information on serum Mg levels in the studied  
24  
25 population. Despite adjustment for dietary energy, assessment of dietary Mg intake can be  
26  
27 confounded with other constituents such as leafy green vegetables, the primary source of  
28  
29 dietary Mg.<sup>46</sup> In addition, previous studies have found that dietary Mg intake might not  
30  
31 strongly correlate with serum Mg levels ( $r=0.28$ ,  $p<0.05$ ).<sup>47</sup> That may lead to different  
32  
33 magnitudes of associations, such as the impact of dietary/serum Mg on the risk of a disease,  
34  
35 such as described for hypertension.<sup>48</sup> Moreover, supplemental Mg intake was collected for  
36  
37 ‘other supplement mixtures’ and single supplements but not for standard multivitamins with  
38  
39 minerals which was the most common type of supplement used by WHI women. Although  
40  
41 this limitation might lead to under-ascertainment of Mg from supplements, whether it was the  
42  
43 major flaw of this study was arguable, since the total Mg intake has demonstrated significant  
44  
45 association with MCI/PD. Last but not least, the present cohort included only postmenopausal  
46  
47 women, and the findings may not be generalizable to elder men. Despite these limitations,  
48  
49 this study adds important information regarding Mg intake for cognitive benefit in  
50  
51 postmenopausal women.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## *Conclusions*

Among postmenopausal women from WHIMS with over 20 years of follow-up, total Mg intake between Estimated Average Requirement and Recommended Dietary Allowances was associated with lower risk of composite MCI/PD and MCI despite not in a dose-response manner.

*Contributors:* KL, QL, TM, AHS, LP, XL, SS, JEM searched the literature; analyzed and interpreted the data; and wrote the manuscript. SR, JCC, MN, SL participated in the study design; collected, analyzed, and interpreted the data; and wrote the manuscript.

*Funding:* The Women's Health Initiative (WHI) was funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, and U.S. Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. The Women's Health Initiative Memory Study (WHIMS) was funded in part by Wyeth Pharmaceuticals, St. Davids, PA. The WHIMS Extension was funded by the National Institute on Aging contract HHSN26820044221C, and WHIMS-ECHO was funded by the National Institute on Aging through contracts HHSN26820044221C, and HHSN 271201100004C. The funding sources had no role in study design, data collection, data analysis, data interpretation, or the writing of this report; and in the decision to submit the manuscript for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

*Ethics approval:* The WHI study was approved by the research ethics committees at each of the participating centers.

*Competing interests:* None declared.

*Data sharing:* No additional data available.

*Provenance and peer review:* Not commissioned; externally peer reviewed.

Figure 1 Identification of an Analytical Cohort from the Women's Health Initiative Memory Study (WHI-MS)






Table 1 Baseline Characteristics of Participants in The Women's Health Initiative Memory Study by tertiles of Total Mg Intake

	Mean (SD) / N (%)			p value
	T1	T2	T3	
Time-to-event/censored	9.2 (4.4)	9.8 (4.3)	9.8 (4.3)	<0.01*
Age at baseline in years	70.0 (3.7)	70.1 (3.9)	70.2 (3.9)	0.37
BMI at baseline	28.6 (5.3)	28.2 (5.4)	28.3 (5.4)	0.04*
Recreational physical activity in MET-hour	9.8 (12.4)	11.1 (12.6)	13.0 (14.3)	<0.01*
Total B6 intake in mg	4.1 (19.9)	5.8 (21.5)	10.6 (39.2)	<0.01*
Total B9 intake in mcg	265.5 (200.0)	455.1 (203.0)	652.1 (261.6)	<0.01*
Total B12 intake in mcg	15.1 (75.4)	17.0 (55.0)	29.3 (84.6)	<0.01*
Total calcium intake in mg	717.0 (578.3)	1100.7 (545.9)	1599.8 (663.9)	<0.01*
Total vitamin D intake in mcg	4.8 (4.3)	9.4 (5.4)	14.2 (6.6)	<0.01*
Dietary energy in kcal	1183.0 (350.2)	1595.6 (451.8)	2036.6 (694.1)	<0.01*
Region in U.S.				0.56
● Northeast	597 (27.7%)	596 (27.6%)	578 (26.8%)	
● South	461 (21.4%)	430 (19.9%)	424 (19.6%)	
● Midwest	506 (23.5%)	533 (24.7%)	559 (25.9%)	
● West	593 (27.5%)	599 (27.8%)	597 (27.7%)	
Race/Ethnicity				<0.01*
● Non-Hispanic White	1782 (82.6%)	1940 (89.9%)	1961 (90.9%)	
● Black or African-American	208 (9.6%)	108 (5.0%)	99 (4.6%)	
● Hispanic/Latino	77 (3.6%)	35 (1.6%)	32 (1.5%)	
● Other	86 (4.0%)	72 (3.3%)	59 (2.7%)	
HRT Arm				<0.01*
● E-alone	495 (22.9%)	387 (17.9%)	366 (17.0%)	
● E-alone control	443 (20.5%)	385 (17.8%)	429 (19.9%)	
● E+P intervention	603 (28.0%)	692 (32.1%)	640 (29.7%)	
● E+P control	616 (28.6%)	694 (32.2%)	723 (33.5%)	
7+ alcohol drinks per week	219 (10.2%)	264 (12.2%)	327 (15.2%)	<0.01*
Prevalent diabetes	184 (8.5%)	160 (7.4%)	163 (7.6%)	0.32
Prevalent cardiovascular disease	355 (16.5%)	351 (16.3%)	377 (17.5%)	0.56
Prevalent cancer	88 (4.1%)	72 (3.3%)	72 (3.3%)	0.32
Hormone Replacement Therapy				0.15
● Never used	1482 (68.7%)	1495 (69.3%)	1467 (68.0%)	
● Past user	571 (26.5%)	529 (24.5%)	557 (25.8%)	
● Current user	104 (4.8%)	134 (6.2%)	134 (6.2%)	
Treated high cholesterol	391 (18.1%)	370 (17.1%)	390 (18.1%)	0.61

History of hypertension	856 (39.7%)	831 (38.5%)	805 (37.3%)	0.27
Family history of diabetes, heart attack or stroke	1662 (77.1%)	1689 (78.3%)	1640 (76.0%)	0.21
Medication use <sup>a</sup>	1007 (46.7%)	986 (45.7%)	1016 (47.1%)	0.64
Smoking status				<0.01*
● Never Smoked	1134 (52.6%)	1168 (54.1%)	1144 (53.0%)	
● Past Smoker	838 (38.9%)	845 (39.2%)	914 (42.4%)	
● Current Smoker	185 (8.6%)	145 (6.7%)	100 (4.6%)	
Received college education or above	1070 (49.6%)	1312 (60.8%)	1379 (63.9%)	<0.01*

MCI: mild cognitive impairment; PD: probable dementia; HRT: Hormone replacement therapy; E-alone: Estrogen-alone; E+P: Estrogen+Progestin

\* P value < 0.05

<sup>a</sup> Any use of anti-inflammatory, anti-hyperlipidemic, anti-depressant, anti-hypertensive or diuretic drug

Table 2 Associations of total magnesium intake with the risk of mild cognitive impairment and/or probable dementia

	Cases/Total	Model 1 (95% C.I.) <sup>a</sup>	p value	Model 2 (95% C.I.) <sup>b</sup>	p value
		N=6,473		N=6,183	
<b>MCI/PD</b>					
Total magnesium intake (per 100mg increment)		0.86 (0.77, 0.97)	0.02*	0.95 (0.84, 1.08)	0.43
Total magnesium intake by tertiles					
● T1 (<238.6 mg/day)	295/2157	Ref		Ref	
● T2 (238.6-341.2 mg/day)	222/2158	0.61 (0.48, 0.78)	<0.01*	0.67 (0.51, 0.88)	<0.01*
● T3 (>341.2 mg/day)	248/2158	0.60 (0.41, 0.88)	0.01*	0.72 (0.46, 1.12)	0.14
<b>Mild Cognitive Impairment</b>					
Total magnesium intake (per 100mg increment)		0.82 (0.72, 0.94)	<0.01*	0.86 (0.74, 1.00)	0.05
Total magnesium intake by tertiles					
● T1 (<238.6 mg/day)	208/2157	Ref		Ref	
● T2 (238.6-341.2 mg/day)	142/2158	0.59 (0.45, 0.77)	<0.01*	0.65 (0.47, 0.88)	0.01*
● T3 (>341.2 mg/day)	155/2158	0.55 (0.36, 0.84)	0.01*	0.63 (0.38, 1.04)	0.07
<b>Probable dementia</b>					
Total magnesium intake (per 100mg increment)		1.00 (0.86, 1.17)	0.98	1.04 (0.89, 1.21)	0.66
Total magnesium intake by tertiles					
● T1 (<238.6 mg/day)	133/2157	Ref		Ref	
● T2 (238.6-341.2 mg/day)	118/2158	0.81 (0.56, 1.17)	0.26	0.86 (0.58, 1.28)	0.46
● T3 (>341.2 mg/day)	144/2158	0.93 (0.51, 1.68)	0.80	1.10 (0.56, 2.16)	0.78

<sup>a</sup> Model adjustment: age at baseline, region in U.S., assignment of hormone therapy trial, BMI at baseline, and smoking status.

<sup>b</sup> Model 2 adjustment: covariates in model 1 along with race/ethnicity, education, alcohol intake, energy expenditure from recreational physical activity, total intake of vitamin B6/9/12, total intake of calcium and vitamin D, dietary energy in kcal, baseline status of diabetes/cardiovascular disease/cancer, prior use of hormone replacement therapy, personal history of hypertension, personal history of high cholesterol requiring medications, family medical history of diabetes, family history of heart attack or stroke, use of anti-inflammatory drug, anti-hyperlipidemia drug, anti-depressant, anti-hypertensive drug or the use of diuretics at baseline \*P<0.05.

Table 3 Associations of dietary magnesium intake with the risk of mild cognitive impairment and/or probable dementia

	Cases/Total	Model 1 (95% C.I.) <sup>a</sup>	p value	Model 2 (95% C.I.) <sup>b</sup>	p value
		N=6,473		N=6,183	
<b>MCI/PD</b>					
Dietary magnesium intake (per 100mg increment)		0.89 (0.75, 1.06)	0.19	0.92 (0.75, 1.14)	0.45
Dietary magnesium intake by tertiles					
● T1 (<203.0mg/day)	276/2157	Ref		Ref	
● T2 (203.0-280.6mg/day)	242/2158	0.77 (0.60, 0.98)	0.03*	0.82 (0.63, 1.07)	0.14
● T3 (>280.6mg/day)	247/2158	0.70 (0.47, 1.03)	0.07	0.79 (0.50, 1.24)	0.31
<i>Mild Cognitive Impairment</i>					
Dietary magnesium intake (per 100mg increment)		0.85 (0.71, 1.03)	0.09	0.87 (0.69, 1.10)	0.25
Dietary magnesium intake by tertiles					
● T1 (<203.0mg/day)	190/2157	Ref		Ref	
● T2 (203.0-280.6mg/day)	169/2158	0.81 (0.61, 1.06)	0.13	0.87 (0.64, 1.18)	0.36
● T3 (>280.6mg/day)	146/2158	0.62 (0.40, 0.96)	0.03	0.73 (0.44, 1.23)	0.24
<i>Probable dementia</i>					
Dietary magnesium intake (per 100mg increment)		1.04 (0.81, 1.34)	0.75	1.05 (0.78, 1.42)	0.73
Dietary magnesium intake by tertiles					
● T1 (<203.0mg/day)	132/2157	Ref		Ref	
● T2 (203.0-280.6mg/day)	119/2158	0.86 (0.60, 1.24)	0.42	0.93 (0.62, 1.38)	0.70
● T3 (>280.6mg/day)	144/2158	1.01 (0.56, 1.83)	0.98	1.06 (0.54, 2.09)	0.86

<sup>a</sup> Model adjustment: age at baseline, region in U.S., assignment of hormone therapy trial, BMI at baseline, and smoking status. <sup>b</sup> Model 2 adjustment: covariates in model 1 along with race/ethnicity, education, alcohol intake, energy expenditure from recreational physical activity, total intake of vitamin B6/9/12, total intake of calcium and vitamin D, dietary energy in kcal, baseline status of diabetes/cardiovascular disease/cancer, prior use of hormone replacement therapy, personal history of hypertension, personal history of high cholesterol requiring medications, family medical history of diabetes, family history of heart attack or stroke, use of anti-inflammatory drug, anti-hyperlipidemia drug, anti-depressant, anti-hypertensive drug or the use of diuretics at baseline \**P*<0.05.

## Reference

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol*. 1999;56:303-308.
2. Arevalo-Rodriguez I, Smailagic N, Roque IFM, et al. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). *Cochrane Database Syst Rev*. 2015:CD010783.
3. World Health Organization. The Epidemiology and Impact of Dementia Current State and Future Trends. 2015.
4. Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. *Neurology*. 1999;53:1992-1997.
5. Chene G, Beiser A, Au R, et al. Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. *Alzheimers Dement*. 2015;11:310-320.
6. Lin KA, Choudhury KR, Rathakrishnan BG, et al. Marked gender differences in progression of mild cognitive impairment over 8 years. *Alzheimers Dement*. 2015;1:103-110.
7. Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development. An update. *Drug News Perspect*. 1998;11:523-569.
8. Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. *Neurochem Int*. 2004;45:583-595.
9. Ozawa M, Ninomiya T, Ohara T, et al. Self-reported dietary intake of potassium, calcium, and magnesium and risk of dementia in the Japanese: the Hisayama Study. *J Am Geriatr Soc*. 2012;60:1515-1520.
10. Tzeng NS, Chung CH, Lin FH, et al. Magnesium oxide use and reduced risk of dementia: a retrospective, nationwide cohort study in Taiwan. *Curr Med Res Opin*. 2018;34:163-169.
11. Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. *Controlled Clin Trials*. 1998;19:604-621.
12. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA*. 2003;289:2663-2672.
13. Malouf R, Areosa Sastre A. Vitamin B12 for cognition. *Cochrane Database Syst Rev*. 2003:CD004326.
14. Welsh KA, Breitner J, Magruder-Habib KM. Detection of dementia in the elderly using the telephone interview for cognitive status. *Neuropsychiatry Neuropsychol Behav Neurol*. 1993;6:103-110.
15. Rapp SR, Legault C, Espeland MA, et al. Validation of a cognitive assessment battery administered over the telephone. *J Am Geriatr Soc*. 2012;60:1616-1623.
16. Arnold AM, Newman AB, Dermond N, Haan M, Fitzpatrick A. Using telephone and informant

- assessments to estimate missing Modified Mini-Mental State Exam scores and rates of cognitive decline. The cardiovascular health study. *Neuroepidemiology*. 2009;33:55-65.
17. Espeland MA, Chen JC, Weitlauf J, et al. Trajectories of Relative Performance with 2 Measures of Global Cognitive Function. *J Am Geriatr Soc*. 2018; 1575-1580.
18. Ellis RJ, Jan K, Kawas C, et al. Diagnostic validity of the dementia questionnaire for Alzheimer disease. *Arch Neurol*. 1998;55:360-365.
19. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA*. 2003;289:2651-2662.
20. Hogervorst E, Bandelow S, Combrinck M, Irani SR, Smith AD. The validity and reliability of 6 sets of clinical criteria to classify Alzheimer's disease and vascular dementia in cases confirmed post-mortem: added value of a decision tree approach. *Dement Geriatr Cogn Dis*. 2003;16:170-180.
21. Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T. Measurement characteristics of the Women's Health Initiative food frequency questionnaire. *Ann Epidemiol*. 1999;9:178-187.
22. Schakel SF, Sievert YA, Buzzard IM. Sources of data for developing and maintaining a nutrient database. *J Am Diet Assoc*. 1988;88:1268-1271.
23. Neuhouser ML, Wassertheil-Smoller S, Thomson C, et al. Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts. *Arch Intern Med*. 2009;169:294-304.
24. Patterson RE, Levy L, Tinker LF, Kristal AR. Evaluation of a simplified vitamin supplement inventory developed for the Women's Health Initiative. *Public Health Nutr*. 1999;2:273-276.
25. Ammann EM, Pottala JV, Robinson JG, Espeland MA, Harris WS. Erythrocyte omega-3 fatty acids are inversely associated with incident dementia: Secondary analyses of longitudinal data from the Women's Health Initiative Memory Study (WHIMS). *Prostaglandins Leukot Essent Fatty Acids*. 2017;121:68-75.
26. Hayden KM, Beavers DP, Steck SE, et al. The association between an inflammatory diet and global cognitive function and incident dementia in older women: The Women's Health Initiative Memory Study. *Alzheimers Dement*. 2017;13:1187-1196.
27. Agnew-Blais JC, Wassertheil-Smoller S, Kang JH, et al. Folate, vitamin B-6, and vitamin B-12 intake and mild cognitive impairment and probable dementia in the Women's Health Initiative Memory Study. *J Acad Nutr Diet*. 2015;115:231-241.
28. Moga DC, Abner EL, Brouwer ES. Dementia and "obesity paradox": is this for real or are we missing something? An epidemiologist's perspective. *J Am Med Dir Assoc*. 2015;16:78-79.
29. Batty GD, Shipley MJ, Kvaavik E, et al. Biomarker assessment of tobacco smoking exposure and risk of dementia death: pooling of individual participant data from 14 cohort studies. *J Epidemiol Community Health*. 2018;72:513-515.
30. Xu W, Tan L, Wang HF, et al. Education and Risk of Dementia: Dose-Response Meta-Analysis of

- 1  
2  
3  
4 Prospective Cohort Studies. *Mol Neurobiol*. 2016;53:3113-3123.
- 5 31. Littlejohns TJ, Henley WE, Lang IA, et al. Vitamin D and the risk of dementia and Alzheimer  
6 disease. *Neurology*. 2014;83:920-928.
- 7  
8 32. Kern J, Kern S, Blenow K, et al. Calcium supplementation and risk of dementia in women with  
9 cerebrovascular disease. *Neurology*. 2016;87:1674-1680.
- 10  
11 33. Ilomaki J, Jokanovic N, Tan EC, Lonroos E. Alcohol Consumption, Dementia and Cognitive  
12 Decline: An Overview of Systematic Reviews. *Curr Clin Pharmacol*. 2015;10:204-212.
- 13  
14 34. Blondell SJ, Hammersley-Mather R, Veerman JL. Does physical activity prevent cognitive  
15 decline and dementia?: A systematic review and meta-analysis of longitudinal studies. *Bmc Public*  
16 *Health*. 2014;14:510.
- 17  
18 35. Espeland MA, Brinton RD, Hugenschmidt C, et al. Impact of Type 2 Diabetes and  
19 Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women.  
20 *Diabetes Care*. 2015;38:2316-2324.
- 21  
22  
23 36. Eriksson UK, Bennet AM, Gatz M, Dickman PW, Pedersen NL. Nonstroke cardiovascular disease  
24 and risk of Alzheimer disease and dementia. *Alzheimer Dis Assoc Disord*. 2010;24:213-219.
- 25  
26 37. Ganguli M. Cancer and Dementia: It's Complicated. *Alzheimer Dis Assoc Disord*. 2015;29:177-  
27 182.
- 28  
29 38. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects  
30 on cognitive function and dementia. *JAMA*. 1998;279:688-695.
- 31  
32 39. Peters R, Beckett N. Hypertension, dementia, and antihypertensive treatment: implications for  
33 the very elderly. *Curr Hypertens Rep*. 2009;11:277-282.
- 34  
35 40. Reitz C. Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms  
36 behind the associations. *J Alzheimers Dis*. 2012;30 Suppl 2:S127-145.
- 37  
38 41. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. *Lancet*.  
39 2000;356:1627-1631.
- 40  
41 42. Tully PJ, Hanon O, Cosh S, Tzourio C. Diuretic antihypertensive drugs and incident dementia  
42 risk: a systematic review, meta-analysis and meta-regression of prospective studies. *J Hypertens*.  
43 2016;34:1027-1035.
- 44  
45 43. Kieboom BCT, Licher S, Wolters FJ, et al. Serum magnesium is associated with the risk of  
46 dementia. *Neurology*. 2017;89:1716-1722.
- 47  
48 44. Bergman C, Gray-Scott D, Chen JJ, Meacham S. What is next for the Dietary Reference Intakes  
49 for bone metabolism related nutrients beyond calcium: phosphorus, magnesium, vitamin D, and  
50 fluoride? *Crit Rev Food Sci Nutr*. 2009;49:136-144.
- 51  
52 45. Murphy SP, Poos MI. Dietary Reference Intakes: summary of applications in dietary  
53 assessment. *Public Health Nutr*. 2002;5:843-849.
- 54  
55 46. Chen GC, Koh WP, Yuan JM, Qin LQ, van Dam RM. Green leafy and cruciferous vegetable  
56 consumption and risk of type 2 diabetes: results from the Singapore Chinese Health Study and  
57 meta-analysis. *Br J Nutr*. 2018:1-11.
- 58  
59  
60

1  
2  
3 47. Akizawa Y, Koizumi S, Itokawa Y, et al. Daily magnesium intake and serum magnesium  
4 concentration among Japanese people. *J Epidemiol.* 2008;18:151-159.

5  
6 48. Han H, Fang X, Wei X, et al. Dose-response relationship between dietary magnesium intake,  
7 serum magnesium concentration and risk of hypertension: a systematic review and meta-analysis  
8 of prospective cohort studies. *Nutr J.* 2017;16:26.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



1 STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	4
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-6
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-8
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	8
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8-9
		(b) Give reasons for non-participation at each stage	14
		(c) Consider use of a flow diagram	14
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9
		(b) Indicate number of participants with missing data for each variable of interest	14
		(c) Summarise follow-up time (eg, average and total amount)	15
Outcome data	15*	Report numbers of outcome events or summary measures over time	17-18
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear	17-18

		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	17-18
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	10-12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

\*Give information separately for exposed and unexposed groups.

# BMJ Open

## Relations of magnesium intake to cognitive impairment and dementia among participants in the Women's Health Initiative Memory Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030052.R1
Article Type:	Research
Date Submitted by the Author:	01-Jul-2019
Complete List of Authors:	Lo, Kenneth; Brown University, Liu, Qing; Brown University Madsen, Tracy; Brown University Rapp, Steve; Wake Forest University Chen, Jiu-Chiuan; University of Southern California Neuhouser, Marian; Fred Hutchinson Cancer Research Center Shadyab, Aladdin; University of California San Diego Pal, Lubna; Yale University Lin, Xiaochen; Brown University Shumaker, Sally; Wake Forest University Manson, JoAnn; Brigham and Women's Hospital Liu, Prof. Simin; Brown University
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Geriatric medicine
Keywords:	Dementia < NEUROLOGY, NUTRITION & DIETETICS, EPIDEMIOLOGY

SCHOLARONE™  
Manuscripts

1  
2 Title: Relations of magnesium intake to cognitive impairment and dementia among  
3  
4 participants in the Women's Health Initiative Memory Study  
5  
6  
7  
8

9 Authors' names and positions: Kenneth Lo (0000-0003-4624-2737), postdoctoral fellow,  
10 kenneth\_lo@brown.edu <sup>1,2</sup>, Qing Liu, PhD, qing\_liu@brown.edu <sup>2</sup>, Tracy Madsen, assistant  
11 professor, tracy\_madsen@brown.edu <sup>3</sup>, Steve Rapp, professor, srapp@wakehealth.edu <sup>4</sup>, Jiu-  
12 Chuan Chen, associate professor, jcchen@usc.edu <sup>5</sup>, Marian Neuhouser, professor,  
13 mneuhaus@WHI.org <sup>6</sup>, Aladdin H. Shadyab, postdoctoral fellow, aladdinhs@yahoo.com <sup>7</sup>,  
14 Lubna Pal, professor, lubna.pal@yale.edu <sup>8</sup>, Xiaochen Lin, postdoctoral fellow,  
15 xiaochen\_lin@brown.edu <sup>2</sup>, Sally Shumaker, professor, sshumake@wakehealth.edu <sup>4</sup>, JoAnn  
16 E Manson, professor, jmanson@rics.bwh.harvard.edu <sup>9</sup>, Simin Liu (0000-0002-8696-4833),  
17 professor, simin\_liu@brown.edu <sup>1,2,10</sup>  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 Address of each author: 1: Departments of Cardiology and Endocrinology, Guangdong  
31 Provincial People's Hospital, Guangdong Academy of Medical Sciences, China, 2: Centre for  
32 Global Cardiometabolic Health, Department of Epidemiology, School of Public Health,  
33 Brown University, USA, 3: Department of Emergency Medicine, Alpert Medical School,  
34 Brown University, USA, 4: School of Medicine, Wake Forest University, USA, 5: Department of  
35 Preventive Medicine, University of Southern California, USA, 6: Division of Public Health  
36 Sciences, Fred Hutchinson Cancer Research Center, USA, 7: Department of Family and  
37 Preventive Medicine, University of California, San Diego, USA, 8: School of Medicine, Yale  
38 University, USA, 9: Division of Preventive Medicine, Department of Medicine, Brigham and  
39 Women's Hospital, Harvard Medical School, 10: Departments of Surgery and Medicine,  
40 Brown University Alpert School of Medicine  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 Correspondence to: Simin Liu, Brown Centre for Global Cardiometabolic Health and  
51 Department of Epidemiology, Brown University, Providence, Rhode Island, USA  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

Objective: Dietary and supplemental magnesium (Mg) as assessed by food frequency questionnaire at baseline to examine their associations with cognitive outcomes in aging women.

Design, setting and participants: We analyzed data from postmenopausal women that enrolled in Women's Health Initiative Memory Study (WHIMS). WHIMS was subsequently extended and named WHIMS-Epidemiology of Cognitive Health (WHIMS-ECHO). WHIMS-ECHO involved the same group participants that remained in the cohort.

Main outcome measures: Physician adjudicated mild cognitive impairment (MCI) and/or probable dementia (PD).

Results: After excluding women who had extreme values of dietary energy intake, had missing or extreme BMI values, with prevalent MCI/PD at baseline, received only one cognitive assessment, or had been followed-up for less than one year, we included 6,473 of them in the analysis. With over 20 years of follow-up, 765 participants (11.8%) developed MCI or PD. When compared with the lowest quintile, the third quintile of total Mg intake was significantly associated with a 33% lower adjusted risk of combined MCI/PD (HR = 0.69, 95% CI = 0.53, 0.91, p=0.01) and MCI (HR = 0.63, 95% CI = 0.45, 0.87, p=0.01) after adjustment for every conceivable variable (demographic characteristics, diet, lifestyle, medication use and medical history).

Conclusions: Total Mg intake between the Estimated Average Requirement and the Recommended Dietary Allowances may be associated with a lower risk of composite MCI/PD and MCI. Further increment of Mg intake did not provide additional benefit. Higher Mg intake from diet should be an effective strategy in preventing cognitive decline.

Trial registration: [clinicaltrials.gov](http://clinicaltrials.gov) (NCT00685009)

#### Strengths and limitations of this study

- A large prospective cohort with long follow-up, and careful adjudication of MCI/PD events to ensure a high quality of outcome assessment.
- Lacking information on serum Mg levels in the studied population.
- The present cohort included only postmenopausal women, and the findings may not be generalizable to elder men.

#### Background

Mild cognitive impairment (MCI) involves the onset and evolution of cognitive impairments beyond those expected based on an individual's age and education but not significant enough to interfere with her or his daily activities.<sup>1</sup> Cognitive function might decline progressively over time for people with MCI, which impaired their memory, reasoning, language and visuospatial abilities. Individuals are diagnosed with dementia when their cognitive decline has interfered with daily function.<sup>2</sup>

Dementia affects approximately 47 million people worldwide, and its prevalence is expected to more than triple by 2050.<sup>3</sup> The prevalence of dementia and associated medical costs have increased dramatically in recent years in parallel with the aging population globally, which has increased the healthcare burden to communities, families and individuals.<sup>3</sup> Compared to older men, older women have a higher lifetime risk for dementia<sup>4, 5</sup> and faster progression of cognitive impairment following diagnosis.<sup>6</sup> Therefore, identifying the strategies for dementia prevention particularly those that are safe, cost-effective, and readily accessible to elderly women is of both public health and clinical significance.

Magnesium (Mg) has long been thought of to prevent vascular outcomes. Recent work has shown that magnesium may regulate N-methyl-D-aspartate (NMDA)

1  
2  
3  
4 receptors, which affect critical functions of the central nervous system including  
5  
6 neuronal development, plasticity and neurodegeneration. NMDA receptor is  
7  
8 permeable to calcium, sodium and potassium ions and can be blocked by Mg ions.<sup>7</sup>  
9  
10 While strong neurobiological data are in support of the role of Mg intake for normal  
11  
12 neuron functioning by helping to prevent the destruction of neurons resulting from  
13  
14 NMDA-induced excitotoxicity<sup>8</sup>, few prospective studies have directly examined the  
15  
16 relation between Mg intake (dietary and/or supplements) and the risk of dementia.<sup>9, 10</sup>  
17  
18 We therefore conducted a prospective investigation of the role of Mg intake in the  
19  
20 development of two constructs of cognitive decline, namely mild cognitive  
21  
22 impairment (MCI) and probable dementia (PD) among older women who participated  
23  
24 in the Women's Health Initiative Memory Study (WHIMS; 1995-2008) and were  
25  
26 followed in the WHIMS-Epidemiology of Cognitive Health Outcomes (WHIMS-  
27  
28 ECHO; 2008-onwards) Study.  
29  
30  
31  
32  
33  
34

## 35 **Methods**

### 36 *Data source*

37  
38 The WHI Memory Study (WHIMS) is an ancillary study to the WHI Hormone Trial  
39  
40 (N=27,347 for the whole trial) that was designed to assess the effect of  
41  
42 postmenopausal hormone therapy (HT) on dementia risk.<sup>11</sup> Invitation to participate  
43  
44 was sent to WHI Hormone Therapy Trial women that aged 65 to 79 years without  
45  
46 dementia at enrollment.<sup>12</sup> Following termination of the HT intervention, in WHIMS  
47  
48 (1995-2008, 7,479 participants) and subsequent WHIMS-ECHO follow-up (2008  
49  
50 onwards, ~2900 participants), there were continued annual assessments of cognitive  
51  
52 function and adjudication of all-cause dementia and MCI status. The ethical approval  
53  
54 of all protocols were obtained from the institutional review boards (IRBs) of all  
55  
56 participating institutions (40 clinical site IRBs, the coordinating center IRB and  
57  
58  
59  
60

1  
2  
3  
4 ethical review at National Institutes of Health). Written informed consent was  
5  
6 obtained from participants.  
7  
8  
9

10 Participants were eligible for inclusion in the present analysis if they completed the  
11 WHI Food Frequency Questionnaire (FFQ) and dietary supplement questionnaire at  
12 baseline. We further excluded women who had extreme values of dietary energy  
13 intake (<600 kcal or >5000 kcal), had missing or extreme BMI values (BMI<15  
14 kg/m<sup>2</sup> or BMI>50 kg/m<sup>2</sup>), women with prevalent MCI/PD at baseline and received  
15 only one Modified Mini- Mental State Examination (3MSE) for cognitive assessment.  
16  
17 Lastly, to avoid reverse causation between dietary intake and disease onset, we only  
18 included women who had been followed-up for at least one year. The details of  
19 participant selection are illustrated in **Supplementary Figure 1**.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

### 33 *Outcome Variable*

34  
35 The WHIMS and WHIMS-ECHO protocol used a multi-phase approach to identify  
36 cases of MCI and PD. From 1995 through 2007 (WHIMS), participants were screened  
37 annually in clinic by trained and certified examiners with the Modified Mini- Mental  
38 State Examination (3MSE). The 3MSE ranges from 0 to 100, and initial cut-points for  
39 further testing are 72 or lower for participants with <9 years of education, and 76 or  
40 lower for participants with 9 years or more of education. After 1<sup>st</sup> July 1998, the cut  
41 points were 80 and 88 respectively. Participants who scored below the education-  
42 adjusted 3MSE cut-point received the in-depth multi-phased evaluation,<sup>13</sup> including a  
43 battery of neuropsychologic tests, history and physical, neuropsychiatric evaluation,  
44 and an interview of friend or family member to assess functional status<sup>11</sup>.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Beginning in 2008 (WHIMS-ECHO), an annual validated cognitive test battery that



1  
2  
3  
4 included the Telephone Interview for Cognitive Status-modified (TICSm)<sup>14</sup> and other  
5  
6 validated tests of cognitive function were administered by telephone. <sup>15</sup> To justify  
7  
8 replacing 3MSE assessment with TICSm, a validation study was conducted. Results  
9  
10 showed that the 3MSE scores predicted by TICSm was highly correlated (0.82) with  
11  
12 3MSE scores,<sup>16</sup> while the transformation of WHIMS 3MSE and WHIMS-ECHO  
13  
14 TICSm data into relative percentile ranks fit the trajectories of global cognitive  
15  
16 function.<sup>17</sup> For women who were screened positive (i.e., TICSm<31) during WHIMS-  
17  
18 ECHO follow-up, a reliable and pre-identified informant was interviewed by  
19  
20 telephone using the standardized Dementia Questionnaire to assess the history of  
21  
22 cognitive and behavioral changes, functional impairments, and health events that can  
23  
24 affect cognitive functioning.<sup>18</sup>  
25  
26  
27  
28  
29

30  
31 All available participant data in both WHIMIS and WHIMS-ECHO were submitted to  
32  
33 a central adjudication committee at the WHIMS clinical coordinating center. The  
34  
35 committee had experts experienced in neurological examinations and neuropsychiatric  
36  
37 evaluations, where cases are classified as no impairment, MCI or PD. <sup>19</sup> Outcome  
38  
39 classification was based on the DSM-IV criteria for dementia <sup>20</sup> and Petersen's MCI  
40  
41 criteria<sup>1</sup> .  
42  
43  
44  
45

#### 46 *Exposure variable*

47  
48 The dietary Mg intake at baseline was derived using the baseline WHI semi-  
49  
50 quantitative food frequency questionnaire (FFQ).<sup>21</sup> The nutrient database for the WHI  
51  
52 FFQ uses the Nutrition Data Systems for Research (NDS-R, version 2005, University  
53  
54 of Minnesota Nutrition Coordinating Center, Minneapolis, MN) food and nutrient  
55  
56 database.<sup>22</sup> The data on current dietary supplements at baseline were assessed by a  
57  
58 special dietary supplement inventory interviewer-administered questionnaire.<sup>23</sup>  
59  
60

1  
2  
3  
4 Participants were asked to bring all current supplements to the WHI baseline clinic  
5  
6 visit. Staff members directly transcribed the ingredients for each supplement, which  
7  
8 has demonstrated high correlation (ranged from 0.8 to 1.0) with photo-copied labels in  
9  
10 validation study.<sup>24</sup> Total Mg intake was calculated by the summation of dietary and  
11  
12 supplemental Mg intake. To test the relationship between total Mg intake and  
13  
14 MCI/PD, levels of Mg intake were categorized into quintiles.  
15  
16

### 17 18 19 *Covariates*

20  
21 At WHI baseline, WHIMS participants completed questionnaires on various  
22  
23 information, including demographics (age, race-ethnicity), socioeconomic status  
24  
25 (education in years), lifestyle factors (diet, smoking, alcohol use, physical activity),  
26  
27 family or personal disease history (family history of diabetes or heart diseases,  
28  
29 personal history of diabetes, heart diseases, cancer or related risk factors) and  
30  
31 medication use (use of anti-inflammatory drugs, anti-hyperlipidemia drugs, anti-  
32  
33 depressants, anti-hypertensive drugs or diuretics). Height and weight were measured  
34  
35 at baseline for calculating Body Mass Index (BMI).  
36  
37  
38  
39  
40  
41

### 42 *Data analysis*

43  
44 Descriptive statistics were demonstrated by the quintiles of total magnesium intake.  
45  
46 The differences between quintiles were tested by one-way ANOVA for continuous  
47  
48 variables and chi-square test for categorical variables. To examine the relationship  
49  
50 between total Mg intake and incident MCI and/or PD, Cox proportional hazards  
51  
52 regression models were used with results presented as hazard ratios (HRs) and  
53  
54 associated 95% confidence intervals (95% CI). Non-cases were censored at the time  
55  
56 of the last follow-up (WHIMS or WHIMS-ECHO), death, or at the end of 2012 (the  
57  
58 year with the most updated data from WHIMS-ECHO), whichever came first. With  
59  
60

1  
2  
3  
4 reference to the common analysis strategies of other WHIMS studies,<sup>25-27</sup> the end-  
5  
6 point of MCI/PD was presented as a combined end-point in primary analyses. MCI  
7  
8 and PD were treated as secondary end-points respectively. The event time was  
9  
10 defined as the time of screening by global cognitive tests (either 3MS or TICSm) that  
11  
12 triggered the subsequent work-up that concluded with the central adjudication of first  
13  
14 MCI/PD. If a participant had progressed from MCI to PD, she was classified as a case  
15  
16 of PD instead of MCI. The test for linear relationship by conducted by assigning  
17  
18 median values for quintiles, then treated it as a continuous variable in regression  
19  
20 model. To examine potential non-linear relationship between Mg intake (total intake  
21  
22 or from diet only) and cognitive decline, we conducted a likelihood ratio test to  
23  
24 compare the fit of continuous models with or without quadratic terms of Mg intake. A  
25  
26 likelihood test with  $p < 0.05$  would suggest a better fit regression model by including  
27  
28 the quadratic term, hence non-linear relationship between Mg intake and cognitive  
29  
30 outcomes. To test the assumption of Cox proportional hazards model, we examined  
31  
32 all models using the Schoenfeld residual test. A sensitivity analysis was performed by  
33  
34 using dietary Mg intake only.  
35  
36  
37  
38  
39  
40  
41

42 To ensure robustness of regression analysis, we have controlled for confounders with  
43  
44 reference to previous studies of cognitive decline. Model 1 was the minimally  
45  
46 adjusted model and included age at baseline, region in U.S., race/ethnicity,  
47  
48 assignment arm of HT trial, BMI at baseline<sup>28</sup> and smoking status.<sup>29</sup> Model 2 included  
49  
50 covariates in Model 1 plus education,<sup>30</sup> dietary variables and physical activity (alcohol  
51  
52 intake, energy expenditure from recreational physical activity, total intake of vitamin  
53  
54 B6/9/12, total intake of calcium and vitamin D),<sup>27, 31-34</sup> as well as the medical history  
55  
56 and medication use (baseline self-reported status of diabetes identified by the question  
57  
58 'Did a doctor ever say that you had sugar diabetes or high blood sugar when you were  
59  
60

1  
2  
3  
4 not pregnant?''),<sup>35</sup> cardiovascular disease (includes cardiac arrest, congestive heart  
5  
6 failure, cardiac catheterization, coronary bypass surgery, angioplasty of coronary  
7  
8 arteries, carotid endarterectomy/angioplasty, atrial fibrillation or aortic aneurysm)<sup>36</sup>  
9  
10 and cancer (except for skin melanoma),<sup>37</sup> prior use of menopausal replacement  
11  
12 therapy,<sup>38</sup> personal history of hypertension,<sup>39</sup> personal history of high cholesterol  
13  
14 requiring medications,<sup>40</sup> family medical history of diabetes, family history of heart  
15  
16 attack or stroke, medication use (anti-inflammatory drugs, anti-hyperlipidemia drugs,  
17  
18 anti-depressants, anti-hypertensive drugs or diuretics at baseline).<sup>41, 42</sup> Only  
19  
20 participants with complete data were included in each regression model. All statistical  
21  
22 analyses were performed with R 3.6.0. P values less than 0.05 were considered  
23  
24 statistically significant.  
25  
26  
27  
28  
29

### 30 *Patient and public involvement*

31  
32 No patients were involved in the design process of this study, setting the research  
33  
34 question, or the outcome measures nor were they involved in the analysis,  
35  
36 interpretation, and writing of the results. With regard to the long follow-up period,  
37  
38 dissemination to these groups is not applicable.  
39  
40  
41  
42  
43

## 44 **Results**

### 45 *Participant Characteristics*

46  
47 A total of 6,473 participants were included in the analyses. The baseline  
48  
49 characteristics of participants in the WHIMS by quintiles are presented in **Table 1**.  
50  
51 Women in the highest quintiles of Mg intake tended to have, on average, longer time  
52  
53 to event/censorship, greater energy expenditure from recreational physical activity  
54  
55 and higher levels of all dietary variables as shown by one-way ANOVA. As  
56  
57 demonstrated by chi-square test, Non-Hispanic White women, participants enrolled in  
58  
59  
60

1  
2  
3  
4 controlled group of Estrogen+Progestin trial, participants with  $\geq 7$  alcohol drinks per  
5  
6 week, having a history of cardiovascular disease or hypertension, being a past smoker  
7  
8 or receiving post-college education were more prevalent to have the highest level of  
9  
10 Mg intake. The baseline characteristics of participants included (N=6473) or excluded  
11  
12 (N=1006) from the analysis was compared in **Supplementary Table 1**. Between-  
13  
14 group difference was significant for majority of variables except for the baseline age,  
15  
16 recreational physical activity, total B6 and B12 intake, prevalent cancer, use of  
17  
18 hormonal replacement therapy, treated high cholesterol, and family history of  
19  
20 diabetes/heart attack/stroke.  
21  
22

#### 23 24 25 26 *Total Magnesium intake and risk of Mild Cognitive Impairment/Probable Dementia*

27  
28 **Table 2** illustrates the association between total Mg intake and risk of MCI and/or  
29  
30 PD. A total of 505 (7.8%) women developed MCI across the increasing quintiles of  
31  
32 total Mg intake, while 395 (6.1%) women developed PD. When using the lowest  
33  
34 quintile as the referent, the third quintile of total Mg intake was associated with risk of  
35  
36 composite MCI/PD (HR = 0.69, 95% CI = 0.53, 0.91, p=0.01) in the fully adjusted  
37  
38 model. Comparing with the lowest quintile, the third (HR = 0.63, 95% CI = 0.45,  
39  
40 0.87, p=0.01), fourth (HR = 0.67, 95% CI = 0.46, 0.97, p=0.04) and fifth (HR = 0.61,  
41  
42 95% CI = 0.39, 0.96, p=0.03) quintile associated with lower risk of MCI in the fully  
43  
44 adjusted model. None of the associations between Mg intake (both continuous or  
45  
46 categorical variable) and the risk of PD were significant. The test for linear  
47  
48 relationship was insignificant in all fully adjusted models (Model 2). For the  
49  
50 association of total Mg intake with MCI/PD or MCI, adding the quadratic term of Mg  
51  
52 intake into the regression model significantly improved the model fit as shown by the  
53  
54 likelihood ratio test (both p=0.01), which indicated a non-linear relationship between  
55  
56 total Mg intake and cognitive decline. None of the models in Table 2 violated the  
57  
58  
59  
60

1  
2  
3  
4 assumption of Cox proportional hazards model.  
5  
6  
7

### 8 *Dietary Magnesium intake and risk of Mild Cognitive Impairment/Probable Dementia*

9  
10 **Table 3** illustrates the association between dietary Mg intake and risk of MCI and/or  
11 PD. None of the associations between dietary Mg intake (both categorical variable  
12 and the test for trend) and the risk of MCI and/or PD were significant in the fully  
13 adjusted model (Model 2). The test for linearity was insignificant in all regression  
14 models, while adding the quadratic term of Mg intake did not improve the model fit.  
15 None of the models in Table 3 violated the assumption of Cox proportional hazards  
16 model.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

## 28 **Discussion**

### 29 *Summary of findings*

30  
31 We examined the association between dietary Mg intake and cognitive impairment in  
32 a geographically diverse cohort of post-menopausal women in a sub-cohort of the  
33 WHI. When compared with the lowest quintile, the third quintile of total daily Mg  
34 intake (257.3-317.8 mg/day) was associated with a lower risk of composite MCI/PD  
35 and MCI after the statistical adjustment for demographic characteristics, diet,  
36 lifestyle, medication use and medical history. No association was found between Mg  
37 intake and PD. Higher Mg intake may be associated with a lower risk of mild  
38 cognitive impairment but not necessarily in a dose-response manner. The association  
39 between total Mg intake, MCI/PD and MCI were non-linear as suggested by the  
40 likelihood test. Although Mg intake from dietary source only did were not  
41 significantly associate with MCI/PD, the results appeared to be intuitive because the  
42 levels of Mg intake from dietary source was lower than the sum of dietary and  
43 supplemental source.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Comparison with previous literature*

Our findings were consistent with two previous studies that demonstrated the lowest risk cognitive decline among participants with a moderate Mg intake. Ozawa and colleagues assessed the association between self-reported dietary intake of minerals (potassium, calcium, and magnesium) and dementia risk among Japanese older adults.<sup>9</sup> The hazard ratio for the development of all-cause dementia was 0.63 (95% CI = 0.40–1.01) for the highest quartile ( $\geq 196$  mg/d) of Mg intake compared to the lowest quartile ( $\leq 147$  mg/d). For our study, the hazard ratio for the development of probable dementia was also insignificant (HR: 1.05, 95% CI = 0.48–2.29) for the highest quintile ( $> 337.6$  mg/d) of Mg intake compared to the lowest quintile ( $< 236.9$  mg/d). In another study from the Netherlands, a “U” shaped distribution in the association between Mg levels and cognition was observed such that both low ( $\leq 0.79$  mmol/L) levels (HR=1.32) and high ( $\geq 0.90$  mmol/L) serum Mg levels (HR=1.30) were associated with increased risk of all-cause dementia.<sup>43</sup> For our study, comparing with the lowest quintile, the second quintile of total Mg intake was associated with lowest risk of combined MCI/PD and MCI after adjusting for various confounders. The present findings do support total Mg intake (257.3–317.8 mg/day) between Estimated Average Requirement (estimated nutrient intake to meet the requirement of half the healthy individuals, 265mg/day for women  $> 51$  years old) and Recommended Dietary Allowances (sufficient average daily dietary intake level to meet the nutrient requirement of 97 to 98% healthy individuals, 320mg/day for women  $> 51$  years old) is optimal for preventing cognitive decline,<sup>44, 45</sup> while further increment of Mg intake did not provide additional benefit. Another observation is that total Mg intake had similar magnitude of association with MCI/PD and MCI but associated with the risk of PD without statistical significance. In other words, total Mg intake is more

1  
2  
3  
4 protective against MCI. Since we only assessed the baseline diet, it is possible that  
5  
6 long follow-up period weakened the association between Mg intake and dementia.  
7  
8  
9

### 10 *Strengths and Limitations*

11  
12 Strengths of the current analyses include the use of data from a large prospective  
13  
14 cohort with long follow-up, and the careful adjudication of MCI/PD events to ensure a  
15  
16 high quality of outcome assessment. However, some limitations of assessment of Mg  
17  
18 intake from dietary sources should be noted, such as assessing Mg intake at baseline  
19  
20 only. However, the test based on the Schoenfeld residuals were statistically  
21  
22 insignificant, therefore the impact of Mg intake on MCI and/or PD was less likely to  
23  
24 change over time. Moreover, we are lacking information on serum Mg levels in the  
25  
26 studied population. Despite the adjustment for dietary energy, assessment of dietary  
27  
28 Mg intake can be confounded with other constituents such as leafy green vegetables,  
29  
30 the primary source of dietary Mg.<sup>46</sup> In addition, previous studies have found that  
31  
32 dietary Mg intake might not strongly correlate with serum Mg levels ( $r=0.28$ ,  
33  
34  $p<0.05$ ).<sup>47</sup> That may lead to the different magnitudes of associations, such as the  
35  
36 impact of dietary/serum Mg on the risk of a disease, such as described for  
37  
38 hypertension.<sup>48</sup> Moreover, supplemental Mg intake was collected for ‘other  
39  
40 supplement mixtures’ and single supplements but not for standard multivitamins with  
41  
42 minerals which was the most common type of supplement used by WHI women.  
43  
44 Although this limitation might lead to an under-ascertainment of Mg from  
45  
46 supplements, whether it was the major flaw of this study was arguable, since the total  
47  
48 Mg intake has demonstrated significant association with MCI/PD. Last but not least,  
49  
50 the present cohort included only postmenopausal women, and the findings may not be  
51  
52 generalizable to elder men. Despite these limitations, this study adds important  
53  
54 information regarding Mg intake for cognitive benefit in postmenopausal women.  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6 *Conclusions*  
7

8 Among postmenopausal women from WHIMS with over 20 years of follow-up, total  
9 Mg intake between Estimated Average Requirement and Recommended Dietary  
10 Allowances was associated with lower risk of composite MCI/PD and MCI despite  
11  
12  
13  
14  
15 not in a dose-response manner.  
16

17  
18  
19 *Contributors:* KL, QL, TM, AHS, LP, XL, JEM, SL searched the literature; analyzed  
20 and interpreted the data; and wrote the manuscript. SR, JCC, MN, SS participated in  
21 the study design; collected, analyzed, and interpreted the data; and wrote the  
22 manuscript.  
23  
24  
25  
26  
27

28 *Funding:* The Women's Health Initiative (WHI) was funded by the National Heart,  
29 Lung, and Blood Institute, National Institutes of Health, and U.S. Department of  
30 Health and Human Services through contracts HHSN268201600018C,  
31 HHSN268201600002C, HHSN26820 1600003C, and HHSN268201600004C. The  
32 Women's Health Initiative Memory Study (WHIMS) was funded in part by Wyeth  
33 Pharmaceuticals, St. Davids, PA. The WHIMS Extension was funded by the National  
34 Institute on Aging contract HHSN26820044221C, and WHIMS-ECHO was funded  
35 by the National Institute on Aging through contracts HHSN26820044221C, and  
36 HHSN 271201100004C. The funding sources had no role in study design, data  
37 collection, data analysis, data interpretation, or the writing of this report; and in the  
38 decision to submit the manuscript for publication. The corresponding author had full  
39 access to all the data in the study and had final responsibility for the decision to  
40 submit for publication.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

57 *Ethics approval:* The WHI study was approved by the research ethics committees at  
58 each of the participating centers  
59  
60

1  
2  
3  
4 (<https://www.who.org/about/SitePages/Study%20Organization.aspx>).  
5

6 *Competing interests:* None declared.  
7

8 *Data sharing:* No additional data available.  
9

10 *Provenance and peer review:* Not commissioned; externally peer reviewed.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 1 Baseline Characteristics of Participants in The Women's Health Initiative Memory Study by quintiles of Total Mg Intake

	Mean (SD) / N (%)					p value
	Q1 (<197.4 mg/day)	Q2 (197.4-257.3 mg/day)	Q3 (257.3-317.8 mg/day)	Q4 (317.8-398.7 mg/day)	Q5 (>398.7 mg/day)	
Number of participants	1294	1295	1295	1295	1294	
Time-to-event/censored in years	9.1 (4.4)	9.6 (4.3)	9.9 (4.3)	9.8 (4.3)	9.7 (4.4)	<0.01*
Age at baseline in years	69.9 (3.7)	70.1 (3.8)	70.1 (3.8)	70.1 (3.9)	70.2 (3.9)	0.34
BMI at baseline	28.6 (5.5)	28.5 (5.3)	28.3 (5.4)	28.3 (5.3)	28.3 (5.5)	0.41
Recreational physical activity in MET-hour	9.4 (12.4)	10.5 (12.2)	11.2 (12.9)	12.3 (13.2)	13.3 (14.9)	<0.01*
Total magnesium intake in mg	153.7 (29.9)	228.2 (17.7)	287.1 (17.6)	355.3 (23)	531.1 (172.3)	<0.01*
Total B6 intake in mg	3.7 (20.3)	5.1 (22.7)	5.7 (18.2)	6.9 (21.2)	12.9 (47.6)	<0.01*
Total B9 intake in mcg	219.2 (144.3)	349.5 (227.7)	451.3 (195.4)	569.3 (215)	698.8 (278.9)	<0.01*
Total B12 intake in mcg	12 (54.5)	17.3 (83.7)	16.2 (51.9)	19.5 (54.8)	37.3 (102.9)	<0.01*
Total calcium intake in mg	632.9 (632.6)	877.6 (459.3)	1091.1 (537.7)	1335.8 (566.8)	1758.9 (686.7)	<0.01*
Total vitamin D intake in mcg	3.9 (3.9)	6.7 (4.8)	9.4 (5.3)	11.8 (5.4)	15.5 (7.1)	<0.01*
Dietary energy in kcal	1080.1 (306.1)	1375.4 (365)	1589.4 (444.6)	1845 (537.6)	2135.7 (758)	<0.01*
Region in U.S.						
Northeast	336 (26.0%)	377 (29.1%)	365 (28.2%)	333 (25.7%)	360 (27.8%)	0.17
South	278 (21.5%)	264 (20.4%)	255 (19.7%)	280 (21.6%)	238 (18.4%)	
Midwest	310 (24.0%)	310 (23.9%)	316 (24.4%)	349 (26.9%)	313 (24.2%)	
West	370 (28.6%)	344 (26.6%)	359 (27.7%)	333 (25.7%)	383 (29.6%)	
Race/Ethnicity						
Non-Hispanic White	1040 (80.6%)	1121 (86.7%)	1160 (89.6%)	1194 (92.4%)	1168 (90.5%)	<0.01*
Black or African-American	139 (10.8%)	94 (7.3%)	70 (5.4%)	45 (3.5%)	67 (5.2%)	
Hispanic/Latino	52 (4.0%)	32 (2.5%)	23 (1.8%)	15 (1.2%)	22 (1.7%)	

1						
2	Other	59 (4.6%)	46 (3.6%)	41 (3.2%)	38 (2.9%)	33 (2.6%)
3						
4	HRT Arm					
5	E-alone	285 (22.0%)	291 (22.5%)	247 (19.1%)	198 (15.3%)	227 (17.5%)
6	E-alone control	286 (22.1%)	241 (18.6%)	225 (17.4%)	248 (19.2%)	257 (19.9%)
7	E+P intervention	359 (27.7%)	374 (28.9%)	402 (31.0%)	414 (32.0%)	386 (29.8%)
8	E+P control	364 (28.1%)	389 (30%)	421 (32.5%)	435 (33.6%)	424 (32.8%)
9						
10						
11	7+ alcohol drinks per week	116 (9.0%)	151 (11.7%)	161 (12.5%)	191 (14.8%)	191 (14.8%)
12	Prevalent diabetes	107 (8.3%)	112 (8.7%)	92 (7.1%)	93 (7.2%)	103 (8.0%)
13	Prevalent cardiovascular disease	196 (15.4%)	236 (18.5%)	212 (16.6%)	198 (15.5%)	241 (18.8%)
14	Prevalent cancer	54 (4.2%)	42 (3.3%)	43 (3.3%)	50 (3.9%)	43 (3.3%)
15	Hormone Replacement Therapy					0.31
16	Never used	878 (67.9%)	913 (70.5%)	885 (68.3%)	885 (68.3%)	883 (68.2%)
17	Past user	353 (27.3%)	318 (24.6%)	329 (25.4%)	334 (25.8%)	323 (25%)
18	Current user	63 (4.9%)	64 (4.9%)	81 (6.3%)	76 (5.9%)	88 (6.8%)
19	Treated high cholesterol	220 (17.3%)	239 (18.7%)	245 (19.1%)	222 (17.4%)	225 (17.5%)
20	History of hypertension	497 (38.9%)	528 (41.1%)	498 (38.7%)	455 (35.5%)	514 (40.0%)
21	Family history of diabetes, heart attack or stroke	983 (76.0%)	999 (77.1%)	1024 (79.1%)	1003 (77.5%)	982 (75.9%)
22	Medication use <sup>a</sup>	594 (45.9%)	610 (47.1%)	592 (45.7%)	592 (45.7%)	621 (48.0%)
23	Smoking status					<0.01*
24	Never Smoked	689 (53.2%)	691 (53.4%)	707 (54.6%)	663 (51.2%)	696 (53.8%)
25	Past Smoker	488 (37.7%)	500 (38.6%)	509 (39.3%)	566 (43.7%)	534 (41.3%)
26	Current Smoker	117 (9.0%)	104 (8.0%)	79 (6.1%)	66 (5.1%)	64 (4.9%)
27	Received college education or above	622 (48.3%)	698 (54%)	795 (61.5%)	817 (63.1%)	829 (64.4%)
28						<0.01*

Q: Quintile MCI; mild cognitive impairment; PD: probable dementia; HRT: Hormone replacement therapy; E-alone: Estrogen-alone; E+P: Estrogen+Progestin \* P value < 0.05<sup>a</sup> Any use of anti-inflammatory, anti-hyperlipidemic, anti-depressant, anti-hypertensive or diuretic drug

Table 2 Associations of total magnesium intake with the risk of mild cognitive impairment and/or probable dementia

	Cases/Total	N=6,473		N=6,183	
		Model 1 HR (95% CI)	p value	Model 2 HR (95% CI)	p
		a		b	value
<b>MCI/PD</b>					
Total magnesium intake by quintiles			0.01* <sup>c</sup>		0.42 <sup>c</sup>
Q1 (<197.4 mg/day)	184/1294	Ref		Ref	
Q2 (197.4-257.3 mg/day)	157/1295	0.82 (0.66, 1.02)	0.08	0.86 (0.68, 1.08)	0.20
Q3 (257.3-317.8 mg/day)	134/1295	0.65 (0.52, 0.81)	<0.01***	0.69 (0.53, 0.91)	0.01*
Q4 (317.8-398.7 mg/day)	142/1295	0.73 (0.59, 0.92)	0.01*	0.77 (0.57, 1.05)	0.10
Q5 (>398.7 mg/day)	148/1294	0.73 (0.59, 0.91)	0.01*	0.81 (0.57, 1.17)	0.27
<b>Mild Cognitive Impairment</b>					
Total magnesium intake by quintiles			<0.01** <sup>c</sup>		0.06 <sup>c</sup>
Q1 (<197.4 mg/day)	131/1294	Ref		Ref	
Q2 (197.4-257.3 mg/day)	106/1295	0.79 (0.61, 1.02)	0.07	0.77 (0.58, 1.03)	0.08
Q3 (257.3-317.8 mg/day)	87/1295	0.61 (0.47, 0.81)	<0.01**	0.63 (0.45, 0.87)	0.01*
Q4 (317.8-398.7 mg/day)	91/1295	0.71 (0.54, 0.93)	0.01*	0.67 (0.46, 0.97)	0.04*
Q5 (>398.7 mg/day)	90/1294	0.66 (0.50, 0.86)	<0.01**	0.61 (0.39, 0.96)	0.03*
<b>Probable dementia</b>					
Total magnesium intake by quintiles			0.76 <sup>c</sup>		0.29 <sup>c</sup>
Q1 (<197.4 mg/day)	81/1294	Ref		Ref	
Q2 (197.4-257.3 mg/day)	77/1295	0.89 (0.65, 1.22)	0.48	1.02 (0.73, 1.44)	0.90
Q3 (257.3-317.8 mg/day)	72/1295	0.76 (0.55, 1.05)	0.10	0.87 (0.60, 1.28)	0.49
Q4 (317.8-398.7 mg/day)	80/1295	0.86 (0.63, 1.18)	0.36	1.06 (0.69, 1.63)	0.80
Q5 (>398.7 mg/day)	85/1294	0.92 (0.68, 1.26)	0.61	1.25 (0.75, 2.08)	0.39

<sup>a</sup> Model 1 adjustment: age at baseline, region in U.S., assignment of hormone therapy trial, BMI at baseline, and smoking status.

<sup>b</sup> Model 2 adjustment: covariates in model 1 along with race/ethnicity, education, alcohol intake, energy expenditure from recreational physical activity, total intake of vitamin B6/9/12, total intake of calcium and vitamin D, dietary energy in kcal, baseline status of diabetes/cardiovascular disease/cancer, prior use of hormone replacement therapy, personal history of hypertension, personal history of high cholesterol requiring medications, family medical history of diabetes, family history of heart attack or stroke, use of anti-inflammatory drug, anti-hyperlipidemia drug, anti-depressant, anti-hypertensive drug or the use of diuretics at baseline <sup>c</sup> p-value for trend. \* $p < 0.05$ . \*\* $p < 0.01$  \*\*\* $p < 0.001$ .

Table 3 Associations of dietary magnesium intake with the risk of mild cognitive impairment and/or probable dementia

	Cases/Total	N=6,473		N=6,183	
		Model 1 HR (95% CI) <sup>a</sup>	p value	Model 2 HR (95% CI) <sup>b</sup>	p value
<b>MCI/PD</b>					
Dietary magnesium intake by quintiles			0.03 <sup>*c</sup>		0.34 <sup>c</sup>
Q1 (<170.1 mg/day)	168/1294	Ref		Ref	
Q2 (170.1-216.1 mg/day)	160/1295	0.93 (0.75, 1.16)	0.53	0.96 (0.76, 1.22)	0.73
Q3 (216.1-263.2 mg/day)	144/1295	0.84 (0.67, 1.05)	0.13	0.86 (0.66, 1.12)	0.26
Q4 (263.2-323.3 mg/day)	144/1295	0.79 (0.63, 0.99)	0.04 <sup>*</sup>	0.84 (0.63, 1.13)	0.25
Q5 (>323.3 mg/day)	149/1294	0.81 (0.65, 1.01)	0.07	0.86 (0.59, 1.24)	0.42
<b>Mild Cognitive Impairment</b>					
Dietary magnesium intake by quintiles			0.01 <sup>*c</sup>		0.11 <sup>c</sup>
Q1 (<170.1 mg/day)	118/1294	Ref		Ref	
Q2 (170.1-216.1 mg/day)	111/1295	0.95 (0.73, 1.23)	0.69	0.97 (0.73, 1.29)	0.85
Q3 (216.1-263.2 mg/day)	99/1295	0.87 (0.66, 1.14)	0.32	0.85 (0.62, 1.17)	0.33
Q4 (263.2-323.3 mg/day)	89/1295	0.76 (0.57, 1.00)	0.05	0.78 (0.55, 1.13)	0.19
Q5 (>323.3 mg/day)	88/1294	0.73 (0.55, 0.97)	0.03 <sup>*</sup>	0.71 (0.45, 1.14)	0.16
<b>Probable dementia</b>					
Dietary magnesium intake by quintiles			0.92 <sup>c</sup>		0.66 <sup>c</sup>
Q1 (<170.1 mg/day)	76/1294	Ref		Ref	
Q2 (170.1-216.1 mg/day)	77/1295	0.95 (0.69, 1.31)	0.75	1.00 (0.70, 1.42)	0.98
Q3 (216.1-263.2 mg/day)	71/1295	0.86 (0.62, 1.19)	0.37	0.97 (0.66, 1.41)	0.86
Q4 (263.2-323.3 mg/day)	86/1295	0.97 (0.71, 1.33)	0.86	1.11 (0.74, 1.67)	0.61
Q5 (>323.3 mg/day)	85/1294	0.96 (0.70, 1.31)	0.79	1.08 (0.64, 1.81)	0.78

<sup>a</sup> Model 1 adjustment: age at baseline, region in U.S., assignment of hormone therapy trial, BMI at baseline, and smoking status. <sup>b</sup> Model 2 adjustment: covariates in model 1 along with race/ethnicity, education, alcohol intake, energy expenditure from recreational physical activity, total intake of vitamin B6/9/12, total intake of calcium and vitamin D, dietary energy in kcal, baseline status of diabetes/cardiovascular disease/cancer, prior use of hormone replacement therapy, personal history of hypertension, personal history of high cholesterol requiring medications, family medical history of diabetes, family history of heart attack or stroke, use of anti-inflammatory drug, anti-hyperlipidemia drug, anti-depressant, anti-hypertensive drug or the use of diuretics at baseline <sup>c</sup> p-value for trend. \* $p < 0.05$ . \*\* $p < 0.01$  \*\*\* $p < 0.001$

## Reference

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol*. 1999;56:303-308.
2. Arevalo-Rodriguez I, Smailagic N, Roque IFM, et al. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). *Cochrane Database Syst Rev*. 2015:CD010783.
3. World Health Organization. The Epidemiology and Impact of Dementia Current State and Future Trends. 2015.
4. Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. *Neurology*. 1999;53:1992-1997.
5. Chene G, Beiser A, Au R, et al. Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. *Alzheimers Dement*. 2015;11:310-320.
6. Lin KA, Choudhury KR, Rathakrishnan BG, et al. Marked gender differences in progression of mild cognitive impairment over 8 years. *Alzheimers Dement*. 2015;1:103-110.
7. Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development. An update. *Drug News Perspect*. 1998;11:523-569.
8. Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. *Neurochem Int*. 2004;45:583-595.
9. Ozawa M, Ninomiya T, Ohara T, et al. Self-reported dietary intake of potassium, calcium, and magnesium and risk of dementia in the Japanese: the Hisayama Study. *J Am Geriatr Soc*. 2012;60:1515-1520.
10. Tzeng NS, Chung CH, Lin FH, et al. Magnesium oxide use and reduced risk of dementia: a retrospective, nationwide cohort study in Taiwan. *Curr Med Res Opin*. 2018;34:163-169.
11. Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. *Controlled Clin Trials*. 1998;19:604-621.
12. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA*. 2003;289:2663-2672.
13. Malouf R, Areosa Sastre A. Vitamin B12 for cognition. *Cochrane Database Syst Rev*. 2003:CD004326.
14. Welsh KA, Breitner J, Magruder-Habib KM. Detection of dementia in the elderly using the telephone interview for cognitive status. *Neuropsychiatry Neuropsychol Behav Neurol*. 1993;6:103-110.
15. Rapp SR, Legault C, Espeland MA, et al. Validation of a cognitive assessment battery administered over the telephone. *J Am Geriatr Soc*. 2012;60:1616-1623.
16. Arnold AM, Newman AB, Dermond N, Haan M, Fitzpatrick A. Using telephone and informant

- assessments to estimate missing Modified Mini-Mental State Exam scores and rates of cognitive decline. The cardiovascular health study. *Neuroepidemiology*. 2009;33:55-65.
17. Espeland MA, Chen JC, Weitlauf J, et al. Trajectories of Relative Performance with 2 Measures of Global Cognitive Function. *J Am Geriatr Soc*. 2018; 1575-1580.
18. Ellis RJ, Jan K, Kawas C, et al. Diagnostic validity of the dementia questionnaire for Alzheimer disease. *Arch Neurol*. 1998;55:360-365.
19. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA*. 2003;289:2651-2662.
20. Hogervorst E, Bandelow S, Combrinck M, Irani SR, Smith AD. The validity and reliability of 6 sets of clinical criteria to classify Alzheimer's disease and vascular dementia in cases confirmed post-mortem: added value of a decision tree approach. *Dement Geriatr Cogn Dis*. 2003;16:170-180.
21. Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T. Measurement characteristics of the Women's Health Initiative food frequency questionnaire. *Ann Epidemiol*. 1999;9:178-187.
22. Schakel SF, Sievert YA, Buzzard IM. Sources of data for developing and maintaining a nutrient database. *J Am Diet Assoc*. 1988;88:1268-1271.
23. Neuhouser ML, Wassertheil-Smoller S, Thomson C, et al. Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts. *Arch Intern Med*. 2009;169:294-304.
24. Patterson RE, Levy L, Tinker LF, Kristal AR. Evaluation of a simplified vitamin supplement inventory developed for the Women's Health Initiative. *Public Health Nutr*. 1999;2:273-276.
25. Ammann EM, Pottala JV, Robinson JG, Espeland MA, Harris WS. Erythrocyte omega-3 fatty acids are inversely associated with incident dementia: Secondary analyses of longitudinal data from the Women's Health Initiative Memory Study (WHIMS). *Prostaglandins Leukot Essent Fatty Acids*. 2017;121:68-75.
26. Hayden KM, Beavers DP, Steck SE, et al. The association between an inflammatory diet and global cognitive function and incident dementia in older women: The Women's Health Initiative Memory Study. *Alzheimers Dement*. 2017;13:1187-1196.
27. Agnew-Blais JC, Wassertheil-Smoller S, Kang JH, et al. Folate, vitamin B-6, and vitamin B-12 intake and mild cognitive impairment and probable dementia in the Women's Health Initiative Memory Study. *J Acad Nutr Diet*. 2015;115:231-241.
28. Moga DC, Abner EL, Brouwer ES. Dementia and "obesity paradox": is this for real or are we missing something? An epidemiologist's perspective. *J Am Med Dir Assoc*. 2015;16:78-79.
29. Batty GD, Shipley MJ, Kvaavik E, et al. Biomarker assessment of tobacco smoking exposure and risk of dementia death: pooling of individual participant data from 14 cohort studies. *J Epidemiol Community Health*. 2018;72:513-515.
30. Xu W, Tan L, Wang HF, et al. Education and Risk of Dementia: Dose-Response Meta-Analysis of




- 1  
2  
3  
4 Prospective Cohort Studies. *Mol Neurobiol*. 2016;53:3113-3123.
- 5 31. Littlejohns TJ, Henley WE, Lang IA, et al. Vitamin D and the risk of dementia and Alzheimer  
6 disease. *Neurology*. 2014;83:920-928.
- 7  
8 32. Kern J, Kern S, Blenow K, et al. Calcium supplementation and risk of dementia in women with  
9 cerebrovascular disease. *Neurology*. 2016;87:1674-1680.
- 10  
11 33. Ilomaki J, Jakanovic N, Tan EC, Lonroos E. Alcohol Consumption, Dementia and Cognitive  
12 Decline: An Overview of Systematic Reviews. *Curr Clin Pharmacol*. 2015;10:204-212.
- 13  
14 34. Blondell SJ, Hammersley-Mather R, Veerman JL. Does physical activity prevent cognitive  
15 decline and dementia?: A systematic review and meta-analysis of longitudinal studies. *Bmc Public*  
16 *Health*. 2014;14:510.
- 17  
18 35. Espeland MA, Brinton RD, Hugenschmidt C, et al. Impact of Type 2 Diabetes and  
19 Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women.  
20 *Diabetes Care*. 2015;38:2316-2324.
- 21  
22  
23 36. Eriksson UK, Bennet AM, Gatz M, Dickman PW, Pedersen NL. Nonstroke cardiovascular disease  
24 and risk of Alzheimer disease and dementia. *Alzheimer Dis Assoc Disord*. 2010;24:213-219.
- 25  
26 37. Ganguli M. Cancer and Dementia: It's Complicated. *Alzheimer Dis Assoc Disord*. 2015;29:177-  
27 182.
- 28  
29 38. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects  
30 on cognitive function and dementia. *JAMA*. 1998;279:688-695.
- 31  
32 39. Peters R, Beckett N. Hypertension, dementia, and antihypertensive treatment: implications for  
33 the very elderly. *Curr Hypertens Rep*. 2009;11:277-282.
- 34  
35 40. Reitz C. Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms  
36 behind the associations. *J Alzheimers Dis*. 2012;30 Suppl 2:S127-145.
- 37  
38 41. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. *Lancet*.  
39 2000;356:1627-1631.
- 40  
41 42. Tully PJ, Hanon O, Cosh S, Tzourio C. Diuretic antihypertensive drugs and incident dementia  
42 risk: a systematic review, meta-analysis and meta-regression of prospective studies. *J Hypertens*.  
43 2016;34:1027-1035.
- 44  
45 43. Kieboom BCT, Licher S, Wolters FJ, et al. Serum magnesium is associated with the risk of  
46 dementia. *Neurology*. 2017;89:1716-1722.
- 47  
48 44. Bergman C, Gray-Scott D, Chen JJ, Meacham S. What is next for the Dietary Reference Intakes  
49 for bone metabolism related nutrients beyond calcium: phosphorus, magnesium, vitamin D, and  
50 fluoride? *Crit Rev Food Sci Nutr*. 2009;49:136-144.
- 51  
52 45. Murphy SP, Poos MI. Dietary Reference Intakes: summary of applications in dietary  
53 assessment. *Public Health Nutr*. 2002;5:843-849.
- 54  
55 46. Chen GC, Koh WP, Yuan JM, Qin LQ, van Dam RM. Green leafy and cruciferous vegetable  
56 consumption and risk of type 2 diabetes: results from the Singapore Chinese Health Study and  
57 meta-analysis. *Br J Nutr*. 2018:1-11.
- 58  
59  
60

- 1  
2  
3 47. Akizawa Y, Koizumi S, Itokawa Y, et al. Daily magnesium intake and serum magnesium  
4 concentration among Japanese people. *J Epidemiol*. 2008;18:151-159.  
5  
6 48. Han H, Fang X, Wei X, et al. Dose-response relationship between dietary magnesium intake,  
7 serum magnesium concentration and risk of hypertension: a systematic review and meta-analysis  
8 of prospective cohort studies. *Nutr J*. 2017;16:26.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Supplementary Figure 1 Identification of an Analytical Cohort from the Women's Health Initiative Memory Study (WHI-MS)



Supplementary Table 1 Baseline Characteristics of Participants Included or Excluded from Analysis

	Mean (SD) / N (%)		
	Excluded	Included	p value
Number of participants	1006	6473	
Time-to-event/censored in years	5.5 (5.3)	9.6 (4.3)	<0.01*
Age at baseline in years	70.3 (3.9)	70.1 (3.8)	0.05
BMI at baseline	29.5 (7.5)	28.4 (5.4)	<0.01*
Recreational physical activity in MET-hour	10.7 (13.8)	11.3 (13.2)	0.18
Total magnesium intake in mg	251 (162.1)	311.1 (151.2)	<0.01*
Total B6 intake in mg	6.1 (21)	6.8 (28.4)	0.44
Total B9 intake in mcg	374.7 (272.4)	457.6 (273.5)	<0.01*
Total B12 intake in mcg	18.2 (63.6)	20.5 (73)	0.36
Total calcium intake in mg	871.3 (689.7)	1139.2 (698.8)	<0.01*
Total vitamin D intake in mcg	7.2 (6.5)	9.5 (6.7)	<0.01*
Dietary energy in kcal	1344.9 (976.7)	1605.1 (625.3)	<0.01*
Region in U.S.			
● Northeast	234 (23.3%)	1771 (27.4%)	<0.01*
● South	263 (26.1%)	1315 (20.3%)	
● Midwest	208 (20.7%)	1598 (24.7%)	
● West	301 (29.9%)	1789 (27.6%)	
Race/Ethnicity			<0.01*
● Non-Hispanic White	810 (80.7%)	5683 (88.0%)	
● Black or African-American	120 (12.0%)	415 (6.4%)	
● Hispanic/Latino	35 (3.5%)	144 (2.2%)	
● Other	39 (3.9%)	217 (3.4%)	
HRT Arm			<0.01*
● E-alone	221 (22.0%)	1248 (19.3%)	
● E-alone control	227 (22.6%)	1257 (19.4%)	
● E+P intervention	289 (28.7%)	1935 (29.9%)	
● E+P control	269 (26.7%)	2033 (31.4%)	
7+ alcohol drinks per week	83 (8.5%)	810 (12.6%)	<0.01*
Prevalent diabetes	120 (12.0%)	507 (7.8%)	<0.01*
Prevalent cardiovascular disease	204 (20.8%)	1083 (17.0%)	<0.01*
Prevalent cancer	35 (3.6%)	232 (3.6%)	0.93
Hormone Replacement Therapy			0.57
● Never used	702 (69.8%)	4444 (68.7%)	
● Past user	254 (25.2%)	1657 (25.6%)	
● Current user	50 (5.0%)	372 (5.7%)	
Treated high cholesterol	194 (19.8%)	1151 (18.0%)	0.16
History of hypertension	424 (43.4%)	2492 (38.8%)	0.01*

1				
2	Family history of diabetes, heart attack or			
3	stroke	768 (76.3%)	4991 (77.1%)	0.59
4				
5	Medication use <sup>a</sup>	510 (50.7%)	3009 (46.5%)	0.01*
6	Smoking status			<0.01*
7				
8	● Never Smoked	463 (51.7%)	3446 (53.2%)	
9	● Past Smoker	333 (37.2%)	2597 (40.1%)	
10				
11	● Current Smoker	99 (11.1%)	430 (6.6%)	
12	Received college education or above	514 (51.2%)	3761 (58.3%)	<0.01*
13	<hr/>			

MCI: mild cognitive impairment; PD: probable dementia; HRT: Hormone replacement therapy; E-alone: Estrogen-alone;E+P:Estrogen+Progestin

<sup>a</sup> P value < 0.05 <sup>a</sup> Any use of anti-inflammatory, anti-hyperlipidemic, anti-depressant, anti-hypertensive or diuretic drug

1 STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	4
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-6
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-8
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	8
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8-9
		(b) Give reasons for non-participation at each stage	14
		(c) Consider use of a flow diagram	14
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9
		(b) Indicate number of participants with missing data for each variable of interest	14
		(c) Summarise follow-up time (eg, average and total amount)	15
Outcome data	15*	Report numbers of outcome events or summary measures over time	17-18
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear	17-18

		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	17-18
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	10-12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

\*Give information separately for exposed and unexposed groups.

# BMJ Open

## Relations of magnesium intake to cognitive impairment and dementia among participants in the Women's Health Initiative Memory Study: a prospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030052.R2
Article Type:	Research
Date Submitted by the Author:	30-Jul-2019
Complete List of Authors:	Lo, Kenneth; Brown University, Liu, Qing; Brown University Madsen, Tracy; Brown University Rapp, Steve; Wake Forest University Chen, Jiu-Chiuan; University of Southern California Neuhouser, Marian; Fred Hutchinson Cancer Research Center Shadyab, Aladdin; University of California San Diego Pal, Lubna; Yale University Lin, Xiaochen; Brown University Shumaker, Sally; Wake Forest University Manson, JoAnn; Brigham and Women's Hospital Liu, Prof. Simin; Brown University
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Geriatric medicine
Keywords:	Dementia < NEUROLOGY, NUTRITION & DIETETICS, EPIDEMIOLOGY

SCHOLARONE™  
Manuscripts



1  
2 Title: Relations of magnesium intake to cognitive impairment and dementia among  
3  
4 participants in the Women's Health Initiative Memory Study: a prospective cohort study  
5  
6  
7

8  
9 Authors' names and positions: Kenneth Lo (0000-0003-4624-2737), postdoctoral fellow,  
10 kenneth\_lo@brown.edu <sup>1,2</sup>, Qing Liu, PhD, qing\_liu@brown.edu <sup>2</sup>, Tracy Madsen, assistant  
11 professor, tracy\_madsen@brown.edu <sup>3</sup>, Steve Rapp, professor, srapp@wakehealth.edu <sup>4</sup>, Jiu-  
12 Chuan Chen, associate professor, jcchen@usc.edu <sup>5</sup>, Marian Neuhouser, professor,  
13 mneuhaus@WHI.org <sup>6</sup>, Aladdin H. Shadyab, postdoctoral fellow, aladdinhs@yahoo.com <sup>7</sup>,  
14 Lubna Pal, professor, lubna.pal@yale.edu <sup>8</sup>, Xiaochen Lin, postdoctoral fellow,  
15 xiaochen\_lin@brown.edu <sup>2</sup>, Sally Shumaker, professor, sshumake@wakehealth.edu <sup>4</sup>, JoAnn  
16 E Manson, professor, jmanson@rics.bwh.harvard.edu <sup>9</sup>, Simin Liu (0000-0002-8696-4833),  
17 professor, simin\_liu@brown.edu <sup>1,2,10</sup>  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 Address of each author: 1: Departments of Cardiology and Endocrinology, Guangdong  
31 Provincial People's Hospital, Guangdong Academy of Medical Sciences, China, 2: Centre for  
32 Global Cardiometabolic Health, Department of Epidemiology, School of Public Health,  
33 Brown University, USA, 3: Department of Emergency Medicine, Alpert Medical School,  
34 Brown University, 4: School of Medicine, Wake Forest University, USA, 5: Department of  
35 Preventive Medicine, University of Southern California, USA, 6: Division of Public Health  
36 Sciences, Fred Hutchinson Cancer Research Center, USA, 7: Department of Family and  
37 Preventive Medicine, University of California, San Diego, USA, 8: School of Medicine, Yale  
38 University, USA, 9: Division of Preventive Medicine, Department of Medicine, Brigham and  
39 Women's Hospital, Harvard Medical School, 10: Departments of Surgery and Medicine,  
40 Brown University Alpert School of Medicine  
41  
42  
43  
44  
45  
46  
47  
48

49 Correspondence to: Correspondence to: Dr. Kenneth Lo or Professor Simin Liu, Departments  
50 of Cardiology and Endocrinology, Guangdong Provincial People's Hospital, Guangdong  
51 Academy of Medical Sciences, China  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objective:** To examine the associations of dietary and supplemental magnesium (Mg) as assessed by a semi-quantitative food frequency questionnaire with cognitive outcomes in aging women.

**Design:** A Prospective Cohort Study of participants enrolled in the Women's Health Initiative Memory Study (WHIMS) which extended and named WHIMS-Epidemiology of Cognitive Health (WHIMS-ECHO).

**Setting:** 40 Clinical Centers in United States.

**Participants:** Postmenopausal women aged 65 to 79 years without dementia at enrolment.

**Main outcome measures:** Physician adjudicated mild cognitive impairment (MCI) and/or probable dementia (PD).

**Results:** After excluding 1,006 women who had extreme values of dietary energy intake, had missing or extreme BMI values, with prevalent MCI/PD at baseline, received only one cognitive assessment, or had been followed-up for less than one year. During > 20 years of follow-up, 765 (11.8%) out of 6,473 participants developed MCI/PD. For MCI/PD and MCI, the risks tended to be lower among participants in quintiles Q2 to Q5 of Mg consumption compared with those in the lowest quintile.

Participants in Q3 had a significant lower risk of MCI/PD (HR = 0.69, 95% CI 0.53-0.91) and MCI (0.63, 0.45-0.87), after adjustment for covariates of demographics, diet, lifestyle, medication use, and medical history. No significant association was observed between total Mg intake and PD. The association between total Mg intake, MCI/PD and MCI were non-linear as suggested by the likelihood test.

**Conclusions:** Total Mg intake between the Estimated Average Requirement and the Recommended Dietary Allowances may associate with a lower risk of MCI/PD and MCI.

**Trial registration:** [clinicaltrials.gov](http://clinicaltrials.gov) (NCT00685009)

#### Strengths and limitations of this study

- A large prospective cohort with long follow-up, and careful adjudication of MCI/PD events to ensure a high quality of outcome assessment.
- Lacking information on serum Mg levels in the studied population.
- The present cohort included only postmenopausal women, and the findings may not be generalizable to elder men.

#### Background

Mild cognitive impairment (MCI) involves the onset and evolution of cognitive impairments beyond those expected based on an individual's age and education but not significant enough to interfere with her or his daily activities.(1) Cognitive function might decline progressively over time for people with MCI, which would impair their memory, reasoning, language and visuospatial abilities. Individuals are diagnosed with dementia when their cognitive decline has interfered with daily function.(2) Dementia affects approximately 47 million people worldwide, and its prevalence is expected to more than triple by 2050.(3) The prevalence of dementia and associated medical costs have increased dramatically in recent years in parallel with the aging population globally, which has increased the healthcare burden to communities, families and individuals.(3) Compared to older men, older women have a higher lifetime risk for dementia(4, 5) and faster progression of cognitive impairment following diagnosis.(6) Therefore, identifying the strategies for dementia prevention particularly those that are safe, cost-effective, and readily accessible to elderly women is of both public health and clinical significance.

Magnesium (Mg) has long been thought of to prevent vascular outcomes. Recent work has shown that magnesium may regulate N-methyl-D-aspartate (NMDA)

1  
2  
3  
4 receptors, which affect critical functions of the central nervous system including  
5  
6 neuronal development, plasticity and neurodegeneration. NMDA receptor is  
7  
8 permeable to calcium, sodium and potassium ions and can be blocked by Mg ions.(7)  
9  
10 While strong neurobiological data are in support of the role of Mg intake for normal  
11  
12 neuron functioning by helping to prevent the destruction of neurons resulting from  
13  
14 NMDA-induced excitotoxicity(8), few prospective studies have directly examined the  
15  
16 relation between Mg intake (dietary and/or supplements) and the risk of dementia.(9,  
17  
18 10) We therefore conducted a prospective investigation of the role of Mg intake in the  
19  
20 development of two constructs of cognitive decline, namely mild cognitive  
21  
22 impairment (MCI) and probable dementia (PD) among older women who participated  
23  
24 in the Women's Health Initiative Memory Study (WHIMS; 1995-2008) and were  
25  
26 followed in the WHIMS-Epidemiology of Cognitive Health Outcomes (WHIMS-  
27  
28 ECHO; 2008-onwards) Study.  
29  
30  
31  
32  
33  
34

## 35 **Methods**

### 36 *Data source*

37  
38 The WHI Memory Study (WHIMS) is an ancillary study to the WHI Hormone Trial  
39  
40 (N=27,347 for the whole trial) that was designed to assess the effect of  
41  
42 postmenopausal hormone therapy (HT) on dementia risk.(11) Invitation to participate  
43  
44 was sent to women in the WHI Hormone Therapy Trial who were aged 65 to 79 years  
45  
46 and without dementia at enrolment.(12) Following the termination of the HT  
47  
48 intervention, the WHIMS (1995-2008, 7,479 participants) and subsequent WHIMS-  
49  
50 Epidemiology of Cognitive Health (ECHO) follow-up (2008 onwards, ~2900  
51  
52 participants) continued annual assessments of cognitive function and adjudication of  
53  
54 all-cause dementia and MCI status. The ethical approval of all protocols was obtained  
55  
56 from the institutional review boards (IRBs) of all participating institutions (40 clinical  
57  
58  
59  
60

1  
2  
3  
4 site IRBs, the coordinating center IRB and ethical review at National Institutes of  
5  
6 Health). Written informed consent was obtained from participants.  
7  
8  
9

10 Participants were eligible for inclusion in the present analysis if they completed the  
11  
12 WHI Food Frequency Questionnaire (FFQ) and dietary supplement questionnaire at  
13  
14 baseline. We further excluded women who had implausible dietary energy intake  
15  
16 (<600 kcal or >5000 kcal), missing or extreme BMI values (BMI<15 kg/m<sup>2</sup> or  
17  
18 BMI>50 kg/m<sup>2</sup>), and prevalent MCI/PD at baseline, or received only one Modified  
19  
20 Mini- Mental State Examination (3MSE) for cognitive assessment. Lastly, to avoid  
21  
22 reverse causation between dietary intake and disease onset, we only included women  
23  
24 who had been followed-up for at least one year. The detailed participant selection is  
25  
26 illustrated in **Supplementary Figure 1**.  
27  
28  
29  
30  
31  
32

### 33 *Outcome Variable*

34  
35 The WHIMS and WHIMS-ECHO protocol used a multi-phase approach to identify  
36  
37 cases of MCI and PD. From 1995 through 2007 (WHIMS), participants were screened  
38  
39 annually in clinic by trained and certified examiners using the Modified Mini- Mental  
40  
41 State Examination (3MSE). The 3MSE ranges from 0 to 100, and the initial cut-points  
42  
43 for further testing were 72 or lower for participants with <9 years of education, and 76  
44  
45 or lower for participants with 9 years or more of education. After 1<sup>st</sup> July 1998, the cut  
46  
47 points were 80 and 88, respectively. Participants who scored below the education-  
48  
49 adjusted 3MSE cut-points received the in-depth multi-phased evaluation,(13)  
50  
51 including a battery of neuropsychological tests, history and physical, neuropsychiatric  
52  
53 evaluation, and an interview of friend or family member to assess functional  
54  
55 status(11).  
56  
57  
58  
59  
60

1  
2  
3  
4 Beginning in 2008 (WHIMS-ECHO), an annual validated cognitive test battery that  
5  
6 included the Telephone Interview for Cognitive Status-modified (TICSm)(14) and  
7  
8 other validated tests of cognitive function were administered by telephone. (15) To  
9  
10 justify replacing 3MSE assessment with TICSm, a validation study was conducted.  
11  
12 Results showed that the 3MSE scores predicted by TICSm was highly correlated  
13  
14 (0.82) with 3MSE scores,(16) while the transformation of WHIMS 3MSE and  
15  
16 WHIMS-ECHO TICSm data into relative percentile ranks fit the trajectories of global  
17  
18 cognitive function.(17) For women who were screened positive (i.e., TICSm<31)  
19  
20 during WHIMS-ECHO follow-up, a reliable and pre-identified informant was  
21  
22 interviewed by telephone using the standardized Dementia Questionnaire to assess the  
23  
24 history of cognitive and behavioral changes, functional impairments, and health  
25  
26 events that can affect cognitive functioning.(18)  
27  
28  
29  
30  
31  
32

33 All available participant data in both WHIMIS and WHIMS-ECHO were submitted to  
34  
35 a central adjudication committee at the WHIMS clinical coordinating center. The  
36  
37 committee had experts experienced in neurological examinations and neuropsychiatric  
38  
39 evaluations, where cases are classified as no impairment, MCI or PD. (19) Outcome  
40  
41 classification was based on the DSM-IV criteria for dementia (20) and Petersen's  
42  
43 MCI criteria(1) .  
44  
45  
46  
47  
48

#### 49 *Exposure variable*

50  
51 The dietary Mg intake at baseline was derived using the baseline WHI semi-  
52  
53 quantitative food frequency questionnaire (FFQ).(21) The nutrient database for the  
54  
55 WHI FFQ uses the Nutrition Data Systems for Research (NDS-R, version 2005,  
56  
57 University of Minnesota Nutrition Coordinating Center, Minneapolis, MN) food and  
58  
59 nutrient database.(22) The data on current dietary supplements at baseline were  
60

1  
2  
3  
4 assessed by a special dietary supplement inventory interviewer-administered  
5  
6 questionnaire.(23) Participants were asked to bring all current supplements to the  
7  
8 WHI baseline clinic visit. Staff members directly transcribed the ingredients for each  
9  
10 supplement, which has demonstrated high correlation (ranged from 0.8 to 1.0) with  
11  
12 photo-copied labels in validation study.(24) Total Mg intake was calculated by the  
13  
14 summation of dietary and supplemental Mg intake. To test the relationship between  
15  
16 total Mg intake and MCI/PD, levels of Mg intake were categorized into quintiles.  
17  
18  
19  
20  
21

### 22 *Covariates*

23  
24 At WHI baseline, WHIMS participants completed questionnaires on various  
25  
26 information, including demographics (age, race-ethnicity), socioeconomic status  
27  
28 (education in years), lifestyle factors (diet, smoking, alcohol use, physical activity),  
29  
30 family or personal disease history (family history of diabetes or heart diseases,  
31  
32 personal history of diabetes, heart diseases, cancer or related risk factors) and  
33  
34 medication use (use of anti-inflammatory drugs, anti-hyperlipidemia drugs, anti-  
35  
36 depressants, anti-hypertensive drugs or diuretics). Height and weight were measured  
37  
38 at baseline for calculating Body Mass Index (BMI).  
39  
40  
41  
42  
43  
44  
45

### 46 *Data analysis*

47  
48 Descriptive statistics were demonstrated by the quintiles of total magnesium intake.  
49  
50 The differences between quintiles were tested by one-way ANOVA for continuous  
51  
52 variables and chi-square test for categorical variables. To examine the relationship  
53  
54 between total Mg intake and incident MCI and/or PD, Cox proportional hazards  
55  
56 regression models were used with results presented as hazard ratios (HRs) and  
57  
58 associated 95% confidence intervals (95% CI). Non-cases were censored at the time  
59  
60 of the last follow-up (WHIMS or WHIMS-ECHO), death, or at the end of 2012 (the

1  
2  
3  
4 year with the most updated data from WHIMS-ECHO), whichever came first. With  
5  
6 reference to the common analysis strategies of other WHIMS studies,(25-27) the end-  
7  
8 point of MCI/PD was presented as a combined end-point in primary analyses. MCI  
9  
10 and PD were treated as secondary end-points respectively. The event time was  
11  
12 defined as the time of screening by global cognitive tests (either 3MS or TICSm) that  
13  
14 triggered the subsequent work-up that concluded with the central adjudication of first  
15  
16 MCI/PD. If a participant had progressed from MCI to PD, she was classified as a case  
17  
18 of PD instead of MCI. The test for linear relationship was conducted by assigning  
19  
20 median values for quintiles, then treated it as a continuous variable in regression  
21  
22 model. To examine the potential non-linear relationship between Mg intake (total  
23  
24 intake or from diet only) and cognitive decline, we conducted a likelihood ratio test to  
25  
26 compare the fit of continuous models with or without quadratic terms of Mg intake. A  
27  
28 likelihood test with  $p < 0.05$  would suggest a better fit regression model by including  
29  
30 the quadratic term, hence a non-linear relationship between Mg intake and cognitive  
31  
32 outcomes. To test the assumption of Cox proportional hazards model, we examined  
33  
34 all models using the Schoenfeld residual test. A sensitivity analysis was performed by  
35  
36 using dietary Mg intake only.  
37  
38  
39  
40  
41  
42  
43

44 To ensure robustness of regression analysis, we have controlled for confounders with  
45  
46 reference to previous studies of cognitive decline. Model 1 was the minimally  
47  
48 adjusted model and included age at baseline, region in U.S., race/ethnicity,  
49  
50 assignment arm of HT trial, BMI at baseline(28) and smoking status.(29) Model 2  
51  
52 included covariates in Model 1 plus education,(30) dietary variables and physical  
53  
54 activity (alcohol intake, energy expenditure from recreational physical activity, total  
55  
56 intake of vitamin B6/9/12, total intake of calcium and vitamin D),(27, 31-34) as well  
57  
58 as the medical history and medication use (baseline self-reported status of diabetes  
59  
60



1  
2  
3  
4 identified by the question ‘Did a doctor ever say that you had sugar diabetes or high  
5  
6 blood sugar when you were not pregnant?’),<sup>(35)</sup> cardiovascular disease (includes  
7  
8 cardiac arrest, congestive heart failure, cardiac catheterization, coronary bypass  
9  
10 surgery, angioplasty of coronary arteries, carotid endarterectomy/angioplasty, atrial  
11  
12 fibrillation or aortic aneurysm)<sup>(36)</sup> and cancer (except for skin melanoma),<sup>(37)</sup> prior  
13  
14 use of menopausal replacement therapy,<sup>(38)</sup> personal history of hypertension,<sup>(39)</sup>  
15  
16 personal history of high cholesterol requiring medications,<sup>(40)</sup> family medical history  
17  
18 of diabetes, family history of heart attack or stroke, medication use (anti-  
19  
20 inflammatory drugs, anti-hyperlipidemia drugs, anti-depressants, anti-hypertensive  
21  
22 drugs or diuretics at baseline). (41, 42) Only participants with complete data were  
23  
24 included in each regression model. All statistical analyses were performed with R  
25  
26 3.6.0. P values less than 0.05 were considered statistically significant.  
27  
28  
29  
30  
31  
32

### 33 *Patient and public involvement*

34  
35 No patients were involved in the design process of this study, setting the research  
36  
37 question, or the outcome measures nor were they involved in the analysis,  
38  
39 interpretation, and writing of the results. With regard to the long follow-up period,  
40  
41 dissemination to these groups is not applicable.  
42  
43  
44  
45

## 46 **Results**

### 47 *Participant Characteristics*

48  
49 A total of 6,473 participants were included in the analyses. The baseline  
50  
51 characteristics of participants in the WHIMS by quintiles are presented in **Table 1**.  
52  
53 Women in the highest quintiles of Mg intake tended to have, on average, a longer  
54  
55 time to event/censorship, greater energy expenditure from recreational physical  
56  
57 activity and higher levels of all dietary variables as shown by one-way ANOVA. As  
58  
59  
60

1  
2  
3  
4 demonstrated by the chisquared test, Non-Hispanic White women, participants  
5  
6 enrolled in the control group of the Estrogen+Progestin trial, with  $\geq 7$  alcohol drinks  
7  
8 per week, with a history of cardiovascular disease, being a past smoker or receiving  
9  
10 post-college education were more likely to have a higher level of Mg intake. The  
11  
12 baseline characteristics of participants included (N=6473) or excluded (N=1006) from  
13  
14 the analysis was compared in **Supplementary Table 1**. Between-group difference  
15  
16 was significant for the majority of variables except for baseline age, recreational  
17  
18 physical activity, total B6 and B12 intake, prevalent cancer, use of hormonal  
19  
20 replacement therapy, treated high cholesterol, and family history of diabetes/heart  
21  
22 attack/stroke.  
23  
24  
25  
26  
27

#### 28 *Total Magnesium intake and risk of Mild Cognitive Impairment/Probable Dementia*

29  
30 **Table 2** illustrates the association between total Mg intake and risk of MCI and/or  
31  
32 PD. A total of 505 (7.8%) women developed MCI across the increasing quintiles of  
33  
34 total Mg intake, while 395 (6.1%) women developed PD. When using the lowest  
35  
36 quintile as the referent, the third quintile of total Mg intake was associated with risk of  
37  
38 composite MCI/PD (HR = 0.69, 95% CI = 0.53, 0.91, p=0.01) in the fully adjusted  
39  
40 model. Comparing with the lowest quintile, the third (HR = 0.63, 95% CI = 0.45,  
41  
42 0.87, p=0.01), fourth (HR = 0.67, 95% CI = 0.46, 0.97, p=0.04) and fifth (HR = 0.61,  
43  
44 95% CI = 0.39, 0.96, p=0.03) quintile associated with lower risk of MCI in the fully  
45  
46 adjusted model. None of the associations between Mg intake (both continuous or  
47  
48 categorical variable) and the risk of PD were significant. The test for linear  
49  
50 relationship was not significant in all fully adjusted models (Model 2). For the  
51  
52 association of total Mg intake with MCI/PD or MCI, adding the quadratic term of Mg  
53  
54 intake into the regression model significantly improved the model fit as shown by the  
55  
56 likelihood ratio test (both p<0.01), which indicated a non-linear relationship between  
57  
58  
59  
60

total Mg intake and cognitive decline. None of the models in Table 2 violated the assumption of the Cox proportional hazards model.

### *Dietary Magnesium intake and risk of Mild Cognitive Impairment/Probable Dementia*

**Table 3** illustrates the association between dietary Mg intake and risk of MCI and/or PD. None of the associations between dietary Mg intake (both categorical variable and the test for trend) and the risk of MCI and/or PD were significant in the fully adjusted model (Model 2). The test for linearity was not significant in all regression models, while adding the quadratic term of Mg intake did not improve the model fit. None of the models in Table 3 violated the assumption of the Cox proportional hazards model.

## **Discussion**

### *Summary of findings*

We examined the association between dietary Mg intake and cognitive impairment in a geographically diverse cohort of post-menopausal women in a sub-cohort of the WHI. When compared with the lowest quintile, the third quintile of total daily Mg intake (257.3-317.8 mg/day) was associated with a lower risk of composite MCI/PD and MCI after the statistical adjustment for demographic characteristics, diet, lifestyle, medication use and medical history. For MCI/PD and MCI, the HR estimates in Model 1 and Model 2 were similar in magnitude, the lesser significance in Model 2 being might due to the increased width of the 95% CI following statistical adjustment. No association was found between Mg intake and PD. Higher Mg intake may be associated with a lower risk of mild cognitive impairment but not necessarily in a dose-response manner. The association between total Mg intake, MCI/PD and MCI were non-linear as suggested by the likelihood test. Although Mg intake only

1  
2  
3  
4 from the dietary source did not significantly associate with MCI/PD, this may be  
5  
6 because the levels of Mg intake from dietary source was lower than the sum of dietary  
7  
8 and supplemental source.  
9

### 10 11 12 *Comparison with previous literature*

13  
14  
15 Our findings are consistent with two previous studies that demonstrated the lowest  
16  
17 risk cognitive decline among participants with a moderate Mg intake. Ozawa and  
18  
19 colleagues assessed the association between self-reported dietary intake of minerals  
20  
21 (potassium, calcium, and magnesium) and dementia risk among Japanese older  
22  
23 adults.<sup>(9)</sup> The hazard ratio for the development of all-cause dementia was 0.63 (95%  
24  
25 CI = 0.40–1.01) for the highest quartile ( $\geq 196$  mg/d) of Mg intake compared to the  
26  
27 lowest quartile ( $\leq 147$  mg/d). For our study, the hazard ratio for the development of  
28  
29 probable dementia was also not significant (HR: 1.05, 95% CI = 0.48–2.29) for the  
30  
31 highest quintile ( $> 337.6$  mg/d) of Mg intake compared to the lowest quintile  
32  
33 ( $< 236.9$  mg/d). In another study from the Netherlands, a “U” shaped distribution in the  
34  
35 association between Mg levels and cognition was observed such that both low ( $\leq 0.79$   
36  
37 mmol/L) levels (HR=1.32) and high ( $\geq 0.90$  mmol/L) serum Mg levels (HR=1.30)  
38  
39 were associated with increased risk of all-cause dementia.<sup>(43)</sup> For our study,  
40  
41 comparing with the lowest quintile, the second quintile of total Mg intake was  
42  
43 associated with lowest risk of combined MCI/PD and MCI after adjusting for various  
44  
45 confounders. The present findings do support total Mg intake (257.3–317.8 mg/day)  
46  
47 between Estimated Average Requirement (estimated nutrient intake to meet the  
48  
49 requirement of half the healthy individuals, 265mg/day for women  $> 51$  years old) and  
50  
51 Recommended Dietary Allowances (sufficient average daily dietary intake level to  
52  
53 meet the nutrient requirement of 97 to 98% healthy individuals, 320mg/day for  
54  
55 women  $> 51$  years old) is optimal for preventing cognitive decline.<sup>(44, 45)</sup> Although  
56  
57  
58  
59  
60

1  
2  
3  
4 further increment of Mg intake did not provide additional benefit for preventing  
5  
6 MCI/PD, comparing with the lowest quintile, the fourth and fifth quintile of total Mg  
7  
8 intake associated with lower risk of MCI. Another observation is that total Mg intake  
9  
10 had similar magnitude of association with MCI/PD and MCI but associated with the  
11  
12 risk of PD without statistical significance. In other words, total Mg intake is more  
13  
14 protective against MCI. Since we only assessed the baseline diet, it is possible that  
15  
16 long follow-up period weakened the association between Mg intake and dementia.  
17  
18  
19  
20

### 21 *Strengths and Limitations*

22  
23  
24 Strengths of the current analyses include the use of data from a large prospective  
25  
26 cohort with long follow-up, and the careful adjudication of MCI/PD events to ensure a  
27  
28 high quality of outcome assessment. However, some limitations of assessment of Mg  
29  
30 intake from dietary sources should be noted, such as assessing Mg intake at baseline  
31  
32 only. However, the test based on the Schoenfeld residuals were not statistically  
33  
34 significant, therefore the impact of Mg intake on MCI and/or PD was less likely to  
35  
36 change over time. Moreover, we are lacking information on serum Mg levels in the  
37  
38 studied population. Despite the adjustment for dietary energy, assessment of dietary  
39  
40 Mg intake can be confounded with other constituents such as leafy green vegetables,  
41  
42 the primary source of dietary Mg.(46) In addition, previous studies have found that  
43  
44 dietary Mg intake might not strongly correlate with serum Mg levels ( $r=0.28$ ,  
45  
46  $p<0.05$ ).(47) That may lead to the different magnitudes of associations, such as the  
47  
48 impact of dietary/serum Mg on the risk of a disease, such as described for  
49  
50 hypertension.(48) Moreover, supplemental Mg intake was collected for ‘other  
51  
52 supplement mixtures’ and single supplements but not for standard multivitamins with  
53  
54 minerals which was the most common type of supplement used by WHI women.  
55  
56  
57  
58  
59  
60 Although this limitation might lead to an under-ascertainment of Mg from

1  
2  
3  
4 supplements, whether it was the major flaw of this study was arguable, since the total  
5  
6 Mg intake has demonstrated significant association with MCI/PD. Furthermore, there  
7  
8 might be residual confounding due to inaccuracy of measurement of some adjustment  
9  
10 variables, such as self-reported diet and physical activity. Last but not least, the  
11  
12 present cohort included only postmenopausal women, and the findings may not be  
13  
14 generalizable to elder men. Despite these limitations, this study adds important  
15  
16 information regarding Mg intake for cognitive benefit in postmenopausal women.  
17  
18  
19  
20  
21

### 22 *Conclusions*

23  
24 Among postmenopausal women from WHIMS with over 20 years of follow-up, total  
25  
26 Mg intake between Estimated Average Requirement and Recommended Dietary  
27  
28 Allowances was associated with lower risk of composite MCI/PD and MCI but not in  
29  
30 a dose-response manner.  
31  
32  
33  
34

35  
36 *Contributors:* KL, QL, TM, AHS, LP, XL, JEM, SL searched the literature; analyzed  
37  
38 and interpreted the data; and wrote the manuscript. SR, JCC, MN, SS participated in  
39  
40 the study design; collected, analyzed, and interpreted the data; and wrote the  
41  
42 manuscript.  
43

44  
45 *Funding:* The Women's Health Initiative (WHI) was funded by the National Heart,  
46  
47 Lung, and Blood Institute, National Institutes of Health, and U.S. Department of  
48  
49 Health and Human Services through contracts HHSN268201600018C,  
50  
51 HHSN268201600002C, HHSN26820 1600003C, and HHSN268201600004C. The  
52  
53 Women's Health Initiative Memory Study (WHIMS) was funded in part by Wyeth  
54  
55 Pharmaceuticals, St. Davids, PA. The WHIMS Extension was funded by the National  
56  
57 Institute on Aging contract HHSN26820044221C, and WHIMS-ECHO was funded  
58  
59 by the National Institute on Aging through contracts HHSN26820044221C, and  
60

1  
2  
3  
4 HHSN 271201100004C. The funding sources had no role in study design, data  
5  
6 collection, data analysis, data interpretation, or the writing of this report; and in the  
7  
8 decision to submit the manuscript for publication. The corresponding author had full  
9  
10 access to all the data in the study and had final responsibility for the decision to  
11  
12 submit for publication.  
13

14  
15 *Ethics approval:* The WHI study was approved by the research ethics committees at  
16  
17 each of the participating centers  
18  
19 (<https://www.whi.org/about/SitePages/Study%20Organization.aspx>).  
20  
21

22 *Competing interests:* None declared.  
23

24 *Data sharing:* No additional data available.  
25

26 *Provenance and peer review:* Not commissioned; externally peer reviewed.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1 Baseline Characteristics of Participants in The Women's Health Initiative Memory Study by quintiles of Total Mg Intake

	Mean (SD) / N (%)					P value
	Q1 (<197.4 mg/day)	Q2 (197.4-257.3 mg/day)	Q3 (257.3-317.8 mg/day)	Q4 (317.8-398.7 mg/day)	Q5 (>398.7 mg/day)	
Number of participants	1294	1295	1295	1295	1294	
Time-to-event/censored in years	9.1 (4.4)	9.6 (4.3)	9.9 (4.3)	9.8 (4.3)	9.7 (4.4)	<0.01***
Age at baseline in years	69.9 (3.7)	70.1 (3.8)	70.1 (3.8)	70.1 (3.9)	70.2 (3.9)	0.34
BMI at baseline	28.6 (5.5)	28.5 (5.3)	28.3 (5.4)	28.3 (5.3)	28.3 (5.5)	0.41
Recreational physical activity in MET-hour	9.4 (12.4)	10.5 (12.2)	11.2 (12.9)	12.3 (13.2)	13.3 (14.9)	<0.01***
Total magnesium intake in mg	153.7 (29.9)	228.2 (17.7)	287.1 (17.6)	355.3 (23)	531.1 (172.3)	<0.01***
Total B6 intake in mg	3.7 (20.3)	5.1 (22.7)	5.7 (18.2)	6.9 (21.2)	12.9 (47.6)	<0.01***
Total B9 intake in mcg	219.2 (144.3)	349.5 (227.7)	451.3 (195.4)	569.3 (215)	698.8 (278.9)	<0.01***
Total B12 intake in mcg	12 (54.5)	17.3 (83.7)	16.2 (51.9)	19.5 (54.8)	37.3 (102.9)	<0.01***
Total calcium intake in mg	632.9 (632.6)	877.6 (459.3)	1091.1 (537.7)	1335.8 (566.8)	1758.9 (686.7)	<0.01***
Total vitamin D intake in mcg	3.9 (3.9)	6.7 (4.8)	9.4 (5.3)	11.8 (5.4)	15.5 (7.1)	<0.01***
Dietary energy in kcal	1080.1 (306.1)	1375.4 (365)	1589.4 (444.6)	1845 (537.6)	2135.7 (758)	<0.01***
Region in U.S.						
Northeast	336 (26.0%)	377 (29.1%)	365 (28.2%)	333 (25.7%)	360 (27.8%)	0.17
South	278 (21.5%)	264 (20.4%)	255 (19.7%)	280 (21.6%)	238 (18.4%)	
Midwest	310 (24.0%)	310 (23.9%)	316 (24.4%)	349 (26.9%)	313 (24.2%)	
West	370 (28.6%)	344 (26.6%)	359 (27.7%)	333 (25.7%)	383 (29.6%)	
Race/Ethnicity						
Non-Hispanic White	1040 (80.6%)	1121 (86.7%)	1160 (89.6%)	1194 (92.4%)	1168 (90.5%)	<0.01***
Black or African-American	139 (10.8%)	94 (7.3%)	70 (5.4%)	45 (3.5%)	67 (5.2%)	
Hispanic/Latino	52 (4.0%)	32 (2.5%)	23 (1.8%)	15 (1.2%)	22 (1.7%)	



1							
2	Other	59 (4.6%)	46 (3.6%)	41 (3.2%)	38 (2.9%)	33 (2.6%)	
3							
4	HRT Arm						
5	E-alone	285 (22.0%)	291 (22.5%)	247 (19.1%)	198 (15.3%)	227 (17.5%)	<0.01***
6	E-alone control	286 (22.1%)	241 (18.6%)	225 (17.4%)	248 (19.2%)	257 (19.9%)	
7	E+P intervention	359 (27.7%)	374 (28.9%)	402 (31.0%)	414 (32.0%)	386 (29.8%)	
8	E+P control	364 (28.1%)	389 (30%)	421 (32.5%)	435 (33.6%)	424 (32.8%)	
9							
10							
11	7+ alcohol drinks per week	116 (9.0%)	151 (11.7%)	161 (12.5%)	191 (14.8%)	191 (14.8%)	<0.01***
12	Prevalent diabetes	107 (8.3%)	112 (8.7%)	92 (7.1%)	93 (7.2%)	103 (8.0%)	0.51
13	Prevalent cardiovascular disease	196 (15.4%)	236 (18.5%)	212 (16.6%)	198 (15.5%)	241 (18.8%)	0.05*
14	Prevalent cancer	54 (4.2%)	42 (3.3%)	43 (3.3%)	50 (3.9%)	43 (3.3%)	0.63
15							
16							
17	Hormone Replacement Therapy						0.31
18	Never used	878 (67.9%)	913 (70.5%)	885 (68.3%)	885 (68.3%)	883 (68.2%)	
19	Past user	353 (27.3%)	318 (24.6%)	329 (25.4%)	334 (25.8%)	323 (25%)	
20	Current user	63 (4.9%)	64 (4.9%)	81 (6.3%)	76 (5.9%)	88 (6.8%)	
21							
22	Treated high cholesterol	220 (17.3%)	239 (18.7%)	245 (19.1%)	222 (17.4%)	225 (17.5%)	0.65
23	History of hypertension	497 (38.9%)	528 (41.1%)	498 (38.7%)	455 (35.5%)	514 (40.0%)	0.05
24	Family history of diabetes, heart attack or						
25	stroke	983 (76.0%)	999 (77.1%)	1024 (79.1%)	1003 (77.5%)	982 (75.9%)	0.29
26	Medication use <sup>a</sup>	594 (45.9%)	610 (47.1%)	592 (45.7%)	592 (45.7%)	621 (48.0%)	0.70
27							
28	Smoking status						<0.01***
29	Never Smoked	689 (53.2%)	691 (53.4%)	707 (54.6%)	663 (51.2%)	696 (53.8%)	
30	Past Smoker	488 (37.7%)	500 (38.6%)	509 (39.3%)	566 (43.7%)	534 (41.3%)	
31	Current Smoker	117 (9.0%)	104 (8.0%)	79 (6.1%)	66 (5.1%)	64 (4.9%)	
32	Received college education or above	622 (48.3%)	698 (54%)	795 (61.5%)	817 (63.1%)	829 (64.4%)	<0.01***
33							
34							
35							
36							
37							

<sup>a</sup> Any use of anti-inflammatory, anti-hyperlipidemic, anti-depressant, anti-hypertensive or diuretic drug. Chi-square (categorical variables) and one-way ANOVA (continuous variables) for subgroup differences: \* $p < 0.05$ . \*\* $p < 0.01$  \*\*\* $p < 0.001$ .

Abbreviations: Q (Quintile); MCI (mild cognitive impairment); PD (probable dementia); HRT (Hormone replacement therapy); E-alone (Estrogen-alone); E+P (Estrogen plus Progestin).

Table 2 Associations of total magnesium intake with the risk of mild cognitive impairment and/or probable dementia

	Model 1 (N=6,473)			Model 2 (N=6,183)	
	Cases/Tota l	HR (95% CI) <sup>a</sup>	P value	HR (95% CI) <sup>b</sup>	P value
<b>MCI/PD</b>					
Total magnesium intake by quintiles					
Q1 (<197.4 mg/day)	184/1294	Ref		Ref	
Q2 (197.4-257.3 mg/day)	157/1295	0.82 (0.66, 1.02)	0.08	0.86 (0.68, 1.08)	0.20
Q3 (257.3-317.8 mg/day)	134/1295	0.65 (0.52, 0.81)	<0.01***	0.69 (0.53, 0.91)	0.01*
Q4 (317.8-398.7 mg/day)	142/1295	0.73 (0.59, 0.92)	0.01*	0.77 (0.57, 1.05)	0.10
Q5 (>398.7 mg/day)	148/1294	0.73 (0.59, 0.91)	0.01*	0.81 (0.57, 1.17)	0.27
p-value for trend					0.42
p-value for non-linearity					<0.01**
<b>MCI</b>					
Total magnesium intake by quintiles					
Q1 (<197.4 mg/day)	131/1294	Ref		Ref	
Q2 (197.4-257.3 mg/day)	106/1295	0.79 (0.61, 1.02)	0.07	0.77 (0.58, 1.03)	0.08
Q3 (257.3-317.8 mg/day)	87/1295	0.61 (0.47, 0.81)	<0.01**	0.63 (0.45, 0.87)	0.01*
Q4 (317.8-398.7 mg/day)	91/1295	0.71 (0.54, 0.93)	0.01*	0.67 (0.46, 0.97)	0.04*
Q5 (>398.7 mg/day)	90/1294	0.66 (0.50, 0.86)	<0.01**	0.61 (0.39, 0.96)	0.03*
p-value for trend					0.06
p-value for non-linearity					<0.01**
<b>PD</b>					
Total magnesium intake by quintiles					
Q1 (<197.4 mg/day)	81/1294	Ref		Ref	
Q2 (197.4-257.3 mg/day)	77/1295	0.89 (0.65, 1.22)	0.48	1.02 (0.73, 1.44)	0.90
Q3 (257.3-317.8 mg/day)	72/1295	0.76 (0.55, 1.05)	0.10	0.87 (0.60, 1.28)	0.49
Q4 (317.8-398.7 mg/day)	80/1295	0.86 (0.63, 1.18)	0.36	1.06 (0.69, 1.63)	0.80
Q5 (>398.7 mg/day)	85/1294	0.92 (0.68, 1.26)	0.61	1.25 (0.75, 2.08)	0.39
p-value for trend					0.29
p-value for non-linearity					0.99

<sup>a</sup> Model 1 adjustment: age at baseline, region in U.S., assignment of hormone therapy trial, BMI at baseline, and smoking status.

<sup>b</sup> Model 2 adjustment: covariates in model 1 along with race/ethnicity, education, alcohol intake, energy expenditure from recreational physical activity, total intake of vitamin B6/9/12, total intake of calcium and vitamin D, dietary energy in kcal, baseline status of diabetes/cardiovascular disease/cancer, prior use of hormone replacement therapy, personal history of hypertension, personal history of high cholesterol requiring medications, family medical history of diabetes, family history of heart attack or

stroke, use of anti-inflammatory drug, anti-hyperlipidemia drug, anti-depressant, anti-hypertensive drug or the use of diuretics at baseline \* $p < 0.05$ . \*\* $p < 0.01$  \*\*\* $p < 0.001$ .

Abbreviations: Mild Cognitive Impairment (MCI), Probable Dementia (PD).

Table 3 Associations of dietary magnesium intake with the risk of mild cognitive impairment and/or probable dementia

	Model 1 (N=6,473)			Model 2 (N=6,183)	
	Cases/Tota 	HR (95% CI) <sup>a</sup>	p value	HR (95% CI) <sup>b</sup>	p value
<b>MCI/PD</b>					
Dietary magnesium intake by quintiles					
Q1 (<170.1 mg/day)	168/1294	Ref		Ref	
Q2 (170.1-216.1 mg/day)	160/1295	0.93 (0.75, 1.16)	0.53	0.96 (0.76, 1.22)	0.73
Q3 (216.1-263.2 mg/day)	144/1295	0.84 (0.67, 1.05)	0.13	0.86 (0.66, 1.12)	0.26
Q4 (263.2-323.3 mg/day)	144/1295	0.79 (0.63, 0.99)	0.04*	0.84 (0.63, 1.13)	0.25
Q5 (>323.3 mg/day)	149/1294	0.81 (0.65, 1.01)	0.07	0.86 (0.59, 1.24)	0.42
p-value for trend					0.34
p-value for non-linearity					0.25
<b>MCI</b>					
Dietary magnesium intake by quintiles					
Q1 (<170.1 mg/day)	118/1294	Ref		Ref	
Q2 (170.1-216.1 mg/day)	111/1295	0.95 (0.73, 1.23)	0.69	0.97 (0.73, 1.29)	0.85
Q3 (216.1-263.2 mg/day)	99/1295	0.87 (0.66, 1.14)	0.32	0.85 (0.62, 1.17)	0.33
Q4 (263.2-323.3 mg/day)	89/1295	0.76 (0.57, 1.00)	0.05	0.78 (0.55, 1.13)	0.19
Q5 (>323.3 mg/day)	88/1294	0.73 (0.55, 0.97)	0.03*	0.71 (0.45, 1.14)	0.16
p-value for trend					0.11
p-value for non-linearity					0.64
<b>PD</b>					
Dietary magnesium intake by quintiles					
Q1 (<170.1 mg/day)	76/1294	Ref		Ref	
Q2 (170.1-216.1 mg/day)	77/1295	0.95 (0.69, 1.31)	0.75	1.00 (0.70, 1.42)	0.98

mg/day)						
Q3 (216.1-263.2	71/1295	0.86 (0.62, 1.19)	0.37	0.97 (0.66, 1.41)	0.86	
mg/day)						
Q4 (263.2-323.3	86/1295	0.97 (0.71, 1.33)	0.86	1.11 (0.74, 1.67)	0.61	
mg/day)						
Q5 (>323.3 mg/day)	85/1294	0.96 (0.70, 1.31)	0.79	1.08 (0.64, 1.81)	0.78	
p-value for trend					0.66	
p-value for non-linearity					0.30	

<sup>a</sup> Model 1 adjustment: age at baseline, region in U.S., assignment of hormone therapy trial, BMI at baseline, and smoking status.

<sup>b</sup> Model 2 adjustment: covariates in model 1 along with race/ethnicity, education, alcohol intake, energy expenditure from recreational physical activity, total intake of vitamin B6/9/12, total intake of calcium and vitamin D, dietary energy in kcal, baseline status of diabetes/cardiovascular disease/cancer, prior use of hormone replacement therapy, personal history of hypertension, personal history of high cholesterol requiring medications, family medical history of diabetes, family history of heart attack or stroke, use of anti-inflammatory drug, anti-hyperlipidemia drug, anti-depressant, anti-hypertensive drug or the use of diuretics at baseline \* $p < 0.05$ . \*\* $p < 0.01$  \*\*\* $p < 0.001$ .

Abbreviations: Mild Cognitive Impairment (MCI), Probable Dementia (PD).

## Reference

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol*. 1999;56:303-8.
2. Arevalo-Rodriguez I, Smailagic N, Roque IFM, et al. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). *Cochrane Database Syst Rev*. 2015:CD010783.
3. World Health Organization. *The Epidemiology and Impact of Dementia Current State and Future Trends*. 2015.
4. Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. *Neurology*. 1999;53:1992-7.
5. Chene G, Beiser A, Au R, et al. Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. *Alzheimers Dement*. 2015;11:310-20.
6. Lin KA, Choudhury KR, Rathakrishnan BG, et al. Marked gender differences in progression of mild cognitive impairment over 8 years. *Alzheimers Dement (N Y)*. 2015;1:103-10.
7. Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development. An update. *Drug News Perspect*. 1998;11:523-69.
8. Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. *Neurochem Int*. 2004;45:583-95.
9. Ozawa M, Ninomiya T, Ohara T, et al. Self-reported dietary intake of potassium, calcium, and magnesium and risk of dementia in the Japanese: the Hisayama Study. *J Am Geriatr Soc*. 2012;60:1515-20.
10. Tzeng NS, Chung CH, Lin FH, et al. Magnesium oxide use and reduced risk of dementia: a retrospective, nationwide cohort study in Taiwan. *Curr Med Res Opin*. 2018;34:163-9.
11. Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. *Control Clin Trials*. 1998;19:604-21.
12. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA*. 2003;289:2663-72.
13. Malouf R, Areosa Sastre A. Vitamin B12 for cognition. *Cochrane Database Syst Rev*. 2003:CD004326.
14. Welsh KA, Breitner J, Magruder-Habib KM. Detection of dementia in the elderly using the telephone interview for cognitive status. *Neuropsychiatry Neuropsychol Behav Neurol*. 1993;6:103-10.
15. Rapp SR, Legault C, Espeland MA, et al. Validation of a cognitive assessment battery administered over the telephone. *J Am Geriatr Soc*. 2012;60:1616-23.
16. Arnold AM, Newman AB, Dermond N, Haan M, Fitzpatrick A. Using telephone and informant

- 1  
2  
3 assessments to estimate missing Modified Mini-Mental State Exam scores and rates of cognitive  
4 decline. The cardiovascular health study. *Neuroepidemiology*. 2009;33:55-65.
- 5  
6 17. Espeland MA, Chen JC, Weitlauf J, et al. Trajectories of Relative Performance with 2 Measures  
7 of Global Cognitive Function. *J Am Geriatr Soc*. 2018.
- 8  
9 18. Ellis RJ, Jan K, Kawas C, et al. Diagnostic validity of the dementia questionnaire for Alzheimer  
10 disease. *Arch Neurol*. 1998;55:360-5.
- 11  
12 19. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia  
13 and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory  
14 Study: a randomized controlled trial. *JAMA*. 2003;289:2651-62.
- 15  
16 20. Hogervorst E, Bandelow S, Combrinck M, Irani SR, Smith AD. The validity and reliability of 6  
17 sets of clinical criteria to classify Alzheimer's disease and vascular dementia in cases confirmed  
18 post-mortem: added value of a decision tree approach. *Dement Geriatr Cogn Disord*. 2003;16:170-  
19 80.
- 20  
21 21. Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T. Measurement  
22 characteristics of the Women's Health Initiative food frequency questionnaire. *Ann Epidemiol*.  
23 1999;9:178-87.
- 24  
25 22. Schakel SF, Sievert YA, Buzzard IM. Sources of data for developing and maintaining a nutrient  
26 database. *J Am Diet Assoc*. 1988;88:1268-71.
- 27  
28 23. Neuhouser ML, Wassertheil-Smoller S, Thomson C, et al. Multivitamin use and risk of cancer  
29 and cardiovascular disease in the Women's Health Initiative cohorts. *Arch Intern Med*.  
30 2009;169:294-304.
- 31  
32 24. Patterson RE, Levy L, Tinker LF, Kristal AR. Evaluation of a simplified vitamin supplement  
33 inventory developed for the Women's Health Initiative. *Public Health Nutr*. 1999;2:273-6.
- 34  
35 25. Ammann EM, Pottala JV, Robinson JG, Espeland MA, Harris WS. Erythrocyte omega-3 fatty  
36 acids are inversely associated with incident dementia: Secondary analyses of longitudinal data from  
37 the Women's Health Initiative Memory Study (WHIMS). *Prostaglandins Leukot Essent Fatty Acids*.  
38 2017;121:68-75.
- 39  
40 26. Hayden KM, Beavers DP, Steck SE, et al. The association between an inflammatory diet and  
41 global cognitive function and incident dementia in older women: The Women's Health Initiative  
42 Memory Study. *Alzheimers Dement*. 2017;13:1187-96.
- 43  
44 27. Agnew-Blais JC, Wassertheil-Smoller S, Kang JH, et al. Folate, vitamin B-6, and vitamin B-12  
45 intake and mild cognitive impairment and probable dementia in the Women's Health Initiative  
46 Memory Study. *J Acad Nutr Diet*. 2015;115:231-41.
- 47  
48 28. Moga DC, Abner EL, Brouwer ES. Dementia and "obesity paradox": is this for real or are we  
49 missing something? An epidemiologist's perspective. *J Am Med Dir Assoc*. 2015;16:78-9.
- 50  
51 29. Batty GD, Shipley MJ, Kvaavik E, et al. Biomarker assessment of tobacco smoking exposure and  
52 risk of dementia death: pooling of individual participant data from 14 cohort studies. *J Epidemiol  
53 Community Health*. 2018;72:513-5.
- 54  
55  
56  
57  
58  
59  
60

- 1
- 2
- 3
- 4 30. Xu W, Tan L, Wang HF, et al. Education and Risk of Dementia: Dose-Response Meta-Analysis of
- 5 Prospective Cohort Studies. *Mol Neurobiol*. 2016;53:3113-23.
- 6
- 7 31. Littlejohns TJ, Henley WE, Lang IA, et al. Vitamin D and the risk of dementia and Alzheimer
- 8 disease. *Neurology*. 2014;83:920-8.
- 9
- 10 32. Kern J, Kern S, Blennow K, et al. Calcium supplementation and risk of dementia in women with
- 11 cerebrovascular disease. *Neurology*. 2016;87:1674-80.
- 12
- 13 33. Ilomaki J, Jokanovic N, Tan EC, Lonroos E. Alcohol Consumption, Dementia and Cognitive
- 14 Decline: An Overview of Systematic Reviews. *Curr Clin Pharmacol*. 2015;10:204-12.
- 15
- 16 34. Blondell SJ, Hammersley-Mather R, Veerman JL. Does physical activity prevent cognitive
- 17 decline and dementia?: A systematic review and meta-analysis of longitudinal studies. *BMC Public*
- 18 *Health*. 2014;14:510.
- 19
- 20 35. Espeland MA, Brinton RD, Hugenschmidt C, et al. Impact of Type 2 Diabetes and
- 21 Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women.
- 22 *Diabetes Care*. 2015;38:2316-24.
- 23
- 24 36. Eriksson UK, Bennet AM, Gatz M, Dickman PW, Pedersen NL. Nonstroke cardiovascular disease
- 25 and risk of Alzheimer disease and dementia. *Alzheimer Dis Assoc Disord*. 2010;24:213-9.
- 26
- 27 37. Ganguli M. Cancer and Dementia: It's Complicated. *Alzheimer Dis Assoc Disord*. 2015;29:177-
- 28 82.
- 29
- 30 38. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects
- 31 on cognitive function and dementia. *JAMA*. 1998;279:688-95.
- 32
- 33 39. Peters R, Beckett N. Hypertension, dementia, and antihypertensive treatment: implications for
- 34 the very elderly. *Curr Hypertens Rep*. 2009;11:277-82.
- 35
- 36 40. Reitz C. Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms
- 37 behind the associations. *J Alzheimers Dis*. 2012;30 Suppl 2:S127-45.
- 38
- 39 41. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. *Lancet*.
- 40 2000;356:1627-31.
- 41
- 42 42. Tully PJ, Hanon O, Cosh S, Tzourio C. Diuretic antihypertensive drugs and incident dementia
- 43 risk: a systematic review, meta-analysis and meta-regression of prospective studies. *J Hypertens*.
- 44 2016;34:1027-35.
- 45
- 46 43. Kieboom BCT, Licher S, Wolters FJ, et al. Serum magnesium is associated with the risk of
- 47 dementia. *Neurology*. 2017;89:1716-22.
- 48
- 49 44. Bergman C, Gray-Scott D, Chen JJ, Meacham S. What is next for the Dietary Reference Intakes
- 50 for bone metabolism related nutrients beyond calcium: phosphorus, magnesium, vitamin D, and
- 51 fluoride? *Crit Rev Food Sci Nutr*. 2009;49:136-44.
- 52
- 53 45. Murphy SP, Poos MI. Dietary Reference Intakes: summary of applications in dietary
- 54 assessment. *Public Health Nutr*. 2002;5:843-9.
- 55
- 56 46. Chen GC, Koh WP, Yuan JM, Qin LQ, van Dam RM. Green leafy and cruciferous vegetable
- 57 consumption and risk of type 2 diabetes: results from the Singapore Chinese Health Study and
- 58
- 59
- 60

1  
2  
3 meta-analysis. *Br J Nutr*. 2018;1-11.  
4


5 47. Akizawa Y, Koizumi S, Itokawa Y, et al. Daily magnesium intake and serum magnesium  
6 concentration among Japanese people. *J Epidemiol*. 2008;18:151-9.  
7

8 48. Han H, Fang X, Wei X, et al. Dose-response relationship between dietary magnesium intake,  
9 serum magnesium concentration and risk of hypertension: a systematic review and meta-analysis  
10 of prospective cohort studies. *Nutr J*. 2017;16:26.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



Supplementary Figure 1 Identification of an Analytical Cohort from the Women's Health Initiative Memory Study (WHI-MS)



Supplementary Table 1 Baseline Characteristics of Participants Included or Excluded from Analysis

	Mean (SD) / N (%)		
	Excluded	Included	p value
Number of participants	1006	6473	
Time-to-event/censored in years	5.5 (5.3)	9.6 (4.3)	<0.01***
Age at baseline in years	70.3 (3.9)	70.1 (3.8)	0.05
BMI at baseline	29.5 (7.5)	28.4 (5.4)	<0.01***
Recreational physical activity in MET-hour	10.7 (13.8)	11.3 (13.2)	0.18
Total magnesium intake in mg	251 (162.1)	311.1 (151.2)	<0.01***
Total B6 intake in mg	6.1 (21)	6.8 (28.4)	0.44
Total B9 intake in mcg	374.7 (272.4)	457.6 (273.5)	<0.01***
Total B12 intake in mcg	18.2 (63.6)	20.5 (73)	0.36
Total calcium intake in mg	871.3 (689.7)	1139.2 (698.8)	<0.01***
Total vitamin D intake in mcg	7.2 (6.5)	9.5 (6.7)	<0.01***
Dietary energy in kcal	1344.9 (976.7)	1605.1 (625.3)	<0.01***
Region in U.S.			
● Northeast	234 (23.3%)	1771 (27.4%)	<0.01***
● South	263 (26.1%)	1315 (20.3%)	
● Midwest	208 (20.7%)	1598 (24.7%)	
● West	301 (29.9%)	1789 (27.6%)	
Race/Ethnicity			<0.01***
● Non-Hispanic White	810 (80.7%)	5683 (88.0%)	
● Black or African-American	120 (12.0%)	415 (6.4%)	
● Hispanic/Latino	35 (3.5%)	144 (2.2%)	
● Other	39 (3.9%)	217 (3.4%)	
HRT Arm			<0.01**
● E-alone	221 (22.0%)	1248 (19.3%)	
● E-alone control	227 (22.6%)	1257 (19.4%)	
● E+P intervention	289 (28.7%)	1935 (29.9%)	
● E+P control	269 (26.7%)	2033 (31.4%)	
7+ alcohol drinks per week	83 (8.5%)	810 (12.6%)	<0.01***
Prevalent diabetes	120 (12.0%)	507 (7.8%)	<0.01***
Prevalent cardiovascular disease	204 (20.8%)	1083 (17.0%)	<0.01**
Prevalent cancer	35 (3.6%)	232 (3.6%)	0.93
Hormone Replacement Therapy			0.57
● Never used	702 (69.8%)	4444 (68.7%)	
● Past user	254 (25.2%)	1657 (25.6%)	
● Current user	50 (5.0%)	372 (5.7%)	
Treated high cholesterol	194 (19.8%)	1151 (18.0%)	0.16
History of hypertension	424 (43.4%)	2492 (38.8%)	0.01**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Family history of diabetes, heart attack or stroke	768 (76.3%)	4991 (77.1%)	0.59
Medication use <sup>a</sup>	510 (50.7%)	3009 (46.5%)	0.01*
Smoking status			<0.01***
● Never Smoked	463 (51.7%)	3446 (53.2%)	
● Past Smoker	333 (37.2%)	2597 (40.1%)	
● Current Smoker	99 (11.1%)	430 (6.6%)	
Received college education or above	514 (51.2%)	3761 (58.3%)	<0.01***

MCI: mild cognitive impairment; PD: probable dementia; HRT: Hormone replacement therapy; E-alone: Estrogen-alone;E+P:Estrogen+Progestin

\* $p < 0.05$ . \*\* $p < 0.01$  \*\*\* $p < 0.001$ . <sup>a</sup> Any use of anti-inflammatory, anti-hyperlipidemic, anti-depressant, anti-hypertensive or diuretic drug

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	4
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-6
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-8
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	8
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8-9
		(b) Give reasons for non-participation at each stage	14
		(c) Consider use of a flow diagram	14
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9
		(b) Indicate number of participants with missing data for each variable of interest	14
		(c) Summarise follow-up time (eg, average and total amount)	15
Outcome data	15*	Report numbers of outcome events or summary measures over time	17-18
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear	17-18

		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	17-18
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	10-12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

\*Give information separately for exposed and unexposed groups.

# BMJ Open

## Relations of magnesium intake to cognitive impairment and dementia among participants in the Women's Health Initiative Memory Study: a prospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030052.R3
Article Type:	Research
Date Submitted by the Author:	27-Aug-2019
Complete List of Authors:	Lo, Kenneth; Brown University, Liu, Qing; Brown University Madsen, Tracy; Brown University Rapp, Steve; Wake Forest University Chen, Jiu-Chiuan; University of Southern California Neuhouser, Marian; Fred Hutchinson Cancer Research Center Shadyab, Aladdin; University of California San Diego Pal, Lubna; Yale University Lin, Xiaochen; Brown University Shumaker, Sally; Wake Forest University Manson, JoAnn; Brigham and Women's Hospital Liu, Prof. Simin; Brown University
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Geriatric medicine
Keywords:	Dementia < NEUROLOGY, NUTRITION & DIETETICS, EPIDEMIOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 Title: Relations of magnesium intake to cognitive impairment and dementia among participants in the  
5  
6 Women's Health Initiative Memory Study: a prospective cohort study  
7  
8  
9

10 Authors' names and positions: Kenneth Lo (0000-0003-4624-2737), postdoctoral fellow,  
11  
12 kenneth\_lo@brown.edu <sup>1,2</sup>, Qing Liu, PhD, qing\_liu@brown.edu <sup>2</sup>, Tracy Madsen, assistant professor,  
13  
14 tracy\_madsen@brown.edu <sup>3</sup>, Steve Rapp, professor, srapp@wakehealth.edu <sup>4</sup>, Jiu-Chiuan Chen, associate  
15  
16 professor, jcchen@usc.edu <sup>5</sup>, Marian Neuhouser, professor, mneuhaus@WHI.org <sup>6</sup>, Aladdin H. Shadyab,  
17  
18 postdoctoral fellow, aladdinhs@yahoo.com <sup>7</sup>, Lubna Pal, professor, lubna.pal@yale.edu <sup>8</sup>, Xiaochen Lin,  
19  
20 postdoctoral fellow, xiaochen\_lin@brown.edu <sup>2</sup>, Sally Shumaker, professor, sshumake@wakehealth.edu  
21  
22  
23  
24 <sup>4</sup>, JoAnn E Manson, professor, jmanson@rics.bwh.harvard.edu <sup>9</sup>, Simin Liu (0000-0002-8696-4833),  
25  
26 professor, simin\_liu@brown.edu <sup>1,2,10</sup>  
27  
28  
29

30 Address of each author: 1: Departments of Cardiology and Endocrinology, Guangdong Provincial  
31  
32 People's Hospital, Guangdong Academy of Medical Sciences, China, 2: Centre for Global  
33  
34 Cardiometabolic Health, Department of Epidemiology, School of Public Health, Brown University, USA,  
35  
36  
37 3: Department of Emergency Medicine, Alpert Medical School, Brown University, 4: School of  
38  
39 Medicine, Wake Forest University, USA, 5: Department of Preventive Medicine, University of Southern  
40  
41 California, USA, 6: Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, USA,  
42  
43 7: Department of Family and Preventive Medicine, University of California, San Diego, USA, 8: School  
44  
45 of Medicine, Yale University, USA, 9: Division of Preventive Medicine, Department of Medicine,  
46  
47 Brigham and Women's Hospital, Harvard Medical School, 10: Departments of Surgery and Medicine,  
48  
49 Brown University Alpert School of Medicine  
50  
51  
52  
53

54  
55 Correspondence to: Correspondence to: Dr. Kenneth Lo or Professor Simin Liu, Departments of  
56  
57 Cardiology and Endocrinology, Guangdong Provincial People's Hospital, Guangdong Academy of  
58  
59 Medical Sciences, China  
60

## Abstract

**Objective:** To examine the associations of dietary and supplemental magnesium (Mg) as assessed by a semi-quantitative food frequency questionnaire with cognitive outcomes amongst ageing women.

**Design:** This work conducts a prospective cohort study of participants enrolled in the Women's Health Initiative Memory Study (WHIMS), which was subsequently extended and named WHIMS-Epidemiology of Cognitive Health (WHIMS-ECHO).

**Setting:** Forty clinical centres in United States.

**Participants:** Postmenopausal women aged 65–79 years without dementia upon enrolment.

**Main outcome measures:** Physician-adjudicated mild cognitive impairment (MCI) and/or probable dementia (PD).

**Results:** Participants were excluded (N=1,006) if they had extreme values of dietary energy intake, had missing or extreme body mass index values, with prevalent MCI/PD at baseline, received only one cognitive assessment or had been followed up for less than 1 year. During >20 years of follow-up, 765 (11.8%) out of 6,473 participants developed MCI/PD. For MCI/PD and MCI, the risks tended to be lower among participants in quintiles Q2 to Q5 of Mg consumption compared with those in the lowest quintile. Participants in Q3 had a significantly lower risk of MCI/PD (hazard ratio = 0.69, 95% confidence interval 0.53–0.91) and MCI (0.63, 0.45–0.87) after multivariate adjustments. No significant association was observed between total Mg intake and PD. The association between total Mg intake, MCI/PD and MCI were nonlinear as suggested by the likelihood test.

**Conclusions:** Total Mg intake between the Estimated Average Requirement and the Recommended Dietary Allowances may associate with a lower risk of MCI/PD and MCI.

**Trial registration:** [clinicaltrials.gov](http://clinicaltrials.gov) (NCT00685009)



1  
2  
3  
4 Strengths and limitations of this study:  
5

- 6 ● A large prospective cohort with long follow-up and careful adjudication of MCI/PD events to  
7 ensure a high quality of outcome assessment.  
8
- 9 ● Lacking information on serum Mg levels in the studied population.  
10
- 11 ● The cohort included only postmenopausal women, and the findings may not be generalisable to  
12 elderly men.  
13  
14  
15  
16  
17  
18

## 19 **Background**

20  
21 Mild cognitive impairment (MCI) involves the onset and evolution of cognitive impairments beyond  
22 those expected based on an individual's age and education but not significant enough to interfere  
23 with her or his daily activities.(1) Cognitive function might decline progressively over time for  
24 people with MCI, which would impair their memory, reasoning, language and visuospatial abilities.  
25  
26 Individuals are diagnosed with dementia when their cognitive decline interferes with their daily  
27 functions.(2) Dementia affects approximately 47 million people worldwide, and its prevalence is  
28 expected to be more than triple by 2050.(3) The prevalence of dementia and associated medical costs  
29 have increased dramatically in recent years in parallel with the ageing population throughout the  
30 world; this situation has increased the healthcare burden to communities, families and individuals.(3)  
31 Compared with elderly men, elderly women have a higher lifetime risk for dementia(4, 5) and faster  
32 progression of cognitive impairment following diagnosis.(6) Therefore, identifying the strategies for  
33 dementia prevention, particularly those that are safe, cost-effective and readily accessible to elderly  
34 women, is of both public health and clinical significance.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 Magnesium (Mg) has long been thought to prevent vascular outcomes. Recent work has shown that  
54 Mg may regulate N-methyl-D-aspartate (NMDA) receptors, which affect critical functions of the  
55 central nervous system, including neuronal development, plasticity and neurodegeneration. The  
56 NMDA receptor is permeable to calcium, sodium and potassium ions and can be blocked by Mg  
57  
58  
59  
60

ions.(7) Strong neurobiological data support the role of Mg intake for normal neuron functioning by helping prevent the destruction of neurons resulting from NMDA-induced excitotoxicity(8).

However, few prospective studies have directly examined the relation between Mg intake (dietary and/or supplements) and the dementia risk.(9, 10) We therefore conducted a prospective investigation of the role of Mg intake in the development of two constructs of cognitive decline, namely, MCI and probable dementia (PD), among elderly women who participated in the Women's Health Initiative Memory Study (WHIMS; 1995–2008). The participants were also followed up in the WHIMS-Epidemiology of Cognitive Health Outcomes (WHIMS-ECHO; 2008–onwards) study.

## Methods

### *Data source*

The WHI Memory Study (WHIMS) is an ancillary study to the WHI Hormone Trial (N = 27,347 for the whole trial) designed to assess the effect of postmenopausal hormone therapy (HT) on dementia risk.(11) Invitation to participate was sent to women in the WHI Hormone Therapy Trial; these women were aged 65–79 years and did not have dementia upon enrolment.(12) Following the termination of the HT intervention, the WHIMS (1995–2008, 7,479 participants) and subsequent WHIMS-Epidemiology of Cognitive Health (ECHO) follow-up (2008 onwards, ~2900 participants) continued the annual assessments of cognitive function and adjudication of all-cause dementia and MCI status. Ethical approval of all protocols was obtained from the institutional review boards (IRBs) of all participating institutions (40 clinical site IRBs, the coordinating centre IRB and ethical review at the National Institutes of Health). Written informed consent was obtained from the participants.

The participants were eligible for inclusion in the present analysis if they completed the WHI Food Frequency Questionnaire (FFQ) and dietary supplement questionnaire at baseline. We further excluded women who had implausible dietary energy intake (<600 kcal or >5000 kcal), missing or

1  
2  
3  
4 extreme body mass index (BMI) values (BMI <15 kg/m<sup>2</sup> or BMI >50 kg/m<sup>2</sup>) and prevalent MCI/PD  
5  
6 at baseline or received only one Modified Mini-Mental State Examination (3MSE) for cognitive  
7  
8 assessment. Lastly, to avoid reverse causation between the dietary intake and disease onset, we  
9  
10 included only women who had been followed up for at least 1 year. The detailed participant selection  
11  
12 is illustrated in **Supplementary Figure 1**.

### 17 *Outcome Variable*

18  
19 The WHIMS and WHIMS-ECHO protocol used a multiphase approach to identify cases of MCI and  
20  
21 PD. From 1995 through 2007 (WHIMS), participants were screened annually in the clinic by trained  
22  
23 and certified examiners by using the Modified Mini-Mental State Examination (3MSE). The 3MSE  
24  
25 ranges from 0 to 100, and the initial cut-points for further testing were 72 or below for participants  
26  
27 with <9 years of education and 76 or below for participants with 9 years or above of education. After  
28  
29 1 July 1998, the cut-points were 80 and 88, respectively. Participants who scored below the  
30  
31 education-adjusted 3MSE cut-points received in-depth multiphased evaluation,(13) including a  
32  
33 battery of neuropsychological tests, history and physical, neuropsychiatric evaluation and an  
34  
35 interview with a friend or family member to assess the functional status(11).

36  
37  
38  
39  
40  
41  
42 Beginning in 2008 (WHIMS-ECHO), an annual validated cognitive test battery that included the  
43  
44 Telephone Interview for Cognitive Status-modified (TICS<sub>m</sub>) was conducted.(14) Other validated  
45  
46 tests of cognitive function were administered by telephone.(15) To justify replacing the 3MSE  
47  
48 assessment with TICS<sub>m</sub>, a validation study was performed. The results showed that the 3MSE scores  
49  
50 predicted by TICS<sub>m</sub> was highly correlated (0.82) with 3MSE scores,(16) whereas the transformation  
51  
52 of WHIMS 3MSE and WHIMS-ECHO TICS<sub>m</sub> data into relative percentile ranks fit the trajectories  
53  
54 of global cognitive function.(17) For women screened positive (i.e. TICS<sub>m</sub><31) during the WHIMS-  
55  
56 ECHO follow-up, a reliable and pre-identified informant was interviewed via telephone by using the  
57  
58 standardised Dementia Questionnaire to assess the history of cognitive and behavioural changes,  
59  
60

1  
2  
3  
4 functional impairments and health events that can affect cognitive functioning.(18)  
5  
6  
7

8 All available participant data in both WHIMIS and WHIMS-ECHO were submitted to a central  
9 adjudication committee at the WHIMS clinical coordinating centre. The committee had experts  
10 experienced in neurological examinations and neuropsychiatric evaluations, wherein cases are  
11 classified as no impairment, MCI or PD.(19) The outcome classification was based on the DSM-IV  
12 criteria for dementia (20) and Petersen's MCI criteria(1).  
13  
14  
15  
16  
17  
18  
19  
20

### 21 *Exposure variable*

22 The dietary Mg intake at baseline was derived using the baseline WHI semi-quantitative FFQ.(21)  
23  
24 The nutrient database for the WHI FFQ uses the Nutrition Data Systems for Research (NDS-R,  
25 version 2005, University of Minnesota Nutrition Coordinating Center, Minneapolis, MN) food and  
26 nutrient database.(22) The data on the current dietary supplements at baseline were assessed by a  
27 special dietary supplement inventory interviewer-administered questionnaire.(23) Participants were  
28 asked to bring all current supplements to the WHI baseline clinic visit. Staff members directly  
29 transcribed the ingredients for each supplement; the result demonstrated high correlation (ranging  
30 from 0.8 to 1.0) with photocopied labels in the validation study.(24) Total Mg intake was calculated  
31 by the summation of dietary and supplemental Mg intake. To test the relationship between total Mg  
32 intake and MCI/PD, the Mg intake levels were categorised into quintiles.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

### 49 *Covariates*

50 At WHI baseline, WHIMS participants completed the questionnaires on various information,  
51 including demographics (age and race ethnicity), socioeconomic status (education in years), lifestyle  
52 factors (diet, smoking, alcohol use and physical activity), family or personal disease history (family  
53 history of diabetes or heart diseases, personal history of diabetes, heart diseases, cancer or related  
54 risk factors) and medication use (use of anti-inflammatory drugs, anti-hyperlipidaemia drugs,  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 antidepressants, antihypertensive drugs or diuretics). Height and weight were measured at baseline to  
5  
6 calculate the BMI.  
7  
8  
9

### 10 *Data analysis*

11  
12 Descriptive statistics were demonstrated by the quintiles of total Mg intake. The differences between  
13  
14 quintiles were tested by one-way ANOVA for continuous variables and chi-squared test for  
15  
16 categorical variables. To examine the relationship between total Mg intake and incident MCI and/or  
17  
18 PD, Cox proportional hazards regression models were used with results presented as hazard ratios  
19  
20 (HRs) and associated 95% confidence intervals (95% CI). Non-cases were censored at the time of the  
21  
22 last follow-up (WHIMS or WHIMS-ECHO), death or at the end of 2012 (the year with the most  
23  
24 updated data from WHIMS-ECHO), whichever came first. With reference to the common analysis  
25  
26 strategies of other WHIMS studies,(25-27) the MCI/PD endpoint was presented as a combined  
27  
28 endpoint in the primary analyses. MCI and PD were treated as secondary endpoints. The event time  
29  
30 was defined as the time of screening by global cognitive tests (either 3MS or TICSm) that triggered  
31  
32 the subsequent work-up that concluded with the central adjudication of first MCI/PD. If a participant  
33  
34 had progressed from MCI to PD, then she was classified as a case of PD instead of MCI. The test for  
35  
36 linear relationship was conducted by assigning median values for quintiles and then treated it as a  
37  
38 continuous variable in the regression model. To examine the potential nonlinear relationship between  
39  
40 the Mg intake (total intake or from diet only) and cognitive decline, we conducted a likelihood ratio  
41  
42 test to compare the fit of continuous models with or without quadratic terms of Mg intake. A  
43  
44 likelihood test with  $p < 0.05$  would suggest a better fit regression model by including the quadratic  
45  
46 term. Thus, a nonlinear relationship between the Mg intake and cognitive outcomes was determined.  
47  
48 To test the assumption of the Cox proportional hazards model, we examined all models by using the  
49  
50 Schoenfeld residual test. A sensitivity analysis was performed by using dietary Mg intake only.  
51  
52  
53  
54  
55  
56  
57  
58  
59

60 To ensure robustness of the regression analysis, we controlled for confounders with reference to

1  
2  
3  
4 previous studies on cognitive decline. Model 1 was the minimally adjusted model and included age  
5  
6 at baseline, region in U.S., race/ethnicity, assignment arm of HT trial, BMI at baseline(28) and  
7  
8 smoking status.(29) Model 2 involved covariates in Model 1 plus education,(30) dietary variables  
9  
10 and physical activity (alcohol intake, energy expenditure from recreational physical activity, total  
11  
12 intake of vitamin B6/9/12, total intake of calcium and vitamin D),(27, 31-34), the medical history  
13  
14 and medication use (baseline self-reported status of diabetes identified by the question ‘Did a doctor  
15  
16 ever say that you had sugar diabetes or high blood sugar when you were not pregnant?’),(35)  
17  
18 cardiovascular disease (including cardiac arrest, congestive heart failure, cardiac catheterisation,  
19  
20 coronary bypass surgery, angioplasty of coronary arteries, carotid endarterectomy/angioplasty, atrial  
21  
22 fibrillation or aortic aneurysm)(36), cancer (except for skin melanoma),(37) prior use of menopausal  
23  
24 replacement therapy,(38) personal history of hypertension,(39) personal history of high cholesterol  
25  
26 requiring medications,(40) family medical history of diabetes, family history of heart attack or stroke  
27  
28 and medication use (anti-inflammatory drugs, anti-hyperlipidaemia drugs, antidepressants,  
29  
30 antihypertensive drugs or diuretics at baseline).(41, 42) Only participants with complete data were  
31  
32 included in each regression model. All statistical analyses were performed with R 3.6.0. P values less  
33  
34 than 0.05 were considered statistically significant.  
35  
36  
37  
38  
39  
40  
41

### 42 *Patient and public involvement*

43  
44 No patients were involved in the design of this study, in the setting of the research question or the  
45  
46 outcome measures nor were they involved in the analysis, interpretation and writing of the results.  
47  
48 With regard to the long follow-up period, dissemination to these groups is not applicable.  
49  
50  
51

## 52 **Results**

### 53 *Participant Characteristics*

54  
55 A total of 6,473 participants were included in the analyses. The baseline characteristics of  
56  
57 participants in the WHIMS by quintiles are presented in **Table 1**. Women in the highest quintiles of  
58  
59  
60

Mg intake tended to have, on average, a longer time to event/censorship, greater energy expenditure from recreational physical activity and higher levels of all dietary variables as shown by one-way ANOVA. As demonstrated by the chi-squared test, non-Hispanic white women, participants enrolled in the control group of the estrogen+progestin trial, consumed  $\geq 7$  alcohol drinks per week, with a history of cardiovascular disease, were former smokers or receiving post-college education were more likely to have a higher level of Mg intake. The baseline characteristics of participants included (N = 6,473) or excluded (N = 1,006) from the analysis are compared in **Supplementary Table 1**. Between-group difference was significant for the majority of variables except for baseline age, recreational physical activity, total B6 and B12 intake, prevalent cancer, use of hormonal replacement therapy, treated high cholesterol and family history of diabetes/heart attack/stroke.

#### *Total Magnesium intake and risk of MCI/PD*

**Table 2** illustrates the association between total Mg intake and risk of MCI and/or PD. Five-hundred and five (7.8%) women developed MCI across the increasing quintiles of total Mg intake, whereas 395 (6.1%) women developed PD. When using the lowest quintile as the referent, the third quintile of total Mg intake was associated with the risk of composite MCI/PD (HR = 0.69, 95% CI = 0.53, 0.91, p = 0.01) in the fully adjusted model. Compared with the lowest quintile, the third (HR = 0.63, 95% CI = 0.45, 0.87, p = 0.01), fourth (HR = 0.67, 95% CI = 0.46, 0.97, p=0.04) and fifth (HR = 0.61, 95% CI = 0.39, 0.96, p = 0.03) quintiles were associated with a lower risk of MCI in the fully adjusted model. None of the associations between Mg intake (both continuous or categorical variable) and the risk of PD were significant. The test for linear relationship was not significant in all fully adjusted models (Model 2). For the association of total Mg intake with MCI/PD or MCI, adding the quadratic term of Mg intake to the regression model significantly improved the model fit, as shown by the likelihood ratio test (both p<0.01). This result indicated a nonlinear relationship between the total Mg intake and cognitive decline. None of the models in Table 2 violated the assumption of the Cox proportional hazards model.

### *Dietary Mg intake and risk of MCI/PD*

**Table 3** illustrates the association between dietary Mg intake and the risk of MCI and/or PD. None of the associations between the dietary Mg intake (both categorical variable and the test for trend) and the risk of MCI and/or PD were significant in the fully adjusted model (Model 2). The test for linearity was not significant in all regression models and adding the quadratic term of Mg intake did not improve the model fit. None of the models in Table 3 violated the assumption of the Cox proportional hazards model.

## **Discussion**

### *Summary of findings*

We examined the association between the dietary Mg intake and cognitive impairment in a geographically diverse cohort of post-menopausal women in a WHI sub-cohort. When compared with the lowest quintile, the third quintile of total daily Mg intake (257.3–317.8 mg/day) was associated with a lower risk of composite MCI/PD and MCI after statistical adjustment for demographic characteristics, diet, lifestyle, medication use and medical history. For MCI/PD and MCI, the HR estimates in Models 1 and 2 were similar in magnitude. The reduced significance in Model 2 possibly being due to the increased width of the 95% CI following statistical adjustment. No association was found between Mg intake and PD. Higher Mg intake may be associated with a lower risk of mild cognitive impairment but not necessarily in a dose-response manner. The association between the total Mg intake, MCI/PD and MCI were nonlinear, as suggested by the likelihood test. The Mg intake from only the dietary source did not significantly associate with MCI/PD, possibly because the level of Mg intake from diet was lower than that from diet and supplementary sources combined.

### *Comparison with previous literature*



1  
2  
3  
4 Our findings are consistent with those of two previous studies that demonstrated the lowest risk  
5  
6 cognitive decline among participants with a moderate Mg intake. Ozawa and colleagues assessed the  
7  
8 association between self-reported dietary intake of minerals (potassium, calcium and Mg) and  
9  
10 dementia risk among older Japanese adults.(9) The HR for the development of all-cause dementia  
11  
12 was 0.63 (95% CI = 0.40–1.01) for the highest quartile ( $\geq 196$  mg/day) of Mg intake compared with  
13  
14 the lowest quartile ( $\leq 147$  mg/day). For our study, the HR for the development of PD was also not  
15  
16 significant (HR: 1.05, 95% CI = 0.48–2.29) for the highest quintile ( $>337.6$  mg/day) of Mg intake  
17  
18 compared with the lowest quintile ( $<236.9$  mg/day). In another study from the Netherlands, a U-  
19  
20 shaped distribution in the association between the Mg levels and cognition was observed such that  
21  
22 both low ( $\leq 0.79$  mmol/L) levels (HR=1.32) and high ( $\geq 0.90$  mmol/L) serum Mg levels (HR = 1.30)  
23  
24 were associated with increased risk of all-cause dementia.(43) For our study, compared with the  
25  
26 lowest quintile, the second quintile of total Mg intake was associated with the lowest risk of  
27  
28 combined MCI/PD and MCI after adjusting for various confounders. The present findings support  
29  
30 the total Mg intake (257.3–317.8 mg/day) between the Estimated Average Requirement (estimated  
31  
32 nutrient intake to meet the requirement of half of healthy individuals; 265 mg/day for women  $>51$   
33  
34 years old) and Recommended Dietary Allowances (sufficient average daily dietary intake level to  
35  
36 meet the nutrient requirement of 97% to 98% healthy individuals; 320 mg/day for women  $>51$  years  
37  
38 old) optimal for preventing cognitive decline.(44, 45) Although further increment of Mg intake did  
39  
40 not provide additional benefit for preventing MCI/PD, the fourth and fifth quintiles of total Mg  
41  
42 intake associated with a lower MCI risk compared with the lowest quintile. Another observation is  
43  
44 that total Mg intake had a similar magnitude of association with MCI/PD and MCI but is associated  
45  
46 with the risk of PD without statistical significance. In other words, total Mg intake is more protective  
47  
48 against MCI. Given that we assessed the baseline diet only, the long follow-up period possibly  
49  
50 weakened the association between the Mg intake and dementia.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Strengths and Limitations*

1  
2  
3  
4 The strengths of the current analyses include the use of data from a large prospective cohort with  
5 long follow-up and the careful adjudication of MCI/PD events to ensure a high quality of outcome  
6 assessment. However, some limitations of assessment of Mg intake from dietary sources should be  
7 noted, for example, assessing the Mg intake at baseline only. The test based on the Schoenfeld  
8 residuals was not statistically significant. Therefore, the impact of Mg intake on MCI and/or PD was  
9 less likely to change over time. Moreover, we lack information on the serum Mg levels in the studied  
10 population. Despite the adjustment for dietary energy, assessment of dietary Mg intake can be  
11 confounded with other constituents, such as leafy green vegetables, which are the primary source of  
12 dietary Mg.(46) In addition, previous studies found that dietary Mg intake might not strongly  
13 correlate with serum Mg levels ( $r = 0.28$ ,  $p < 0.05$ ).(47) This condition may lead to the different  
14 magnitudes of associations, including the impact of dietary/serum Mg on the risk of a disease, such  
15 as hypertension.(48) Moreover, supplemental Mg intake was collected for 'other supplement  
16 mixtures' and single supplements but not for standard multivitamins with minerals, the most  
17 common type of supplement used by WHI women. Although this limitation might lead to an under-  
18 ascertainment of Mg from supplements, whether this condition was the major flaw of this study is  
19 arguable because the total Mg intake demonstrated a significant association with MCI/PD.  
20 Furthermore, residual confounding might occur due to inaccurate measurement of some adjustment  
21 variables, such as self-reported diet and physical activity. Last but not least, the present cohort  
22 included only postmenopausal women, and the findings may not be generalisable to elderly men.  
23 Despite these limitations, this study adds important information regarding Mg intake for cognitive  
24 benefit in postmenopausal women.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

### 53 *Conclusions*

54  
55 Among postmenopausal women from WHIMS with over 20 years of follow-up, the total Mg intake  
56 between the Estimated Average Requirement and Recommended Dietary Allowances was associated  
57 with a low risk of composite MCI/PD and MCI but not in a dose-response manner.  
58  
59  
60

1  
2  
3  
4  
5  
6 *Contributors:* KL, QL, TM, AHS, LP, XL, JEM, SL searched the literature; analyzed and interpreted  
7  
8 the data; and wrote the manuscript. SR, JCC, MN, SS participated in the study design; collected,  
9  
10 analyzed, and interpreted the data; and wrote the manuscript.  
11

12  
13 *Funding:* The Women's Health Initiative (WHI) was funded by the National Heart, Lung, and Blood  
14  
15 Institute, National Institutes of Health, and U.S. Department of Health and Human Services through  
16  
17 contracts HHSN268201600018C, HHSN268201600002C, HHSN26820 1600003C, and  
18  
19 HHSN268201600004C. The Women's Health Initiative Memory Study (WHIMS) was funded in  
20  
21 part by Wyeth Pharmaceuticals, St. Davids, PA. The WHIMS Extension was funded by the National  
22  
23 Institute on Aging contract HHSN26820044221C, and WHIMS-ECHO was funded by the National  
24  
25 Institute on Aging through contracts HHSN26820044221C, and HHSN 271201100004C. The  
26  
27 funding sources had no role in study design, data collection, data analysis, data interpretation, or the  
28  
29 writing of this report; and in the decision to submit the manuscript for publication. The  
30  
31 corresponding author had full access to all the data in the study and had final responsibility for the  
32  
33 decision to submit for publication.  
34  
35

36  
37 *Ethics approval:* The WHI study was approved by the research ethics committees at each of the  
38  
39 participating centers (<https://www.whi.org/about/SitePages/Study%20Organization.aspx>).  
40

41  
42 *Competing interests:* None declared.  
43

44  
45 *Data sharing:* No additional data available.  
46

47  
48 *Provenance and peer review:* Not commissioned; externally peer reviewed.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1 Baseline Characteristics of Participants in The Women's Health Initiative Memory Study by quintiles of Total Mg Intake

	Mean (SD) / N (%)					<i>P</i> value
	Q1 (<197.4 mg/day)	Q2 (197.4-257.3 mg/day)	Q3 (257.3-317.8 mg/day)	Q4 (317.8-398.7 mg/day)	Q5 (>398.7 mg/day)	
Number of participants	1294	1295	1295	1295	1294	
Time-to-event/censored in years	9.1 (4.4)	9.6 (4.3)	9.9 (4.3)	9.8 (4.3)	9.7 (4.4)	***
Age at baseline in years	69.9 (3.7)	70.1 (3.8)	70.1 (3.8)	70.1 (3.9)	70.2 (3.9)	<i>NS</i>
BMI at baseline	28.6 (5.5)	28.5 (5.3)	28.3 (5.4)	28.3 (5.3)	28.3 (5.5)	<i>NS</i>
Recreational physical activity in MET-hour	9.4 (12.4)	10.5 (12.2)	11.2 (12.9)	12.3 (13.2)	13.3 (14.9)	***
Total magnesium intake in mg	153.7 (29.9)	228.2 (17.7)	287.1 (17.6)	355.3 (23)	531.1 (172.3)	***
Total B6 intake in mg	3.7 (20.3)	5.1 (22.7)	5.7 (18.2)	6.9 (21.2)	12.9 (47.6)	***
Total B9 intake in mcg	219.2 (144.3)	349.5 (227.7)	451.3 (195.4)	569.3 (215)	698.8 (278.9)	***
Total B12 intake in mcg	12 (54.5)	17.3 (83.7)	16.2 (51.9)	19.5 (54.8)	37.3 (102.9)	***
Total calcium intake in mg	632.9 (632.6)	877.6 (459.3)	1091.1 (537.7)	1335.8 (566.8)	1758.9 (686.7)	***
Total vitamin D intake in mcg	3.9 (3.9)	6.7 (4.8)	9.4 (5.3)	11.8 (5.4)	15.5 (7.1)	***
Dietary energy in kcal	1080.1 (306.1)	1375.4 (365)	1589.4 (444.6)	1845 (537.6)	2135.7 (758)	***
Region in U.S.						
Northeast	336 (26.0%)	377 (29.1%)	365 (28.2%)	333 (25.7%)	360 (27.8%)	<i>NS</i>
South	278 (21.5%)	264 (20.4%)	255 (19.7%)	280 (21.6%)	238 (18.4%)	
Midwest	310 (24.0%)	310 (23.9%)	316 (24.4%)	349 (26.9%)	313 (24.2%)	
West	370 (28.6%)	344 (26.6%)	359 (27.7%)	333 (25.7%)	383 (29.6%)	
Race/Ethnicity						
Non-Hispanic White	1040 (80.6%)	1121 (86.7%)	1160 (89.6%)	1194 (92.4%)	1168 (90.5%)	***
Black or African-American	139 (10.8%)	94 (7.3%)	70 (5.4%)	45 (3.5%)	67 (5.2%)	
Hispanic/Latino	52 (4.0%)	32 (2.5%)	23 (1.8%)	15 (1.2%)	22 (1.7%)	

1							
2	Other	59 (4.6%)	46 (3.6%)	41 (3.2%)	38 (2.9%)	33 (2.6%)	
3							
4	HRT Arm						
5	E-alone	285 (22.0%)	291 (22.5%)	247 (19.1%)	198 (15.3%)	227 (17.5%)	***
6	E-alone control	286 (22.1%)	241 (18.6%)	225 (17.4%)	248 (19.2%)	257 (19.9%)	
7	E+P intervention	359 (27.7%)	374 (28.9%)	402 (31.0%)	414 (32.0%)	386 (29.8%)	
8	E+P control	364 (28.1%)	389 (30%)	421 (32.5%)	435 (33.6%)	424 (32.8%)	
9							
10							
11	7+ alcohol drinks per week	116 (9.0%)	151 (11.7%)	161 (12.5%)	191 (14.8%)	191 (14.8%)	***
12	Prevalent diabetes	107 (8.3%)	112 (8.7%)	92 (7.1%)	93 (7.2%)	103 (8.0%)	NS
13	Prevalent cardiovascular disease	196 (15.4%)	236 (18.5%)	212 (16.6%)	198 (15.5%)	241 (18.8%)	*
14	Prevalent cancer	54 (4.2%)	42 (3.3%)	43 (3.3%)	50 (3.9%)	43 (3.3%)	NS
15							
16							
17	Hormone Replacement Therapy						NS
18	Never used	878 (67.9%)	913 (70.5%)	885 (68.3%)	885 (68.3%)	883 (68.2%)	
19	Past user	353 (27.3%)	318 (24.6%)	329 (25.4%)	334 (25.8%)	323 (25%)	
20	Current user	63 (4.9%)	64 (4.9%)	81 (6.3%)	76 (5.9%)	88 (6.8%)	
21							
22	Treated high cholesterol	220 (17.3%)	239 (18.7%)	245 (19.1%)	222 (17.4%)	225 (17.5%)	NS
23	History of hypertension	497 (38.9%)	528 (41.1%)	498 (38.7%)	455 (35.5%)	514 (40.0%)	NS
24	Family history of diabetes, heart attack or stroke	983 (76.0%)	999 (77.1%)	1024 (79.1%)	1003 (77.5%)	982 (75.9%)	NS
25	Medication use <sup>a</sup>	594 (45.9%)	610 (47.1%)	592 (45.7%)	592 (45.7%)	621 (48.0%)	NS
26							
27	Smoking status						***
28	Never Smoked	689 (53.2%)	691 (53.4%)	707 (54.6%)	663 (51.2%)	696 (53.8%)	
29	Past Smoker	488 (37.7%)	500 (38.6%)	509 (39.3%)	566 (43.7%)	534 (41.3%)	
30	Current Smoker	117 (9.0%)	104 (8.0%)	79 (6.1%)	66 (5.1%)	64 (4.9%)	
31	Received college education or above	622 (48.3%)	698 (54%)	795 (61.5%)	817 (63.1%)	829 (64.4%)	***
32							
33							
34							
35							

<sup>a</sup> Any use of anti-inflammatory, anti-hyperlipidemic, anti-depressant, anti-hypertensive or diuretic drug. Chi-square (categorical variables) and one-way ANOVA (continuous variables) for subgroup differences: \* $p < 0.05$ . \*\* $p < 0.01$  \*\*\* $p < 0.001$ .

Abbreviations: Q (Quintile); MCI (mild cognitive impairment); PD (probable dementia); HRT (Hormone replacement therapy); E-alone (Estrogen-alone); E+P (Estrogen plus Progestin). NS: not significant

Table 2 Associations of total magnesium intake with the risk of mild cognitive impairment and/or probable dementia

	Model 1 (N=6,473)			Model 2 (N=6,183)	
	Cases/Total	HR (95% CI) <sup>a</sup>	P value	HR (95% CI) <sup>b</sup>	P value
<b>MCI/PD</b>					
Total magnesium intake by quintiles					
Q1 (<197.4 mg/day)	184/1294	Ref		Ref	
Q2 (197.4-257.3 mg/day)	157/1295	0.82 (0.66, 1.02)	NS	0.86 (0.68, 1.08)	NS
Q3 (257.3-317.8 mg/day)	134/1295	0.65 (0.52, 0.81)	***	0.69 (0.53, 0.91)	*
Q4 (317.8-398.7 mg/day)	142/1295	0.73 (0.59, 0.92)	*	0.77 (0.57, 1.05)	NS
Q5 (>398.7 mg/day)	148/1294	0.73 (0.59, 0.91)	*	0.81 (0.57, 1.17)	NS
p-value for trend					NS
p-value for non-linearity					**
<b>MCI</b>					
Total magnesium intake by quintiles					
Q1 (<197.4 mg/day)	131/1294	Ref		Ref	
Q2 (197.4-257.3 mg/day)	106/1295	0.79 (0.61, 1.02)	NS	0.77 (0.58, 1.03)	NS
Q3 (257.3-317.8 mg/day)	87/1295	0.61 (0.47, 0.81)	**	0.63 (0.45, 0.87)	*
Q4 (317.8-398.7 mg/day)	91/1295	0.71 (0.54, 0.93)	*	0.67 (0.46, 0.97)	*
Q5 (>398.7 mg/day)	90/1294	0.66 (0.50, 0.86)	**	0.61 (0.39, 0.96)	*
p-value for trend					NS
p-value for non-linearity					**
<b>PD</b>					
Total magnesium intake by quintiles					
Q1 (<197.4 mg/day)	81/1294	Ref		Ref	
Q2 (197.4-257.3 mg/day)	77/1295	0.89 (0.65, 1.22)	NS	1.02 (0.73, 1.44)	NS
Q3 (257.3-317.8 mg/day)	72/1295	0.76 (0.55, 1.05)	NS	0.87 (0.60, 1.28)	NS
Q4 (317.8-398.7 mg/day)	80/1295	0.86 (0.63, 1.18)	NS	1.06 (0.69, 1.63)	NS
Q5 (>398.7 mg/day)	85/1294	0.92 (0.68, 1.26)	NS	1.25 (0.75, 2.08)	NS
p-value for trend					NS
p-value for non-linearity					NS

<sup>a</sup> Model 1 adjustment: age at baseline, region in U.S., assignment of hormone therapy trial, BMI at baseline, and smoking status. <sup>b</sup> Model 2 adjustment: covariates in model 1 along with race/ethnicity, education, alcohol intake, energy expenditure from recreational physical activity, total intake of vitamin B6/9/12, total intake of calcium and vitamin D, dietary energy in kcal, baseline status of diabetes/cardiovascular disease/cancer, prior use of hormone replacement therapy, personal history of hypertension, personal history of high cholesterol requiring medications, family medical history of diabetes, family history of heart attack or stroke, use of anti-inflammatory drug, anti-hyperlipidaemia drug, anti-depressant, anti-hypertensive drug or the use of diuretics at baseline \**p*<0.05. \*\**p*<0.01 \*\*\**p*<0.001. Abbreviations: Mild Cognitive Impairment

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

(MCI), Probable Dementia (PD). NS: not significant

For peer review only

Table 3 Associations of dietary magnesium intake with the risk of mild cognitive impairment and/or probable dementia

	Model 1 (N=6,473)			Model 2 (N=6,183)	
	Cases/Total	HR (95% CI) <sup>a</sup>	p value	HR (95% CI) <sup>b</sup>	p value
<b>MCI/PD</b>					
Dietary magnesium intake by quintiles					
Q1 (<170.1 mg/day)	168/1294	Ref		Ref	
Q2 (170.1-216.1 mg/day)	160/1295	0.93 (0.75, 1.16)	NS	0.96 (0.76, 1.22)	NS
Q3 (216.1-263.2 mg/day)	144/1295	0.84 (0.67, 1.05)	NS	0.86 (0.66, 1.12)	NS
Q4 (263.2-323.3 mg/day)	144/1295	0.79 (0.63, 0.99)	*	0.84 (0.63, 1.13)	NS
Q5 (>323.3 mg/day)	149/1294	0.81 (0.65, 1.01)	NS	0.86 (0.59, 1.24)	NS
p-value for trend					NS
p-value for non-linearity					NS
<b>MCI</b>					
Dietary magnesium intake by quintiles					
Q1 (<170.1 mg/day)	118/1294	Ref		Ref	
Q2 (170.1-216.1 mg/day)	111/1295	0.95 (0.73, 1.23)	NS	0.97 (0.73, 1.29)	NS
Q3 (216.1-263.2 mg/day)	99/1295	0.87 (0.66, 1.14)	NS	0.85 (0.62, 1.17)	NS
Q4 (263.2-323.3 mg/day)	89/1295	0.76 (0.57, 1.00)	NS	0.78 (0.55, 1.13)	NS
Q5 (>323.3 mg/day)	88/1294	0.73 (0.55, 0.97)	*	0.71 (0.45, 1.14)	NS
p-value for trend					NS
p-value for non-linearity					NS
<b>PD</b>					
Dietary magnesium intake by quintiles					
Q1 (<170.1 mg/day)	76/1294	Ref		Ref	
Q2 (170.1-216.1 mg/day)	77/1295	0.95 (0.69, 1.31)	NS	1.00 (0.70, 1.42)	NS
Q3 (216.1-263.2 mg/day)	71/1295	0.86 (0.62, 1.19)	NS	0.97 (0.66, 1.41)	NS
Q4 (263.2-323.3 mg/day)	86/1295	0.97 (0.71, 1.33)	NS	1.11 (0.74, 1.67)	NS
Q5 (>323.3 mg/day)	85/1294	0.96 (0.70, 1.31)	NS	1.08 (0.64, 1.81)	NS
p-value for trend					NS
p-value for non-linearity					NS

<sup>a</sup> Model 1 adjustment: age at baseline, region in U.S., assignment of hormone therapy trial, BMI at baseline, and smoking status. <sup>b</sup> Model 2 adjustment: covariates in model 1 along with race/ethnicity, education, alcohol intake, energy expenditure from recreational physical activity, total intake of vitamin B6/9/12, total intake of calcium and vitamin D, dietary energy in kcal, baseline status of diabetes/cardiovascular disease/cancer, prior use of hormone replacement therapy, personal history of hypertension, personal history of high cholesterol requiring medications, family medical history of diabetes, family history of heart attack or stroke, use of anti-inflammatory drug, anti-hyperlipidaemia drug, anti-depressant, anti-hypertensive drug or the use of diuretics at baseline \* $p < 0.05$ . \*\* $p < 0.01$  \*\*\* $p < 0.001$ . Abbreviations: Mild Cognitive Impairment (MCI), Probable Dementia (PD). NS: not significant



## Reference

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol*. 1999;56:303-8.
2. Arevalo-Rodriguez I, Smailagic N, Roque IFM, et al. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). *Cochrane Database Syst Rev*. 2015:CD010783.
3. World Health Organization. *The Epidemiology and Impact of Dementia Current State and Future Trends*. 2015.
4. Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. *Neurology*. 1999;53:1992-7.
5. Chene G, Beiser A, Au R, et al. Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. *Alzheimers Dement*. 2015;11:310-20.
6. Lin KA, Choudhury KR, Rathakrishnan BG, et al. Marked gender differences in progression of mild cognitive impairment over 8 years. *Alzheimers Dement (N Y)*. 2015;1:103-10.
7. Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development. An update. *Drug News Perspect*. 1998;11:523-69.
8. Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. *Neurochem Int*. 2004;45:583-95.
9. Ozawa M, Ninomiya T, Ohara T, et al. Self-reported dietary intake of potassium, calcium, and magnesium and risk of dementia in the Japanese: the Hisayama Study. *J Am Geriatr Soc*. 2012;60:1515-20.
10. Tzeng NS, Chung CH, Lin FH, et al. Magnesium oxide use and reduced risk of dementia: a retrospective, nationwide cohort study in Taiwan. *Curr Med Res Opin*. 2018;34:163-9.
11. Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. *Control Clin Trials*. 1998;19:604-21.
12. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA*. 2003;289:2663-72.
13. Malouf R, Areosa Sastre A. Vitamin B12 for cognition. *Cochrane Database Syst Rev*. 2003:CD004326.
14. Welsh KA, Breitner J, Magruder-Habib KM. Detection of dementia in the

- 1  
2  
3 elderly using the telephone interview for cognitive status. *Neuropsychiatry*  
4 *Neuropsychol Behav Neurol.* 1993;6:103-10.  
5  
6 15. Rapp SR, Legault C, Espeland MA, et al. Validation of a cognitive assessment  
7 battery administered over the telephone. *J Am Geriatr Soc.* 2012;60:1616-23.  
8  
9 16. Arnold AM, Newman AB, Dermond N, Haan M, Fitzpatrick A. Using telephone  
10 and informant assessments to estimate missing Modified Mini-Mental State Exam  
11 scores and rates of cognitive decline. The cardiovascular health study.  
12 *Neuroepidemiology.* 2009;33:55-65.  
13  
14 17. Espeland MA, Chen JC, Weitlauf J, et al. Trajectories of Relative Performance  
15 with 2 Measures of Global Cognitive Function. *J Am Geriatr Soc.* 2018.  
16  
17 18. Ellis RJ, Jan K, Kawas C, et al. Diagnostic validity of the dementia questionnaire  
18 for Alzheimer disease. *Arch Neurol.* 1998;55:360-5.  
19  
20 19. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the  
21 incidence of dementia and mild cognitive impairment in postmenopausal women: the  
22 Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA.*  
23 2003;289:2651-62.  
24  
25 20. Hogervorst E, Bandelow S, Combrinck M, Irani SR, Smith AD. The validity and  
26 reliability of 6 sets of clinical criteria to classify Alzheimer's disease and vascular  
27 dementia in cases confirmed post-mortem: added value of a decision tree approach.  
28 *Dement Geriatr Cogn Disord.* 2003;16:170-80.  
29  
30 21. Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T.  
31 Measurement characteristics of the Women's Health Initiative food frequency  
32 questionnaire. *Ann Epidemiol.* 1999;9:178-87.  
33  
34 22. Schakel SF, Sievert YA, Buzzard IM. Sources of data for developing and  
35 maintaining a nutrient database. *J Am Diet Assoc.* 1988;88:1268-71.  
36  
37 23. Neuhouser ML, Wassertheil-Smoller S, Thomson C, et al. Multivitamin use and  
38 risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts.  
39 *Arch Intern Med.* 2009;169:294-304.  
40  
41 24. Patterson RE, Levy L, Tinker LF, Kristal AR. Evaluation of a simplified vitamin  
42 supplement inventory developed for the Women's Health Initiative. *Public Health*  
43 *Nutr.* 1999;2:273-6.  
44  
45 25. Ammann EM, Pottala JV, Robinson JG, Espeland MA, Harris WS. Erythrocyte  
46 omega-3 fatty acids are inversely associated with incident dementia: Secondary  
47 analyses of longitudinal data from the Women's Health Initiative Memory Study  
48 (WHIMS). *Prostaglandins Leukot Essent Fatty Acids.* 2017;121:68-75.  
49  
50 26. Hayden KM, Beavers DP, Steck SE, et al. The association between an  
51 inflammatory diet and global cognitive function and incident dementia in older  
52 women: The Women's Health Initiative Memory Study. *Alzheimers Dement.*  
53  
54  
55  
56  
57  
58  
59  
60

2017;13:1187-96.

27. Agnew-Blais JC, Wassertheil-Smoller S, Kang JH, et al. Folate, vitamin B-6, and vitamin B-12 intake and mild cognitive impairment and probable dementia in the Women's Health Initiative Memory Study. *J Acad Nutr Diet*. 2015;115:231-41.

28. Moga DC, Abner EL, Brouwer ES. Dementia and "obesity paradox": is this for real or are we missing something? An epidemiologist's perspective. *J Am Med Dir Assoc*. 2015;16:78-9.

29. Batty GD, Shipley MJ, Kvaavik E, et al. Biomarker assessment of tobacco smoking exposure and risk of dementia death: pooling of individual participant data from 14 cohort studies. *J Epidemiol Community Health*. 2018;72:513-5.

30. Xu W, Tan L, Wang HF, et al. Education and Risk of Dementia: Dose-Response Meta-Analysis of Prospective Cohort Studies. *Mol Neurobiol*. 2016;53:3113-23.

31. Littlejohns TJ, Henley WE, Lang IA, et al. Vitamin D and the risk of dementia and Alzheimer disease. *Neurology*. 2014;83:920-8.

32. Kern J, Kern S, Blennow K, et al. Calcium supplementation and risk of dementia in women with cerebrovascular disease. *Neurology*. 2016;87:1674-80.

33. Ilomaki J, Jokanovic N, Tan EC, Lonnroos E. Alcohol Consumption, Dementia and Cognitive Decline: An Overview of Systematic Reviews. *Curr Clin Pharmacol*. 2015;10:204-12.

34. Blondell SJ, Hammersley-Mather R, Veerman JL. Does physical activity prevent cognitive decline and dementia?: A systematic review and meta-analysis of longitudinal studies. *BMC Public Health*. 2014;14:510.

35. Espeland MA, Brinton RD, Hugenschmidt C, et al. Impact of Type 2 Diabetes and Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women. *Diabetes Care*. 2015;38:2316-24.

36. Eriksson UK, Bennet AM, Gatz M, Dickman PW, Pedersen NL. Nonstroke cardiovascular disease and risk of Alzheimer disease and dementia. *Alzheimer Dis Assoc Disord*. 2010;24:213-9.

37. Ganguli M. Cancer and Dementia: It's Complicated. *Alzheimer Dis Assoc Disord*. 2015;29:177-82.

38. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. *JAMA*. 1998;279:688-95.


39. Peters R, Beckett N. Hypertension, dementia, and antihypertensive treatment: implications for the very elderly. *Curr Hypertens Rep*. 2009;11:277-82.

40. Reitz C. Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations. *J Alzheimers Dis*. 2012;30 Suppl 2:S127-45.

41. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. *Lancet*. 2000;356:1627-31.

- 1  
2  
3  
4 42. Tully PJ, Hanon O, Cosh S, Tzourio C. Diuretic antihypertensive drugs and  
5 incident dementia risk: a systematic review, meta-analysis and meta-regression of  
6 prospective studies. *J Hypertens*. 2016;34:1027-35.  
7  
8 43. Kieboom BCT, Licher S, Wolters FJ, et al. Serum magnesium is associated with  
9 the risk of dementia. *Neurology*. 2017;89:1716-22.  
10  
11 44. Bergman C, Gray-Scott D, Chen JJ, Meacham S. What is next for the Dietary  
12 Reference Intakes for bone metabolism related nutrients beyond calcium: phosphorus,  
13 magnesium, vitamin D, and fluoride? *Crit Rev Food Sci Nutr*. 2009;49:136-44.  
14  
15 45. Murphy SP, Poos MI. Dietary Reference Intakes: summary of applications in  
16 dietary assessment. *Public Health Nutr*. 2002;5:843-9.  
17  
18 46. Chen GC, Koh WP, Yuan JM, Qin LQ, van Dam RM. Green leafy and  
19 cruciferous vegetable consumption and risk of type 2 diabetes: results from the  
20 Singapore Chinese Health Study and meta-analysis. *Br J Nutr*. 2018:1-11.  
21  
22 47. Akizawa Y, Koizumi S, Itokawa Y, et al. Daily magnesium intake and serum  
23 magnesium concentration among Japanese people. *J Epidemiol*. 2008;18:151-9.  
24  
25 48. Han H, Fang X, Wei X, et al. Dose-response relationship between dietary  
26 magnesium intake, serum magnesium concentration and risk of hypertension: a  
27 systematic review and meta-analysis of prospective cohort studies. *Nutr J*.  
28 2017;16:26.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Supplementary Figure 1 Identification of an Analytical Cohort from the Women's Health Initiative Memory Study (WHI-MS)



Supplementary Table 1 Baseline Characteristics of Participants Included or Excluded from Analysis

	Mean (SD) / N (%)		
	Excluded	Included	p value
Number of participants	1006	6473	
Time-to-event/censored in years	5.5 (5.3)	9.6 (4.3)	***
Age at baseline in years	70.3 (3.9)	70.1 (3.8)	NS
BMI at baseline	29.5 (7.5)	28.4 (5.4)	***
Recreational physical activity in MET-hour	10.7 (13.8)	11.3 (13.2)	NS
Total magnesium intake in mg	251 (162.1)	311.1 (151.2)	***
Total B6 intake in mg	6.1 (21)	6.8 (28.4)	NS
Total B9 intake in mcg	374.7 (272.4)	457.6 (273.5)	***
Total B12 intake in mcg	18.2 (63.6)	20.5 (73)	NS
Total calcium intake in mg	871.3 (689.7)	1139.2 (698.8)	***
Total vitamin D intake in mcg	7.2 (6.5)	9.5 (6.7)	***
Dietary energy in kcal	1344.9 (976.7)	1605.1 (625.3)	***
Region in U.S.			
● Northeast	234 (23.3%)	1771 (27.4%)	***
● South	263 (26.1%)	1315 (20.3%)	
● Midwest	208 (20.7%)	1598 (24.7%)	
● West	301 (29.9%)	1789 (27.6%)	
Race/Ethnicity			***
● Non-Hispanic White	810 (80.7%)	5683 (88.0%)	
● Black or African-American	120 (12.0%)	415 (6.4%)	
● Hispanic/Latino	35 (3.5%)	144 (2.2%)	
● Other	39 (3.9%)	217 (3.4%)	
HRT Arm			**
● E-alone	221 (22.0%)	1248 (19.3%)	
● E-alone control	227 (22.6%)	1257 (19.4%)	
● E+P intervention	289 (28.7%)	1935 (29.9%)	
● E+P control	269 (26.7%)	2033 (31.4%)	
7+ alcohol drinks per week	83 (8.5%)	810 (12.6%)	***
Prevalent diabetes	120 (12.0%)	507 (7.8%)	***
Prevalent cardiovascular disease	204 (20.8%)	1083 (17.0%)	**
Prevalent cancer	35 (3.6%)	232 (3.6%)	NS
Hormone Replacement Therapy			NS
● Never used	702 (69.8%)	4444 (68.7%)	
● Past user	254 (25.2%)	1657 (25.6%)	
● Current user	50 (5.0%)	372 (5.7%)	
Treated high cholesterol	194 (19.8%)	1151 (18.0%)	NS
History of hypertension	424 (43.4%)	2492 (38.8%)	**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Family history of diabetes, heart attack or stroke	768 (76.3%)	4991 (77.1%)	NS
Medication use <sup>a</sup>	510 (50.7%)	3009 (46.5%)	*
Smoking status			***
● Never Smoked	463 (51.7%)	3446 (53.2%)	
● Past Smoker	333 (37.2%)	2597 (40.1%)	
● Current Smoker	99 (11.1%)	430 (6.6%)	
Received college education or above	514 (51.2%)	3761 (58.3%)	***

MCI: mild cognitive impairment; PD: probable dementia; HRT: Hormone replacement therapy; E-alone: Estrogen-alone; E+P: Estrogen+Progestin

\* $p < 0.05$ . \*\* $p < 0.01$  \*\*\* $p < 0.001$ . NS: not significant <sup>a</sup> Any use of anti-inflammatory, anti-hyperlipidaemic, anti-depressant, anti-hypertensive or diuretic drug

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	4
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-6
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-8
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	8
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8-9
		(b) Give reasons for non-participation at each stage	14
		(c) Consider use of a flow diagram	14
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9
		(b) Indicate number of participants with missing data for each variable of interest	14
		(c) Summarise follow-up time (eg, average and total amount)	15
Outcome data	15*	Report numbers of outcome events or summary measures over time	17-18
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear	17-18



		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	17-18
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	10-12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

\*Give information separately for exposed and unexposed groups.